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Introduction and outline of the thesis 11
This thesis describes a series of studies on the clinical relevance of the isolation of non-
tuberculous mycobacteria in Zambia. In this introduction an overview is provided of 
various aspects of mycobacteria described in the literature. Thereafter, the study sites in 
Zambia where the study was performed are presented. In the last part of this chapter the 
aims and the outline of the study are detailed.
introDuCtion to MyCoBACteriA
Mycobacteria are Gram-positive, aerobic bacteria belonging to the family Mycobacteri-
aceae and one of several mycolic-acid-containing genera within the order Actinomyc-
etales (1,2). The family Mycobacteriaceae comprises only one genus; Mycobacterium, a 
name coined by Lehman and Neuman in 1896 (3).
Bacteria of species within the genus Mycobacterium exhibit acid–alcohol fastness, con-
tain genomic DNA with a high G–C content (molecular GC content of 61–71%), and 
have similar mycolic-acid structures in their cell wall (2).
The non-tuberculous mycobacteria (4) are Mycobacterium species different from those 
belonging to the Mycobacterium tuberculosis complex (e.g., M. tuberculosis, M. bovis, 
M. africanum, and M. microti) and M. leprae. NTM can be subdivided in many different 
species with varying rates of evolutionary divergence, variable biochemical character-
istics, clinical presentation, clinical relevance and susceptibility to anti-mycobacterial 
agents. NTM are generally free-living organisms that are ubiquitous in the environment.
These organisms are traditionally designated ‘atypical mycobacteria’ and this term 
was introduced by Pinner in 1935 (5). Atypical mycobacteria, have also been named 
‘anonymous-’, ‘non-tuberculous-’, ‘environmental-’, ‘saprophytic-’, or ‘opportunistic’ 
mycobacteria, and ‘mycobacteria other than tubercle bacilli’. However, these ‘atypical’ 
mycobacteria are not merely, as the name seems to imply, variants of M. tuberculosis- the 
‘typical’ mycobacteria. In contrast, the atypical mycobacteria constitute an evolutionary 
divergent group of bacteria with a wide variability in biological features and in ability to 
cause disease in the humans and animals. Thus, atypical mycobacteria are not ‘unusual’ 
M. tuberculosis strains. The name ‘saprophytes’ seems to be incorrect, since it is not justi-
fied terming a micro-organism ‘non-pathogenic’ for man by means of characteristics such 
as the production of pigment, the rate of growth or the non-virulence in a guinea pig as 
was done early in the last century. During that time teaching held that a non-tuberculous 
acid-fast organism that did not produce disease in the guinea pig was a saprophyte. 
Moreover, a significant proportion of the atypical Mycobacterium species is able to cause 
clinical disease in man similar to what is caused by M. tuberculosis complex bacteria. This 
implies none of these terms have been universally accepted, but the designation ‘non-
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tuberculous mycobacteria’ (NTM) seems to be the most accepted term at this moment in 
the international context. This designation has been endorsed by the American Thoracic 
Society (ATS) in their 1990 statement on the Diagnosis and Treatment of disease caused 
by NTM (6). The diseases caused by NTM have been termed ‘mycobacteriosis’ and ‘op-
portunistic mycobacterial diseases’.
DisCovery AnD ClAssifiCAtion of MyCoBACteriA
Robert Koch discovered the tubercle bacillus in 1882 (7). Shortly thereafter, various 
mycobacteria other than M. tuberculosis were described. A report by Olmacher (8) in 
1901 described an acid-fast organism isolated from the sputum of a young woman who 
was clinically resembling pulmonary tuberculosis. Others reported the isolation of acid-
fast bacilli from the sputum of patients with both normal and abnormal chest X-rays 
(9). But because these micro-organisms lacked pathogenicity in the guinea pig model, 
there was reluctance to accept them as pathogenic for human beings. The recognition 
of these organisms as pathogenic to man is relatively recent, with series of patients suf-
fering from chronic pulmonary disease being reported in the literature since the middle 
1950s (10-12). The earliest understanding that these organisms, known initially as the 
yellow bacillus (M. kansasii) or the Battery bacillus (M. avium complex; after the Battery 
Sanatorium in Georgia where it was first recognized), can act as true pathogens took 
significant time. Early scientist and clinicians such as Ernest Runyon (associated with the 
Runyon classification) (12), William Shaffer (introduction of serotyping of M. avium-
intracellulare-scrofulaceum), John Chapman, Emanuel Wolinsky (the major treatise on 
these organisms as pathogens) (13), and Chai Ahn (diagnostic criteria and drug trials) 
(14) were major contributors to the effort that resulted in the attention these organisms 
nowadays receive.
In 1954, Timpe and Runyon (12) argued that the ‘mycobacteria other than M. tuberculo-
sis’ cause disease in humans, and, subsequently, Runyon developed the first classification 
of these organisms. The NTM were classified into four groups on the basis of growth 
rates, colony morphology, and pigmentation in the presence and absence of light (15). 
Though now outdated, this classification allowed microbiology laboratories to more read-
ily identify individual species of NTM, resulting in clearer characterization of distinct 
diseases or syndromes associated with these organisms.
The identification of mycobacteria was traditionally based on biochemical features and 
growth characteristics. Because mycobacteria generally multiply at a relatively slow pace, 
this process involved weeks of incubation.
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With the availability of 16S ribosomal DNA sequencing, high-performance liquid chro-
matography (HPLC), and 65 KD gene polymerase chain reaction-restriction fragment 
length polymorphism analysis (PRA), the number of new species of NTM has risen dra-
matically in recent years with the naming of species such as M. genavense, M. interjectum, 
M. triplex, M. celatum, and M. lentiflavum. At present over a 100 species are recognized 
in the genus Mycobacterium (13,16).
Within the genus Mycobacterium, four groups of human pathogens can be delineated on 
the basis of genetic, microbiological, clinical, and epidemiologic characteristics:
1. The M. tuberculosis complex (M. tuberculosis, M. bovis, M. bovis BCG, M. africanum, 
M. canettii, M. pinnipedii and M. microti).
2. M. leprae.
3. Slowly growing NTM (photochromogens, scotochromogens and nonchromogens or 
Runyon group I, II and III, respectively).
4. Rapidly growing mycobacteria (Runyon group IV).
Worldwide, the most common NTM species causing human disease are the slowly grow-
ing mycobacteria of the M. avium complex (MAC), and M. kansasii. Less commonly en-
countered human pathogens are the slowly growing bacteria of the species M. marinum, 
M. xenopi, M. simiae, M. malmoense, and M. ulcerans, and the rapidly growing bacteria 
of the species M. abscessus, M. fortuitum, and M. chelonae. Certain relatively common 
laboratory isolates, such as M. gordonae, are important to be known by clinicians because 
they are almost invariably contaminants and not true pathogens.
Traditional methods for speciation of mycobacterial isolates are based upon growth 
characteristics and biochemical test results, requiring 4-6 weeks for the whole identifica-
tion procedure. Furthermore, the reproducibility of this approach was limited. Another 
disadvantage was the inflexibility of this procedure in discovering new species and sub-
species. Test results that did not fit the established schematics of particular (sub-) species 
were seen as exceptional and irreproducible, and it was difficult to link such observations 
to mycobacterial groups, not previously recognised.
In the 1980s, the first molecular tests were introduced to distinguish between M. tuber-
culosis complex bacteria, and the NTM (Gen-probe, San Diego, California, USA). Also 
specific nucleic acid probes tests became available for recognition of the most commonly 
encountered clinical isolates of NTM, including M. kansasii, the M. avium complex, and 
M. gordonae.
In the 1990s, 16S DNA sequencing was introduced and the identification of myco-
bacteria not only became less time consuming, but also much more robust. Phenotypic 
features tend to change and do not always respect the limits of man-made classifications. 
Genetic information by its nature allows accurate phylogenetic grouping and this yields 
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an improved insight in the clinical relevance of certain species and sub-species of myco-
bacteria. However, routine molecular identification of mycobacteria is currently mainly 
based on single genetic traits (mostly 16S and the 16S-23S spacer sequences) (17) and 
the list of new species and sub-species is growing rapidly. Until now (01 Agust 2007), 127 
Mycobacterium species have been described (http://www.bacterio.cict.fr/m/mycobacte-
rium.html).
It is expected that in the near future the insight in the phylogeny of mycobacteria will 
grow significantly. Also many currently recognized species may be further divided in 
two or more new species and sub-species. Particular sub-species may have more clinical 
relevance than other sub-species. For instance, on the basis of DNA polymorphism in the 
gene coding for the 16S-23S rRNA internal transcribed spacer, the species M. kansasii 
was recently divided in several sub-groupings (18). M. kansasii sub-group I is often as-
sociated with clinical disease, whereas the other subgroups are more likely to represent 
environmental bacteria. It is, therefore, expected that with the increase in genetic in-
formation available on NTM, our knowledge on the clinical significance of NTM will 
improve significantly.
environMentAl niChes, ColonizAtion AnD infeCtion
NTM are ubiquitous in the environment and can colonize or infect people and animals. 
In contrast to M. tuberculosis and M. leprae, species that affect only mammals, NTM form 
an integral part of the natural environment and may also prevail in certain man-made 
environments, thereby exposing susceptible individuals leading to colonization and in-
fection. NTM act like saprophytes, commensals, and symbionts and are common inhabit-
ants of a wide variety of environmental reservoirs throughout the world, including natural 
and municipal water, soil, aerosols, protozoans, domestic- and wild animals, milk- and 
food products. NTM may be abundant in certain natural surroundings or niches, where 
climatological factors are advantageous for their growth. There are geographical varia-
tions in the distribution of specific NTM organisms (19), most likely reflecting regional 
differences in the mycobacterial habitats.
However, only a very small proportion of all human-mycobacteria interactions progress 
to outright mycobacterial infection. Such progression is much more common in immune-
compromised patients, especially those with AIDS (20). The relatively low incidence of 
infection due to NTM, despite high levels of exposure, suggests that NTM generally have 
a low pathogenicity for man (21,22).
The ubiquitous distribution of NTM contributes to the difficulties in interpreting 
positive culture results. Most NTM can inhabit body surfaces or secretions without caus-
ing disease. Thus, the mere isolation of NTM from respiratory specimens in itself may 
Introduction and outline of the thesis 15
indicate harmless colonization, but also infection. Furthermore, NTM can potentially 
contaminate smears and cultures during the acquisition, transportation and laboratory 
processing of specimens, which may lead to an incorrect diagnosis of tuberculous disease. 
The clinical manifestations of the infections vary among the NTM species, and distin-
guishing between colonization or contamination and true infection is complicated.
In this thesis, the term ‘colonization’ is used to refer to the repeated recovery of viable 
NTM organisms from properly collected clinical specimens, in the absence of clinical 
manifestations, tissue invasion or other sign of damage to the host. The NTM multiplicate 
on a body surface without evoking an immune response.
The term ‘infection’ will be reserved for disease states in which there are signs or symp-
toms suggesting a pathologic process. NTM have invaded the body tissues.
The term ‘disease’ will be used to indicate the clinical manifestation of damage that 
results from the host-NTM interaction. This is the case in a symptomatic patient who 
does meet the diagnostic criteria in the guidelines formulated by the American Thoracic 
Society (ATS) or British Thoracic Society (BTS), which includes pathology on the chest 
radiograph or chest high-resolution computed tomography (HRCT) scan, repeated spu-
tum samples, bronchial wash or lung biopsy positive for NTM and exclusion of other 
disorders (23,24).
A ‘pseudo-infection’ is defined as a positive culture result from a patient without evi-
dence of true infection or colonization, which is typically caused by contamination dur-
ing specimen handling (25).
These terms (colonization, infection and disease) are used to describe the host-microbe 
relationship and have been in use for nearly a century. Over the years the concepts of 
host-pathogen interaction changed and the definitions for these terms were revised. In 
the literature the definitions of these term are often not clarified. In several publications 
the difference between rates of colonization and rates of infection or disease are not evi-
dent. This may lead to confusion and may overestimate the clinical importance of NTM.
ePiDeMiology of ntM infeCtion
Although reports listing the significance of NTM differ in various geographic parts of the 
world, there does seem to be a definite geographic distribution for some organisms. In the 
United States, NTM lung disease is most commonly attributable to M. avium complex, 
with M. kansasii being second (26). In the United Kingdom, M. kansasii is the pathogen 
most commonly associated with NTM lung disease in England and Wales, while M. mal-
moense is the most commonly encountered NTM in Scotland. M. xenopi predominates 
in Southeast England (23). In Japan, the most common cause of NTM pulmonary disease 
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is M. avium complex, followed by M. kansasii (27). The distribution of NTM and the 
incidence of disease caused by them is not yet fully known in most parts of the world.
The reported rates of NTM colonization and infection are likely to be underestimates, 
with the former probably less accurate than the latter, given that people without sig-
nificant symptoms are not likely to have intensive diagnostic work-up for possible NTM 
infection. The lack of systematic reporting of NTM infection in most nations limits the 
ability to derive accurate estimates of incidence and prevalence of colonization and infec-
tion. Nevertheless, there is sufficient data to conclude that NTM disease rates vary widely 
depending on the population studied and its geographic location. NTM disease is clearly 
a major problem in certain groups, including patients with underlying lung disease and 
also in individuals with impaired immunity. North American rates of colonization and 
infection have been reported to range from approximately 1-15 per 100,000 and 0.1-2 
per 100,000, respectively. Generally, similar rates have been reported in European stud-
ies, with the exception of extremely high rates in an area of the Czech Republic where 
mining is the dominant industry (28). These studies have also shown marked geographic 
variability in prevalence. Rates in Japan and Australia were similar to those reported in 
Europe and North America.
On the whole, the impression seems to be that NTM infections in humans are on the 
increase. However, most data reporting high rates of infection with NTM come from 
Northern European countries or the United States. In African countries, despite the fact 
that environmental exposure to NTM is very high in that part of the world, infections 
with NTM seem to be very rare, even among patients with AIDS (29). Though, not much 
data is available to date regarding NTM infection in Africa.
europe
The NTM isolation rates in Finland between 1991 and 1993 were published in a brief 
report (30). The mean annual isolation rate was 6.6 per 100,000 and 55% of the isolates 
were MAC, 20% M. chelonae and M. fortuitum, 15% M. gordonae and 10% M. malmoense. 
Numerous reports on the epidemiology of NTM in the United Kingdom have been pub-
lished. A report from Wales presents data from the period of 1953 to 1978 (31). Only 
cases with NTM infection are reported, but the definition of NTM infection was not 
explicitly stated in that paper. A greater than twofold increase in rates of disease over a 
decade was found, from 0,2 to 0,5 per 100,000 in the periods 1953-1957 to 1963-1967. 
M. kansasii was the most common cause of disease (67%), followed by MAC (28%) and 
M. xenopi (4%). Data from Scotland suggest high rates of infection with M. malmoense 
(32,33). A study on the period 1990 and 1993 reports an incidence rate of 1.3 per 100,000 
for M. malmoense pulmonary disease in the Lothian region (33). Rates of infection for the 
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nation as a whole and Lothian in particular are also presented, reporting M. malmoense 
as the most common isolate encountered, followed by MAC.
A report from Switzerland assessed the frequency of clinical disease in all 513 HIV-
negative patients from whom NTM were isolated at the University of Zürich between 
1983 and 1988 (34). Thirty-four patients (6.7 percent) were thought to have clinical infec-
tions: twenty-one had pulmonary disease, ten had soft tissue disease, and one suffered 
from disseminated disease. The most common isolates were MAC in 16 patients and 
M. kansasii in nine patients. M. terrae, M. fortuitum, M. marinum, and M. malmoense 
were also found.
A study in France of the period between 1991 and 1995, limited to the prevalence 
of M. kansasii in a Paris suburb with a high prevalence of HIV, reported rates of infec-
tion and disease of 1.1 and 0.5 per 100,000, respectively (35). Several studies from the 
Czech Republic have reviewed the experience with M. kansasii isolation in the Karvina 
district of North Moravia, where mining is a major industry (28,36,37). Over a 12 year 
period ending in 1979, one study reported a greater than 10-fold increase in rates of both 
colonization and infection, determined to be 17 and 12 per 100,000, respectively, with a 
simultaneous decrease in the rate of tuberculosis from 30 to 20 per 100,000 (28).
the netherlands
In the period 2002 through 2006 the number of NTM isolates sent to the National in-
stitute for Public Health and Environment (RIVM) amounted 407, 437, 571, 584 and 
669 yearly. The underlying reasons for this apparent increase in the number of NTM 
isolations are currently unknown. It could be due to increased attention to possible NTM 
infection. However, in the same period the number of newly diagnosed, culture positive 
tuberculosis cases in this period decreased from 1098 in the year 2002 to 790 in the year 
2006. This suggests that there is an inverse correlation between the trends of tuberculosis 
and NTM infection.
M. kansasii infection rates were reported from The Netherlands for 1-year period over 
1978-1979 (38). The data suggest rates of colonization and infection of 0.2 and 0.1 per 
100,000, respectively. The rate of all NTM infections was 2.9 per 100,000. Most isolates 
were from the mining province of Limburg, and the authors speculate that this reflects a 
particular susceptibility of miners, probably due to underlying lung disease that is preva-
lent among them.
northern America
A number of useful studies on isolation of NTM have been performed in North America 
(39-41). A Centers for Disease Control (CDC) laboratory survey of NTM isolates from 
42 of 54 mycobacterial laboratories across the United States was performed in 1979 (42). 
Data were reported as total numbers of isolates rather than on patient denominators. 
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Thirty-two percent of the mycobacterial isolates were NTM, comprising a sample of 
7,764 positive specimens. Of NTM isolates, 58% were MAC, 15% M. fortuitum, 10% 
M. kansasii, and 9% M. scrofulaceum. MAC was most common in all regions, followed by 
M. fortuitum and M. kansasii with exception of the Midwest where isolates of M. kansasii 
outnumbered those of M. fortuitum. National rates of isolation were 2.5, 0.7 and 0.5 per 
100,000 for MAC, M. fortuitum, and M. kansasii, respectively. The highest rates of MAC 
were observed in South Eastern Atlantic states and several states along the U.S.-Canadian 
border. M. kansasii is most commonly found in some Midwestern and several Southern 
states. These data were updated and expanded upon 1980, again including only the total 
number of positive isolates rather than patients (39). A similar proportion of mycobacte-
rial isolates were NTM (35%). Isolation rates and the distribution of the species were 
generally similar as reported previously.
A Canadian study on positive NTM isolates in the province of Manitoba calculated rates 
based on the number of patients with positive cultures from 1988 to 1990 (40). Given that 
438 patients had positive cultures, and the population comprised 1.5 million individuals, 
the mean annual rate of infection over the two-year study period was an astonishing 14.6 
per 100,000. This is much higher than in the bordering state of Minnesota, based on data 
reported 10 years previously by Good (39). Other studies (43,44) did not find similarly 
high rates in British Columbia and reported levels of 2-4 per 100,000.
In a survey of 26 states and 22 city health departments in the United States, recording 
laboratory and clinical information on patients with NTM positive specimens between 
1982 en 1983, MAC was found the most common NTM causing disease (26). Overall 
colonization and infection rates were 4.5 and 1.8 per 100,000, and more than 80% were 
cultured from pulmonary sites.
Studies reviewing both microbiologic and clinical data on the rates of NTM disease in 
North America span nearly four decades (26,43-47). A study of all cases of mycobacte-
rial disease from the province of Newfoundland between 1957 and 1960 reported that 
two percent were caused by NTM (46). Two thirds of NTM cases were pulmonary. The 
average annual rate of NTM disease was 2.0 per 100,000 overall and 1.3 for pulmonary 
disease.
Data on all mycobacterial isolates from the province of British Columbia from 1960-
1981 were reported in two publications (43,44). The annual incidence rate of disease per 
100,000 rose from 0.08 in 1960 to 0.60 in 1980. MAC was the most commonly isolated 
species, followed by rapid growers, M. xenopi, and M. kansasii (44). These two reports 
present a thorough analysis and suggest a steadily increasing rate of NTM infection and 
disease over more than two decades.
Studies from the United States of America have shown tremendous geographic vari-
ability. Rates of colonization and infection for all NTM have generally been reported at 
approximately four and two per 100,000, respectively. About 50-60% of cases was caused 
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by MAC, 20% by M. kansasii and approximately 10% by rapid growers. M. kansasii has 
consistently been reported to cause disease in the majority of cases with a positive iso-
late. Finally, of the few reports that have presented data on disease rates over time, most 
(43,44,48) have found a significant increase.
A recurring observation is the increase in rates of infection and disease in time. The 
reason for this increase is unclear but may be caused by several factors. The possibility 
exists that the apparent increase is either spurious or less significant than studies would 
suggest. Changes in clinician awareness leading to increased investigations, or laboratory 
methods leading to isolation and identification of previously unnoticed organisms, could 
play a role in this trend, and studies have been published that support (49) and refute 
(50) this argument. A true increase could be related to the host, the pathogen, or some 
interaction between the two.
Host changes leading to increased susceptibility could play an important role, with 
increased numbers of patients with inadequate defenses from diseases such as HIV infec-
tion, malignancy, or simply advanced age (50). An increase in susceptibility could also 
relate to the decrease in infection with two other mycobacteria. It has been speculated 
that infection with M. tuberculosis (47) and Bacillus Calmette-Guerin (BCG) (51,52) may 
provide cross-immunity protecting against NTM infection. Many investigations have 
observed decreasing rates of M. tuberculosis concomitant with the increases in NTM. In 
addition, studies from Sweden (51) and the Czech Republic (52) have found that chil-
dren who were not vaccinated with BCG had a far higher rate of extra-pulmonary NTM 
infection.
Potential changes in the pathogens include increases in NTM virulence, and it has been 
argued that this should be considered as a possible contributing factor (53). Finally, an 
interaction between the host and pathogen could involve a major increase in pathogen 
exposure or potential inoculum size. This may be occurring secondary to the increase in 
popularity of showering as a form of bathing (54), a habit that greatly increases respira-
tory exposure to water contaminants. Furthermore, disinfection of drinking water with 
chlorine and disinfection attempts in medical and industrial settings may likewise select 
for mycobacteria (55).
The heterogeneity of study methods in identifying cases and the lack of a uniformly ap-
plied definition of disease makes it difficult to compare rates between studies. Moreover, 
the lack of systematic reporting of NTM infection in most nations limits the ability to 
derive accurate estimates of infection and disease. Regardless, there are more than ade-
quate data to conclude that NTM disease rates vary widely depending on population and 
geographic location. NTM disease is clearly a major problem in certain groups, including 
patients with underlying lung disease and also in individuals with impaired immunity. 
20 Chapter 1
The rates of NTM infection and disease are increasing, so the problem will likely continue 
to grow and become a far more important issue than current rates suggest.
Africa
The only available population-based studies in the continent of Africa have been con-
ducted in South Africa and they report extremely high rates of infection. A number of 
studies on the epidemiology of NTM have been performed in South Africa. These are 
generally limited to select populations. For an overview of the literature on prevalence/in-
cidence rates of colonization/infection/disease of NTM in Africa see Table 1. The results 
of mycobacterial studies of sputum cultures from large random samples of South African 
native people were reported in two studies (56,57). The sputum from 1,196 Zulus in Na-
tal, South Africa, was obtained and examined for the presence of mycobacteria (56). No 
clinical information was collected. Sputum was obtained either spontaneously or induced 
by mechanical irritation of the epiglottis. Nine samples grew M. tuberculosis and 17 grew 
NTM, translating into prevalence rates for M. tuberculosis of 750 per 100,000 and preva-
lence rates of colonization/infection for NTM of 1,400 per 100,000. In the other study 
aerosol-induced sputum from 2,230 Xhosa people in the Transkei region was obtained 
(57). Ninety specimens grew M. tuberculosis and 150 grew NTM, yielding prevalence 
rates for M. tuberculosis of 4,300 and prevalence rates of colonization/infection for NTM 
of 6,700 per 100,000. According to the authors there was no evidence that the isolated 
NTM presented with any health threat. Moreover, 79% of the NTM cultured were mani-
fested as 1-colony isolates. Therefore, the 150 NTM represented probably colonization.
Both studies utilized population-based methods to determine the prevalence of pulmo-
nary mycobacterial infection. However, the selected population had an extremely high 
rate of tuberculosis, probably resulting in bronchiectasis and leading to NTM infection. It 
is doubtful whether these prevalence rates can be generalized to other populations.
Two South African NTM studies focussed on a population of gold miners (58,59). The 
records of a cohort of HIV-negative gold miners, investigated for suspected pulmonary 
mycobacterial disease between 1993 and 1996, were reviewed (59). Annual rates of NTM 
infection/disease were found to be 101 per 100,000 with the two most common organisms 
causing 66 (M. kansasii) and 12 (M. scrofulaceum) per 100,000, respectively. Interestingly, 
MAC made up for only 6% of all isolates and the rate of MAC disease was not reported. 
The same group consequently presented data on another cohort of gold miners, this time 
including HIV-positive patients (58). Rates of NTM disease were somewhat lower than in 
the earlier report (37 M. kansasii and 8.8 M. scrofulaceum per 100,000, respectively).
In Ethiopia the prevalence of pulmonary tuberculosis was assessed in out patients in 
Addis Abada (60). Of 509 consecutive outpatients evaluated on the basis of a clinical 
suspicion of pulmonary tuberculosis 168 (33%) were culture positive for M. tuberculosis. 
In this population were two patients with isolates classified as M. avium complex.
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Kenyan adults who presented with acute radiologically-confirmed pneumonia were 
studied to define the aetiology and outcome of acute pneumonia in a rural and urban 
population (61). In total 281 clinical episodes of acute pneumonia were examined. Acid-
fast bacilli were observed in sputum smears from 23 patients, of which three remained 
culture negative. Mycobacterial cultures were positive in 53 patients (17 from lung aspi-
rates, 47 from sputum) and a Nocardia species was isolated from one patient. M. tubercu-
losis was found in 26 cultures, and 11 were identified as NTM (M. fortuitum/M. chelonae 
(3 cultures), M. szulgai (2), M. kansasii (2), M. terrae (1), and other NTM (3). Three 
cultures were lost in transit, and 13 were too contaminated for further speciation. In a 
cohort study of 355 HIV-positive and HIV-negative patients with suspected tuberculosis 
in Kenya no NTM were found in specimens (mainly sputum) taken at presentation (62).
A number of studies have reported that in sub-Saharan Africa M. tuberculosis is a fre-
quent cause of bloodstream infection (63-65) and that M. avium complex is an uncom-
mon cause of disseminated infection among HIV-1 infected persons (29,63,64,66,67).
In Malawi the aetiology of 70 patients, out of 233 patients, with a bloodstream infection 
was determined (64). Of the isolated pathogens 21 (28%) were belonging to M. tuber-
culosis and one to M. bovis. In addition, three NTM were found: one each of M. avium 
complex, M. simiae, and species belonging to the SAV group (simiae-avium group my-
cobacteria, i.e. organisms that resemble M. avium complex by conventional biochemical 
tests but that have HPLC profiles that are more consistent with M. simiae).
In Nigeria a total of 2,784 cases with persistent symptoms of lower respiratory tract 
infections were seen in chest clinics in Lagos (68). Of these, 668 were randomly selected 
and screened for pulmonary tuberculosis. Repeated sputum samples were cultured and 
102 mycobacterial isolates were obtained. Of these isolates, 87 (85%) were identified as 
M. tuberculosis, four (4%) as M. bovis and 11 (11%) as NTM. Among these NTM, six were 
classified as M. avium, four as M. kansasii and one as M. fortuitum.
In Zambia, 249 patients suspected for tuberculosis were recruited to a cohort study to 
investigate the interaction between tuberculosis and HIV (69). Sputum, pleural fluid or 
tissue were examined. M. tuberculosis was cultured in 57% (39/67) of HIV negative cases 
and 54% (98/182) of HIV positive cases. No NTM were isolated.
In a survey for tuberculin testing in Zambia all people were asked if they had a cough 
more than two weeks duration. If so, sputum was collected from all people over nine 
years old (70). Of 1,692 people, 411 reported a chronic cough and 254 sputum samples 
were obtained. Of these sputum samples 8 M. tuberculosis and 3 NTM were isolated (spe-
cies not mentioned).
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trAnsMission AnD PreDisPosing fACtors
The biological variation among NTM is large when considering the ability to cause clini-
cal disease in man and to affect various target organs or tissues.
In contrast to M. tuberculosis and M. leprae that affect only mammals, NTM form an 
integral part of the natural environment and may also prevail in certain man made envi-
ronments, such as hot water tanks and tap water, thereby infecting and causing disease 
in vulnerable individuals. Transmission of infection occurs by inhalation or ingestion of 
aerosolized organisms from soil, dust and water spray and less frequently from instru-
mentation such as bronchoscopy or by inoculation. Damaged skin tissues favour infec-
tions by particular NTM species including M. abscessus (71). Direct transmission from 
animals is not important for human infections (72), and human-to-human transmission 
has not been demonstrated so far. Therefore, patients with disease are not generally iso-
lated. Disease in humans almost certainly arises as a result of contact with bacilli in the 
environment. Investigation is continuing into the exact mechanisms of transmission of 
NTM disease from the environment to man.
Certain types of conditions including congenital- or acquired immune deficiency of 
T-cells or macrophages, cystic fibrosis (CF) or bronchiectasis, tend to facilitate NTM 
infection. Trauma that is often associated with introduction of foreign material such as 
wood splinters or sand particles, unsterile injections, or surgically implanted cosmetic or 
medical devices in tissue, may promote disease with different NTM (73-79). The course 
of infection depends on the characteristics of the NTM species, the presence of predis-
posing host factors and the clinical setting (80,81).
Risk factors may be divided, in decreasing order of importance, into coexisting medical 
conditions, living and work environment, and patient demographics.
Coexisting medical conditions likely provide the most powerful risk factor for NTM 
infection. These risk factors may be divided into impairment of local pulmonary defences 
and generalized immune defects, with examples including CF and HIV, respectively. Pre-
existing lung disease, including silicosis and other pneumoconiosis (31,36,59), chronic 
obstructive pulmonary disease (32,35,36), bronchiectasis (35,36), and other structural 
changes in the anatomy of the lung consistent with previous tuberculosis (59) have been 
identified as important risk factors. Alcohol abuse (54), diabetes mellitus, malignancy 
(32), and smoking (54) also have been associated with NTM infection.
Living and work environment has consistently been identified as an important risk factor 
for NTM colonization and infection. Studies covering large geographic areas have gener-
ally found an increased risk of NTM colonization in people living in warmer regions (82). 
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Living in urban versus rural settings has been associated with altered rates and patterns 
of NTM colonization in several studies (26,44,45,47). The most commonly cited envi-
ronmental risk factor for NTM is the work environment, specifically mining, other heavy 
industries such as smelting. Also, residence in areas where these industries dominate may 
be a risk factor (38,58,59).
Certain demographic features have been identified as risk factors for NTM infection, 
including age, sex, or combination of the two. Increasing age has almost universally been 
identified as a risk factor for NTM (43,82) as well as male sex (43,45,47). However, expo-
sure to NTM in the work environment during cumulative years could be a confounding 
factor in that respect. Studies have also documented observations regarding the patient 
profiles of ‘elderly females’ and ‘middle-aged males’ being at increased risk for MAC 
(26,47) and M. kansasii (37).
Immune competent patients infected by NTM can be stratified into two groups: the 
first comprises patients, usually men of more than 50 years old, primarily white with pre-
existing lung disease such as chronic airways disease, fibrocavitary diseases and bron-
chiectasis and often alcoholics and/or smokers (14,83,84). A more recently recognized 
group of patients comprises predominantly elderly (over age 50) non-smoking women 
with no pre-existing pulmonary disease and who have interstitial patterns on chest radi-
ography (50,85,86).
CliniCAl MAnifestAtions of infeCtions Due to ntM
In broad terms, the following main categories of clinical symptoms caused by NTM can 
be distinguished: pulmonary disease, superficial lymphadenitis, skin and soft tissue infec-
tion, and disseminated disease. Pulmonary disease accounts for up to 90% of all cases.
Furthermore, NTM are occasionally involved in nosocomial infections and pseudo-
outbreaks (73,74) Unfortunately, official figures on infections due to NTM cannot be 
given because they are mostly not incorporated in surveillance programs.
In The Netherlands one focal centre performs the secondary laboratory diagnosis of 
tuberculosis and mycobacterioses; the RIVM. At the RIVM in the year 2005 nearly 600 
isolates of NTM were received, and the actual number of NTM isolates in this country 
may be much higher. In most of the concerned cases there was a clinical ground underly-
ing the decision to culture mycobacteria. The magnitude of clinical relevance of isolation 
of particular NTM is currently under investigation at the RIVM, in collaboration with 
University lung centre Dekkerswald in Nijmegen.
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NTM infections of the lung often occur in the context of pre-existing lung disease, espe-
cially chronic obstructive pulmonary disease (COPD), bronchiectasis, pneumoconiosis, 
cystic fibrosis, and a history of tuberculosis (87-89). As a result, the clinical manifesta-
tions of NTM-associated lung disease are often similar to those of the underlying disease 
and are also present in patients with NTM lung disease who do not have pre-existing pul-
monary disease. Progressive pulmonary disease is primarily caused by M. avium complex 
(MAC) and M. kansasii. Other species which cause lung disease include M. abscessus, 
M. fortuitum, M. xenopi, M. malmoense, M. szulgai, M. simiae, and M. asiaticum (89).
Differences in geographic distribution play a prominent role in the epidemiology of 
NTM pulmonary disease. M. xenopi is relatively more common in Europe, Great Britain, 
and Canada, while M. malmoense is relatively more common in Scandinavia and North-
ern Europe (13,90).
Cervical lymphadenitis, especially in children younger than 5 years of age, is caused 
mostly by MAC and M. scrofulaceum in the United States, and, in Northern Europe 
mostly by M. malmoense. However, the most common cause of this infection in Europe 
is M. tuberculosis.
Skin and soft tissue infection usually occurs from percutaneous inoculation (e.g.; trauma 
or surgery) and are caused primarily by M. marinum and M. ulcerans and the rapid grow-
ers M. chelonae and M. fortuitum. Chronic granulomatous infections of bursae, joints, 
tendon sheaths and bones are seen after direct inoculation of NTM through accidental 
trauma, surgical incisions, puncture wounds or injections.
Disseminated infections of NTM are rare and most commonly caused by M. chelonae, 
M. abscessus and M. fortuitum. A review of the literature from the early 1990s identified 
worldwide 54 cases over 14 years (91). The diseases occurred most commonly in pa-
tients who had profound immuno-suppression and presented as multiple subcutaneous 
nodules (pseudo erythema nodosum) or abscesses that drained spontaneously (92). The 
majority of disease due to NTM in HIV-infected patients is caused by M. avium complex 
(MAC). In these patients usually disseminated disease is reported, although localized 
forms of MAC infection are currently being reported with the widespread use of more 
effective antiretroviral therapies.
the lABorAtory DiAgnosis of ntM
Microscopy
Microscopic examination of sputum smears after staining, culture on specific (liquid and 
solid) media, and molecular detection are nowadays the cornerstones of the laboratory 
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diagnosis of mycobacterioses, including tuberculosis. Usually, in poor resource settings, 
microscopy is still the only tool available for the diagnosis of tuberculosis. All mycobac-
teria share the characteristic of ‘acid-fastness’, i.e.; after staining with carbol-fuchsin or 
auramine-rhodamine, they do not decolorize with acidified alcohol. Thus, the common 
term acid-fast bacilli (AFB) is essentially synonymous with mycobacteria. Nocardia, the 
main exception, is weakly or variably acid-fast.
Specimens may be stained with the Ziehl-Neelsen stain or one of its modifications, 
such as the Kinyoun stain, and examined by routine light microscopy. However, micros-
copy is relatively insensitive, since at least 10,000 organisms per millilitre of sputum are 
required for smear positivity (93). Thus, other procedures are often performed in order 
to increase the sensitivity of direct microscopy of clinical specimens. Most laboratories in 
the Western world use a fluorochrome stain such as auramine-O or auramine-rhodamine 
and examine specimens by fluorescence microscopy. In order to increase the sensitivity, 
it is also recommended to use N-acetyl l-cysteine (NALC) for liquefaction of the sputum 
together with concentration. Furthermore, liquid specimens may be centrifuged first 
before the sediment is stained.
Culture
Confirmation of the presence of mycobacteria in clinical specimens has traditionally 
required culture, because of the relative insensitivity of direct microscopy. In general, 
clinical specimens that are normally sterile, such as blood, cerebrospinal fluid, or serous 
fluids, can be inoculated directly onto media. In contrast, non-sterile specimens, such as 
sputum or pus, must first be chemically decontaminated, in order to eliminate common 
bacteria and fungi that would overgrow the culture. However, decontamination proce-
dures inhibit the growth of mycobacteria as well. Clinical specimens for mycobacterial 
cultures should be inoculated onto one or more solid media (e.g.; Löwenstein-Jensen 
or Middlebrook 7H11 media) and into a liquid medium such as BACTEC 12B broth or 
MGIT broth (both manufactured by Becton Dickinson). Growth of visible colonies on 
solid media typically requires three to eight weeks. Primary cultures in liquid media, 
such as in the MGIT system, usually produce results within 10 to 14 days. However, this 
method is not hundred percent sensitive; as a result, this culture method supplements but 
not replaces traditional solid media.
Molecular methods
Traditional methods of speciating mycobacterial isolates were based upon growth 
characteristics on solid media and subsequent biochemical tests, requiring additional 
weeks for subcultures. These time-consuming methods are being replaced with more 
rapid techniques. Commercial DNA probes (AMPLICOR nucleic acid amplification 
test (AccuProbe) (Roche Diagnostic Systems, Inc., Branchburg, New Jersey) and Gen-
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Probe Amplified Mycobacterium tuberculosis Direct Test (MTD) (Gen-Probe, San Diego, 
California) have been available for some time for identification of clinically important 
mycobacterial species, including M. tuberculosis complex, M. avium, M. intracellulare, 
M. avium complex, M. kansasii, and M. gordonae. The tests are based on species-specific 
DNA probes that hybridize with ribosomal RNA released from bacteria. Other methods 
(INNO-LiPA Mycobacteria; Innogenetics, Ghent, Belgium and GenoType Mycobacte-
rium CM/AS, Hain Lifescience GmbH, Nehren, Germany) are based on reverse hybrid-
ization, in which the mycobacterial 16S-23S internal transcribed spacer region or the 
23S gene region are amplified by polymerase chain reaction (PCR), and amplicons are 
subsequently hybridized with probes for several mycobacterial species on paper strips.
Polymerase chain reaction (PCR)-based sequencing consists of amplification of my-
cobacterial DNA with genus-specific primers and sequencing of the amplicons. The 
micro-organism is identified by comparison of the nucleotide sequence with reference 
sequences. The target most commonly used is the gene coding for the 16S ribosomal 
RNA. Several other target genes have been characterized for this purpose (genes coding 
for the 32 kDa protein (95), the 65 kDa heat shock protein (96), and the 16S-23S ribo-
somal RNA internal transcribed spacer (94)).
DiAgnosis of ntM DiseAse
The diagnosis of NTM disease is highly complicated. Prior to the 1950s, it was gener-
ally accepted that NTM do not cause human disease. Unlike M. tuberculosis, NTM were 
found of low virulence in the guinea pig model; as a result, when they were found in 
sputum of humans, it was difficult to know whether their presence represented disease or 
simply colonization. Finding any M. tuberculosis in sputum is regarded as abnormal and 
indicative of disease, but such is not the case with NTM. Healthy people may expectorate 
NTM without having evidence of this disease. The isolation of a few colonies of NTM 
from the sputum of a healthy person may have no clinical significance. If these organ-
isms are isolated from a person with an abnormal chest X-ray film, further evaluation is 
necessary.
When NTM are isolated from a usually sterile site (e.g., blood, bone marrow, lymph 
nodes, synovial fluid), the diagnosis of true disease is generally straight forward. How-
ever, when NTM are isolated from non-sterile sites, such as sputum or broncho-alveolar 
lavage (BAL) fluid, the diagnosis is less definitive, especially when the colony numbers 
are low or NTM are isolated from only one cultured specimen. A diagnosis of infection 
in such a case depends upon other clinical findings and the presence or absence of other 
pathogens. Organisms that in immune competent persons are considered ‘commensals’, 
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can be opportunistic pathogens in patients with advanced HIV disease and immunode-
ficiency (97).
The criteria set in a Statement by the American Thoracic Society (ATS) in 1997 and these 
formulated by the British Thoracic Society (BTS) serve as a useful guide to the diagnosis 
of NTM disease in patients with or without HIV co-infection (23,89). The guidelines 
of the ATS have been recently revised (February 2007) (24). The diagnostic criteria for 
NTM pulmonary infections include both imaging studies consistent with pulmonary 
disease and recurrent isolation of mycobacteria from sputum or bronchial wash in a 
symptomatic patient.
Diagnostic criteria for ntM lung disease
In 1997, the American Thoracic Society (ATS) issued a revised set of diagnostic criteria 
for NTM lung disease and recently (February 2007) the third statement was published 
(24,89). In 2000, the British Thoracic Society (BTS) also published its guidelines for the 
management of NTM lung disease (23). According to the BTS guidelines, NTM lung 
disease is indicated when positive cultures develop from specimens of sputum obtained 
at least seven days apart (positive culture twice) in a patient whose chest radiograph sug-
gests mycobacterial infection and who may or may not manifest symptoms or signs.
The ATS guidelines of 1997 included diagnostic criteria that are more strict than those of 
the BTS statement. In this thesis, the ATS criteria of 1997 were applied. In symptomatic 
patients with infiltrate, nodular, or cavitary disease, or a high-resolution CT scan showing 
multi-focal bronchiectasis and/or multiple small nodules, the following apply:
A. If three sputum/bronchial wash results are available from the previous 12 months:
 1. three positive cultures with negative AFB smears results.
 or
 2. two positive cultures and one positive AFB smear.
B. If only one bronchial wash is available:
 1. positive culture with a 2+ to 4+ AFB smear or a 2+ to 4+ growth on solid media.
C. If sputum/bronchial wash evaluation are non-diagnostic or another disease cannot be 
excluded:
 1. trans-bronchial or lung biopsy yielding a NTM.
 or
 2.  biopsy showing mycobacterial histo-pathologic features and one or more sputa or 
bronchial washings are positive for an NTM even if only in low numbers.
 or any growth from usually sterile extra-pulmonary site
The new ATS guidelines (2007) include diagnostic criteria that are more lenient than 
the former statement (24). The clinical criteria include a symptomatic patient with 
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pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or an HRCT 
scan that shows multifocal bronchiectasis with multiple small nodules. In addition, the 
microbiologic criteria comprise positive culture results from at least two separate sputum 
samples, or positive culture results from at least one bronchial wash or lavage, or lung bi-
opsy with mycobacterial histopathologic features (granulomatous inflammation or AFB) 
and positive culture for NTM, or lung biopsy showing mycobacterial histopathologic 
features (granulomatous inflammation or AFB) and one or more sputum or bronchial 
washings that are culture positive for NTM.
Noteworthy is the exclusion of positive smear(s) of sputum or bronchial wash and the 
exclusion of extra-pulmonary NTM isolates from the diagnostic criteria. Furthermore, 
expert consultation should be obtained when NTM are recovered that are either infre-
quently encountered or that usually represent environmental contamination. Patients 
who are suspected of having NTM lung disease but who do not meet the diagnostic crite-
ria should be followed until the diagnosis is firmly established or excluded.
Signs and symptoms of pulmonary disease caused by NTM are variable and non-specific. 
NTM frequently occurs in the context of underlying lung disease, which can also cause 
symptoms. As a result, the distinction between transient infection or contamination and 
true infection is often difficult. Most patients present with cough that becomes produc-
tive as the disease progresses. Fatigue, weight loss, malaise, fever, dyspnoea, haemoptysis, 
and chest discomfort may also occur as the disease progresses. In most patients, the 
symptoms have been present for months to years and attributed to chronic bronchitis or 
bronchiectasis.
The radiographic findings of NTM lung disease are variable, depending in part upon 
the species. Findings consistent with NTM pulmonary infection on chest radiograph 
or high resolution computed tomography scan include infiltrates (usually nodular or 
reticulo-nodular), cavities, multi-focal bronchiectasis, and/or multiple small nodules.
Only for a limited number of NTM infections a skin test is commercially available. 
Cross-reactivity between purified protein derivatives from various NTM species has lim-
ited skin testing with purified protein derivative (PPD) to epidemiologic and descriptive 
studies (98).(99)
Given the lack of diagnostic specificity of chest radiography and skin testing, the diagno-
sis of NTM lung disease requires microbiologic confirmation. The diagnostic evaluation 
should consist of smear and culture of at least three sputum specimens obtained in the 
morning. If the aetiology of the patient’s symptoms remains uncertain and the infiltrate 
persists, bronchoscopy with broncho-alveolar lavage (BAL) should be performed.
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the stuDy site; zAMBiA
Zambia, officially the Republic of Zambia, is a landlocked country in Southern Africa. It 
borders the Democratic Republic of the Congo to the north, Tanzania on the North-East, 
Malawi on the East, Mozambique, Zimbabwe, Botswana, and Namibia to the South, and 
Angola on the West. The former name of this country was Northern Rhodesia, nowadays 
the country is named after the Zambezi river.
Zambia has a tropical climate and consists mainly of high plateau with some hills and 
mountains. At 752,614 square km it is the 39th-largest country in the world. Zambia is 
drained by two major river basins: the Zambezi River basin in the South; and the Congo 
River basin, in the North. Of the two basins, the part of Zambia drained by the Zambezi 
River basin is about three-quarters of the country’s total area.
Zambia is divided into nine provinces, each administered by an appointed deputy min-
ister who essentially performs the duties of a governor. The provinces are divided into 72 
districts. The provinces are: Central, Copperbelt, Eastern, Luapula, Lusaka (home of the 
capital city, Lusaka), Northern, North-Western, Southern, and Western Province. Within 
table 2: Statistics Zambia 2004.
General information
Total population 11,668,000
GDP per capita (Intl $)* 1,013
Life expectancy at birth m/f (years) 40.0/40.0
Healthy life expectancy at birth m/f (years) 34.8/35.0
Adult mortality m/f (per 1000) 683/656
Total health expenditure per capita (Intl $)* 51
Total health expenditure as % of GDP 5.4
* Intl $ (International dollar): a common currency unit that takes into account differences in the relative 
purchasing power of various currencies.
table 3: Health indicators in Zambia.
Health Indicator Estimated figures
Life expectancy at birth 38.1 (2004)
Infant mortality rate (per 1000 live births) 102 (2004)
Under-5 mortality rate (per 1000 live births) 182 (2004)
Total fertility rate 5.5 (2004)
Maternal mortality rate (per 100,000 live births) 750 (2006)
Crude death rate (deaths per 1000 population) 19.9 (2006)
Crude birth rate (births per 1000 population) 41 (2006)
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each district there are administrative subdivisions known as Traditional Authorities, 
which are presided by chiefs. The smallest administrative unit is the village.
Over 70% of Zambians live in poverty. Per capita annual income is currently about 
$395 and places the country among the world’s poorest nations. Zambia is also one of 
Sub-Saharan most highly urbanized countries. Almost one-half of the country’s 10 mil-
lion people are concentrated in a few urban zones strung along the major transportation 
corridors, while rural areas are underpopulated. Unemployment and underemployment 
are serious problems.
Zambia’s population is comprised of about 72 Bantu-speaking ethnic groups but almost 
90% of Zambians belong to the nine main ethnolinguistic groups, which are the Bemba, 
Nyanja-Chewa, Tonga, Tumbuka- spoken in the Eastern Province and Eastern part Noth-
ern Province, Lunda, Luvale, Kaonde, Nkoya and Lozi. Each ethnic group is concentrated 
in a particular geographic region of the country and many groups are very small and not 
as well known. The official language is English. Most Zambians are subsistence farm-
ers. The predominant religion is Christianity which is also the official national religion. 
Islam also has a visible presence, especially in urban settings. Expatriates, mostly British 
(about 15,000) or South African, live mainly in Lusaka and in the Copperbelt in Northern 
Zambia, where they are employed in mines and related activities. Zambia also has a small, 
but economically important Asian population, most of whom are Indians. There is low 
literacy rate: 68% in adults in 2004. Secondary school enrolment is low with 25.8% of the 
children.
Almost 50 percent of the population consists of children under the age of 15 and a further 
20 to 25 percent are women of childbearing age (world resources institute). The World 
Health Organization reports that the life expectancy at birth in Zambia is just 40 years 
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and the under-five child mortality rate is approximately 180 per 1,000. The impact of in-
adequate health care facilities on this group, as well as the population as a whole, is com-
pounded by poverty, disease and malnutrition. The effects of the HIV/AIDS epidemic are 
devastating, with an estimated 15 to 20 percent of adult Zambians being infected, about 
900,000 living with AIDS and over 550,000 AIDS orphans, the great majority of who are 
not infected.
The arrival of the HIV/AIDS pandemic has caused a re-emergence of tuberculosis 
throughout Southern Africa, where the average tuberculosis case rate between 1964 and 
1984 remained constant at 100 per 100,000 people. Since the advent of AIDS, TB case 
rates in Zambia increased nearly fivefold to over 500 per 100,000 people in 1996. There 
are now in excess of 78,000 new tuberculosis cases reported every year with an estimated 
incidence of 650 per 100,000 people. Of the adult people (15-49 years) with tuberculosis, 
54% is HIV positive.
hosPitAls in zAMBiA where the stuDy wAs PerforMeD
st. francis hospital
St. Francis Hospital is a large, rural hospital serving a local population of over 200,000 
within a 60 km radius and receiving specialist referrals from all over Eastern Province 
(about 1.5 million people). It is located in the district of Katete in Zambia’s Eastern Prov-
ince. St. Francis Hospital was started in 1948 by an Anglican Missionary. It first consisted 
of wards and staff accommodation built of wooden poles, mud walls and thatched roofs. 
The hospital rapidly expanded and became a teaching hospital for surgeons and mid-
wives. In 1987, the Roman Catholic Church in Zambia joined the Anglicans in running 
the hospital. The largest mission hospital in Zambia is now fully integrated into the Zam-
bian Health Service and partly funded by the Zambian Government, but also receives 
funding via the Anglican and Catholic Churches and from overseas support groups in 
The Netherlands and the U.K. St. Francis hospital has a predominantly Zambian staff, but 
also uses on volunteers from overseas to compensate for the national shortage of clinical 
staff. It is about 500 km from the capital of Lusaka. This is a five or six hour journey on 
the ‘luxury’ coaches. The hospital contains about 360 beds. However, this total is never 
a limit to the number of in-patients in the hospital, as space on the floor can always be 
found and it is a common occurrence for patients to be found sleeping on the floors of 
the hospital wards. St. Francis Hospital also runs two nursing schools and a network of 14 
rural clinics which serve a population of 157,000. In addition, the hospital supports over 
6,000 AIDS orphans living in proximity to the hospital in a centre for voluntary HIV/
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AIDS testing and counselling. Furthermore, it provides community education on HIV/
AIDS prevention and in home support to those individuals living with HIV/AIDS.
yeta district hospital
Yeta district Hospital in Sesheke in the Western Province of Zambia is a first level hospital 
with 101 beds. The hospital is owned by the government.
our lady’s hospital
Our lady’s Hospital in Chilonga is a 182 bed second level hospital, which means it serves 
as a referral hospital for the Northern Province. A school of nursing and midwifery is 
attached to the hospital, and it participates in the training of clinical officers.
AiMs AnD outline of this thesis
Tuberculosis remains a problem of large dimension in Africa and Mycobacterium tu-
berculosis is the most important causative agent of this infectious disease. However, it 
is known that in developed countries also NTM play a significant role in the aetiology 
of tuberculosis-like syndromes, especially in immune-compromised patients. In Africa, 
where HIV-infection is highly prevalent, the contribution of NTM to the problem of 
tuberculosis has so far been examined on a very limited scale.
From a hospital in Sesheke, Zambia a request was received at the laboratory of medical 
microbiology, Medical Centre Rijnmond-Zuid in Rotterdam to support a research project 
on the diagnosis of tuberculosis. In this African hospital, many patients were clinically 
suspected for tuberculosis but had a negative Ziehl-Neelsen staining of sputum. During 
a tuberculosis surveillance study, we regularly isolated NTM from various clinical speci-
mens of Zambian patients with pulmonary syndromes. The clinical significance of a part 
of these NTM was questionable and the present study aims to resolve this enigma.
Patients who were admitted to different hospitals with chronic complaints during vari-
ous time periods from 2001 to 2004, were included in the study. Most of the study was 
performed in St. Francis Hospital in Katete (Eastern province). Other hospitals involved 
were Yeta District Hospital in Sesheke (Western province) and Our Lady’s Hospital in 
Chilonga (Northern province). Because mycobacterial infections can affect all parts of 
the body, we decided to include all patients over 15 years of age who with signs and 
symptoms in any part of the body for more than two weeks.
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The clinical relevance of the isolation of NTM in patients with a positive or negative 
HIV status in Zambia is evaluated. The role of NTM in human disease in Africa may be 
underestimated and is examined in more detail.
Part i: Diagnosis of tuberculosis
In the study described in Chapter 2, we compare the effect of two decontamination pro-
cedures on the sensitivity to detect M. tuberculosis complex and NTM in sputum samples, 
as culture is considered the gold standard for the diagnosis of tuberculosis. Most clinical 
sputum samples contain a variety of micro-organisms that can easily overgrow M. tuber-
culosis. Decontamination of these samples is therefore crucial in preventing contamina-
tion of a Mycobacterium culture. However, the recovery of mycobacteria is negatively 
influenced by decontamination.
Because usually only microscopic examination is available to confirm the diagnosis of 
tuberculosis in Africa, the involvement of acid-fast NTM in tuberculosis-like syndromes 
might result in the misdiagnosis of tuberculosis. A new promising diagnostic tool for 
the rapid identification of mycobacteria is Raman spectroscopy. Another recent develop-
ment. the ‘electronic nose’ also shows potential for the direct identification of mycobac-
teria in clinical samples. These new methods are evaluated in Chapter 3 and Chapter 4, 
respectively.
Part ii: Clinical relevance of ntM
In the first pilot study described in Chapter 5, the role of NTM in the development of 
tuberculosis-like disease in Sesheke and the confusion that this may cause in the diagno-
sis of tuberculosis by microscopy, is evaluated. In the subsequent pilot study described in 
Chapter 6 the possible role of NTM in tuberculosis-like diseases in various geographic 
locations, in addition to Sesheke, was compared.
Eight patients from whom NTM was cultured from normally sterile body sites were 
described in detail in Chapter 7. In order to exclude the possibility of a laboratory cross-
contamination, a novel amplified fragment length polymorphism (AFLP) DNA typing 
method for a frequently found NTM was applied. Only a limited number of studies on 
the epidemiology of NTM has been performed in Africa. In the study described in Chap-
ter 8 the frequency and clinical relevance of NTM in the population living in the area 
around the hospital was compared with a patient population admitted to the hospital. 
In Chapter 9, the accuracy of clinical diagnosis of tuberculosis in Zambia in the era of 
increasing HIV prevalence is summarized.
Studies have indicated that host genetic factors are major determinants of susceptibility 
to mycobacterial infection in humans. Not much is known on possible racial differences 
involved in the susceptibility to infections diseases like tuberculosis. It is likely that sus-
ceptibility to most micro-organisms is determined by a large number of polymorphic 
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genes, and identification of these markers will provide insights into this mechanism. The 
DNA polymorphism of genes that determine susceptibility to infection with mycobacte-
ria, in Zambian patients, is described in Chapter 10.
Finally, in Chapter 11 the results of the studies described in Chapter 2 to 10 are sum-
marized and discussed. Questions that could be the basis for future research are put 
forward.
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ABstrACt
We compared the NaOH-N-acetyl cysteine (NaOH-NALC) and the sulfuric acid decon-
tamination procedure in the detection of mycobacteria using the Mycobacteria Growth 
Indicator Tube (MGIT). In total 219 sputum specimens were collected from 142 Zambian 
patients and subjected to mycobacterial culture. One half of the specimen was decon-
taminated with NaOH-NALC and the other half was decontaminated with sulfuric acid. 
From the 438 samples a total of 261 (60%) cultures yielded growth of mycobacteria, 
consisting of 22 different species. The sulfuric acid method was more successful than 
the NaOH-NALC method in recovering mycobacteria in MGITs (146 versus 115 respec-
tively, p=0.001). Of the 146 positive mycobacterial cultures recovered after sulfuric acid 
decontamination 28 were Mycobacterium tuberculosis, 84 nontuberculous mycobacteria 
(NTM) and 34 acid fast bacterial isolates which could not be identified to the species 
level. The 115 mycobacteria recovered by the NaOH-NALC method consisted of 34 
M. tuberculosis strains, 55 NTM and 26 acid fast bacteria that could not be identified. 
The most frequently isolated NTM were Mycobacterium lentiflavum and Mycobacterium 
intracellulare. Comparing the two decontamination methods the recovery of NTM in the 
sulfuric acid group was significant higher than in the NaOH-NALC group (p=0.001). In 
contrast, no significant difference was found for the recovery of M. tuberculosis. These re-
sults show that the decontamination method used affects the recovery of nontuberculous 
mycobacteria in particular.
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introDuCtion
Tuberculosis continues to be a tremendous public health problem in both developing and 
industrial countries. Mycobacterium tuberculosis complex strains are still responsible for the 
majority of Mycobacterium infections worldwide (5). However, there has been an increase 
in infections caused by nontuberculous mycobacteria (NTM) mainly due to the AIDS pan-
demic (12). Culture is considered the gold standard for the detection of M. tuberculosis, 
but most clinical sputum samples contain a variety of microorganisms that may overgrow 
M. tuberculosis. Decontamination of these samples is therefore crucial in preventing con-
tamination of the mycobacterial culture. However, also the recovery of mycobacteria is 
negatively influenced by decontamination (13,15). The decontamination method applying 
sulfuric acid was used in our laboratory in the former days and NaOH-N-acetyl cysteine 
(NaOH-NALC) is currently most widely used. It is unclear which method provides maxi-
mum decontamination while maintaining the viability of M. tuberculosis complex and 
which species of mycobacteria are more sensitive to a specific decontamination method 
(9,10). The isolation of M. tuberculosis complex and/or NTM has epidemiological implica-
tions and is also relevant for the management of patients with regard to appropriate treat-
ment, isolation and contact tracing. Antibiotic treatment may vary according to the species 
encountered, and certain species may require no antibiotic therapy at all.
These considerations have prompted us to compare the effect of these two decontami-
nation procedures on the sensitivity of the detection of M. tuberculosis complex and NTM 
in sputum samples. The study was carried out in two rural hospitals in Zambia where the 
HIV prevalence was approximately 20%.
MAteriAls AnD MethoDs
From March to June 2001, 219 sputum specimens were collected from 142 chronically ill 
patients and cultured for mycobacteria in Zambia. After informed consent each patient 
admitted on the medical ward in the hospital and who was coughing for more than two 
weeks was included in the study. During three consecutive days morning sputum was col-
lected from these patients and two separate specimens were cultured for mycobacteria. 
The third morning sputum specimen was stored at −20°C. About 5% of the patients were 
not able to produce sputum and about 35% of the patients could not submit a second 
sputum sample because they did not have a productive cough anymore, discharged them-
selves or died. Before decontamination, the 219 specimens were divided in two samples. 
The specimen was macroscopically divided and the (muco)purulent parts were separated 
equally. The specimen was assessed microscopically according to the criteria from the 
ASM-manual for clinical microbiological procedures, i.e. basically on the basis of the 
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number of squamous epithelial cells and leukocytes (11). One half of the specimen was 
decontaminated with NaOH-NALC and the other half was decontaminated with sulfuric 
acid. All specimens were collected, decontaminated by NaOH-NALC and sulfuric acid, 
inoculated and incubated in Zambia. After transport of all tubes the work-up of the posi-
tive cultures was done in The Netherlands. Each specimen of the patient was collected 
in a container that was never used before and was imported from The Netherlands. The 
stock of decontamination fluid was sterilised twice a week and each day a fresh tube or 
bottle was opened.
Decontamination with naoh-n-acetyl cysteine (13)
For the NaOH-NALC procedure 2.5 ml of the sputum specimen was put in a 15 ml glass 
centrifuge tube with a screw cap. An equal volume of NaOH-NALC decontamination 
solution (6.8% NaOH, 2.9% sodium citrate, 0.5% NALC, final concentration of NaOH: 
1.7%) was added. After vortexing the specimens was left at room temperature for 15 
min. Subsequently 5 ml of sterile 0.067 M phosphate buffer (pH 6.8) was added and 
the mixture was centrifuged at 3660×g for 15 min. The supernatant was discarded and 
the sediment was inoculated in a Mycobacteria Growth Indicator Tube (MGIT; Becton 
Dickinson Microbiology Systems, Cockeysville, MD).
Decontamination with sulfuric acid (15)
For the sulfuric acid (6.0%) decontamination, 2.5 ml of the specimen was put in a 15 ml 
glass centrifuge tube with a screw cap and an equal volume of sulfuric acid (final concen-
tration of sulfuric acid: 3.0%) was added. After vortexing the specimen was left at room 
temperature for 15 min for decontamination. Then, 5 ml sterile normal saline was added 
and the mixture was vortex-mixed again. After centrifugation for 15 min at 3660×g, the 
supernatant was discarded and the sediment was suspended in 10 ml of normal saline. 
After another centrifugation for 15 min at 3660×g, the supernatant was discarded and the 
sediment was inoculated in an MGIT.
Media, incubation, reading, identification
Half a ml of the decontaminated specimens was inoculated into an MGIT with PANTA 
(polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azlocillin) according 
to the protocol of the manufacturer. The inoculated tubes were incubated for at least 8 
weeks at 37°C in Zambia or in The Netherlands. The tubes were incubated between 2 and 
12 weeks in Zambia and the time of incubation was extended for at least 8 weeks in The 
Netherlands. They were read macroscopically every week and smears stained by Ziehl-
Neelsen were made from all tubes in The Netherlands. Mycobacteria were identified by 
the Accuprobe (bioMérieux) or 16S rDNA sequencing (8). From 60 samples, identifica-
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tion of the acid fast bacteria (AFB) was not possible due to contamination or due to loss of 
viability of the bacteria during the process of culture, transport, and/or identification.
Data analysis
Data were analysed with SPSS 11.0. The McNemar test was used to compare paired di-
chotomy variables and a P-value <0.05 was considered significant.
results
From 142 patients 219 sputum specimens were collected. These specimens were divided 
in two parts (in total 438 samples) that were decontaminated with NaOH-NALC or sul-
furic acid. At least 70% of the sputum specimens had a quality representative for the lower 
respiratory tract (Quality score≥1). Of the 142 patients 37 had a sputum culture positive 
for M. tuberculosis and from these patients 18 had also a positive smear for AFB made 
from these samples.
From the 438 samples an overall number of 261 (60%) cultures yielded growth of 
mycobacteria, representative of 22 different species (Table 1). M. tuberculosis was most 
commonly recovered (n=62), followed by Mycobacterium lentiflavum (n=33) and Myco-
bacterium intracellulare (n=31). From 60 cultures positive with acid fast bacteria (AFB) 
no identification was possible (26 were found in the NaOH-NALC decontamination 
method and 34 in the sulfuric acid method).
table 1: Culture results after decontamination with NaOH-NALC or sulfuric acid of split specimens.
Sulfuric acid NaOH-NALC
Negative M. tuber-
culosis
M. lentifla-
vum
M. intra-
cellulare
NTMa AFB no 
idb
Totalc
Negative 48 3 3 2 8 9 73
M. tuberculosis 5 14 0 1 5 3 28
M. lentiflavum 12 3 3 3 1 4 26
M. intracellulare 3 1 0 2 3 4 13
NTMa 19 5 1 6 11 3 45
AFB no idb 17 8 0 3 3 3 34
Totald 104 34 7 17 31 26 438
The numbers indicate the culture results of half of the specimen after decontamination with one of the 
two methods. Reading as a 2×2 table.
aNTM consisted of M. mucogenicum (n=7), M. fortuitum (n=5), M. chelonae (n=5), M. terrae (n=3), M. goodii 
(n=2), M. gordonae (n=1), M. asiaticum (n=1), M. triplex (n=1), M. rhodesia (n=1), M. avium (n=1), M. obuense 
(n=1) and 8 different unidentified Mycobacterium species (n=48).
bFrom 60 positive cultures with acid fast bacteria (AFB) no identification (id) was possible.
cRecovering of mycobacteria by Sulfuric Acid method: 28+26+13+45+34=146.
dRecovering of mycobacteria by Nalc-NaOH method: 34+7+17+31+26=115.
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In many sputum specimens two different mycobacteria species were isolated (Table 
1). For instance, in the samples decontaminated with NaOH-NALC 34 M. tuberculosis 
strains were identified while in the other part of the same specimen decontaminated 
with sulfuric acid in 14 samples M. tuberculosis was also identified but in 3 samples no 
mycobacteria were found, in 3 samples M. lentiflavum and in 1 sample M. intracellulare 
was isolated, in 5 samples other NTM were found and in 8 samples the identification of 
the AFB was not possible.
Of the 261 isolates, 25 were detected exclusively by the NaOH-NALC method (the 
MGIT of the sulfuric acid method was negative) versus 56 by the sulfuric acid method 
(the MGIT of the NaOH-NALC method remained negative). The 25 mycobacteria de-
tected only by the NaOH-NALC method consisted of 3 strains of M. tuberculosis, 13 
NTM and 9 AFB with no identification. Of the 56 mycobacteria detected only in the 
sulfuric acid method 5 strains belonged to M. tuberculosis, 34 to NTM and 17 AFB with 
no identification.
The sulfuric acid method was more successful than the NaOH-NALC method in recov-
ering mycobacteria via MGITs (146 and 115 respectively, p=0.001). Of the 146 mycobac-
teria (recovered by sulfuric acid method) 28 belonged to M. tuberculosis, 84 to NTM and 
34 AFB with no identification. The 115 mycobacteria recovered by NaOH-NALC method 
consisted of 34 strains of M. tuberculosis, 55 NTM and 26 AFB with no identification. 
Comparing the samples decontaminated with NaOH-NALC and those decontaminated 
with sulfuric acid no significant difference was found in recovering M. tuberculosis 
(p=0.39). However, the sulfuric acid method appeared a significantly better decontami-
nation method than the NaOH-NALC method for recovering NTM (p=0.001).
The 146 positive mycobacterial cultures detected by the sulfuric acid method consisted 
mostly of M. tuberculosis (28), M. lentiflavum (26) and M. intracellulare (13). The 115 
mycobacteria isolated after decontamination with NaOH-NALC were mainly identified 
as M. tuberculosis (34), M. intracellulare (17), and M. lentiflavum (7). Of the 62 M. tuber-
culosis isolates 14 were detected by the NaOH-NALC method as well as by the sulfuric 
acid method. 14 M. tuberculosis isolates where detected exclusively by the sulfuric acid 
method and 20 only by the NaOH-NALC method.
DisCussion
In the present study we found a high rate of positive cultures for mycobacteria. Of the 
261 isolates positive for mycobacteria 62 (24%) were identified as M. tuberculosis and 139 
(53%) were identified as NTM. Significantly more NTM were recovered by the sulfuric 
acid decontamination method than by the NaOH-NALC method (84 versus 55 respec-
tively). There was no significant difference between the sulfuric acid decontamination 
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method and the NaOH-NALC method for the detection of M. tuberculosis (28 versus 34 
respectively).
In the study of Burdz et al. no clearly superior method between NaOH-NALC, modified 
Petroffs’ method or the Yamane procedure was found in affecting the viability of M. tu-
berculosis H37Ra (2). A limited number of earlier studies showed differences between the 
recovery of mycobacteria by different decontamination methods. Salfinger and Kafader 
compared NaOH-NALC with sodium dodecyl sulfate (SDS)-sodium hydroxide for the 
detection of mycobacteria by BACTEC Middlebrook 7H12 medium and Löwenstein-
Jensen slants (17). They concluded that SDS-NaOH was superior to NaOH-NALC as a 
pre-treatment method. On the other hand, in the study of Pfyffer et al. clinical specimens 
were processed with SDS and NaOH-NALC using the MGIT (16). Specimens pre-treated 
with SDS resulted in both poor recovery and delayed mean time to detection of AFB. In 
both studies the number of NTM strains isolated were much less than in our study.
The collection and processing of specimens was done in a way to avoid cross contami-
nation. All disposables needed were imported from The Netherlands and for sterilisation 
the autoclave of the hospital was used. The restriction fragment length polymorphism 
(RFLP) patterns of the isolated M. tuberculosis strains were almost all different (data not 
shown) virtually excluding the possibility of a cross contamination in the laboratory in 
Zambia. Furthermore, to assure that the isolated NTM were not contaminants introduced 
in the laboratory, sputum specimens (stored at −20°C) of 20 patients were checked and 
confirmed positive for mycobacteria by amplified rDNA restriction analysis (4). In addi-
tion AFLP DNA typing was performed from 10 M. lentiflavum strains that showed that 
different strains were isolated and therefore a laboratory contamination could be consid-
ered unlikely (1). Although not all M. lentiflavum isolates have clinical significance the 
first case of human disease was a patient with spondylodiscitis who markedly improved 
on multiple antituberculous agents (18). Other clinical cases were reported later: four 
cases of cervical lymphadenitis, a case of cavitary pulmonary disease, one disseminated 
infection in a woman undergoing steroid therapy, a disseminated infection and hepatic 
abscess in an AIDS patient (3,6,7,14,19).
Both decontamination methods eliminate most of the contaminating bacteria in the 
sputum specimen but also reduce the viability of the mycobacteria in the specimen. 
The alkaline or acid environment is toxic not only to contaminating organisms but to 
mycobacteria as well. In the present study a complete shift is observed in the ratio of 
M. intracellulare and M. lentiflavum. In the NaOH-NALC method the ratio is 17/7 and 
in the sulfuric acid method the ratio is 13/26. The cell viability of different species of 
mycobacteria is probably not the same for various decontamination methods. The effect 
of genetic variation of mycobacteria on the sensitivity to the decontamination process is 
probably another reason (20).
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In the present study NTM were apparently more susceptible to killing by NaOH. The 
final concentrations for NaOH (1.7%) and sulfuric acid (3.0%) employed in this study 
were higher than the recommended concentrations (1.0% and 2.0% respectively). These 
concentrations were according to protocols used in The Netherlands because of a higher 
contamination rate of the sputum. This might be another reason for the different percent-
age of recovery of NTM between NaOH-NALC and sulfuric acid decontamination.
The type of decontamination method applied definitely influences the recovery of 
mycobacteria, NTM in particular. This has clear consequences for the quality of both 
microbiological diagnosis and treatment of patients. More research is needed for the 
evaluation of the clinical relevance of the various NTM isolated.
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ABstrACt
A number of rapid identification methods have been developed to improve the diag-
nostic accuracy for tuberculosis (TB) and to speed up presumptive identification of 
Mycobacterium species. Most of these methods are validated for a limited group of micro-
organisms only. Raman spectroscopy was compared with 16S rRNA sequencing for the 
identification of M. tuberculosis complex strains and the most frequently found strains of 
nontuberculous mycobacteria (NTM). Sixty-three strains, belonging to 8 distinct species 
were analysed. The sensitivity of the Raman spectroscopy for the identification of Myco-
bacterium species was 95.2%. All M. tuberculosis strains were correctly identified (7/7; 
100%) as were 54 of 57 NTM strains (94%). The differentiation between M. tuberculosis 
and NTM was invariably correct for all strains.
Moreover, the reproducibility of Raman spectroscopy was evaluated for killed my-
cobacteria (by heat and formalin) versus viable mycobacteria. The spectra of the heat-
inactivated bacteria showed minimal differences as compared to the spectra of viable my-
cobacteria. Therefore, identification of mycobacteria appears possible without biosafety 
level III precautions.
Raman spectroscopy provides an innovative answer to the need for rapid species iden-
tification of cultured mycobacteria in a clinical diagnostic setting.
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introDuCtion
Mycobacteria cause a variety of infections in humans. Classically defined lung tubercu-
losis (TB) is predominantly caused by M. tuberculosis complex. The number of new cases 
is estimated at nine million per year worldwide and the disease causes more than two 
millions deaths annually (16). In addition, the incidence of pulmonary disease caused 
by nontuberculous mycobacteria (NTM) appears to be increasing worldwide (1,6). The 
clinical features of NTM-derived pulmonary disease are in some cases indistinguishable 
from those of tuberculosis. Because the treatment and the epidemiology of NTM-derived 
infections differ significantly from tuberculosis caused by M. tuberculosis complex bacte-
ria, the timely and correct identification of causative organisms is mandatory for diagno-
sis, therapy and tuberculosis control.
Conventional approaches to the diagnosis of mycobacterial infection rely on tests that 
are far from optimal. For example; sputum smear microscopy is insensitive, laborious 
and time-consuming. Culture is technically complex, time-consuming, has a sensitivity 
of only 80-85% and is scarcely available in high prevalence settings. Chest radiography is 
non-specific and not widely implemented either. Tuberculin skin testing is imprecise and 
the results are often non-specific (3). In the last decade, a number of rapid diagnostic tests 
has been developed in an effort to improve the diagnostic accuracy for TB and to speed 
up presumptive identification. PCR and other molecular amplification techniques are the 
most prominent among these new tools. While promising, none are more than adjunctive 
to the diagnosis of TB, since the sensitivity of these tests varies widely. The most reliable 
results are found when tests are applied to smear-positive specimens (2,13). In addition, 
these tests are specific for the detection of particular micro-organisms and not applicable 
to diagnose a wide spectrum of causative agents.
Several commercial techniques are now available for species identification of M. tu-
berculosis complex and NTM. These techniques are fast but expensive and limited to 
selected, frequently encountered species, as is the case for the reverse line blot (RLB) 
assay (e.g. INNO-LiPA Mycobacteria; Innogenetics, Ghent, Belgium and GenoType My-
cobacterium CM/AS, Hain Lifescience GmbH, Nehren, Germany), AMPLICOR nucleic 
acid amplification test (Roche Diagnostic Systems, Inc., Branchburg, New Jersey) and 
Gen-Probe Amplified Mycobacterium tuberculosis Direct Test (MTD) (Gen-Probe, San 
Diego, California) (2).
For more rarely encountered Mycobacterium isolates, DNA sequencing of the 16S 
rRNA gene is mostly used at mycobacteria reference laboratories. However, at peripheral 
laboratories implementation of 16S rRNA gene sequencing in routine practise has many 
drawbacks like high costs, complexity, lack of peer-reviewed databases and clear unam-
biguous interpretations.
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In view of these limitations, there is a continuing need for fast, simple alternatives which 
have the potential to be directly applicable to bacteria in clinical material, enabling iden-
tification of a wide spectrum of micro-organisms.
Vibrational spectroscopies (infrared and Raman spectroscopy) have been developed for 
the rapid identification of clinically important microorganisms (11). Important features 
of these methods are the relative ease by which measurements can be performed, the 
limited amount of sample handling involved, the small amounts of biomass required and 
the high degree of reproducibility. Fourier-Transform Infrared spectroscopy proved to be 
a convenient approach to classify NTM at the species level (14). However, the identifica-
tion of M. tuberculosis complex has not yet been evaluated.
Raman spectroscopy is an optical method, enabling spectroscopic fingerprints to be 
obtained from biological samples in a few seconds. These fingerprints represent the 
molecular composition of a sample and are therefore ideally suited for identification of 
micro-organism at both the species- and strain level (7,9,10).
In general, viable micro-organisms are used for the identification by Raman spec-
troscopy. To work with viable M. tuberculosis complex, a biosafety level III (BSL III) of 
containment is required. To bypass this specific requirement, various methods to kill my-
cobacteria have been described in the literature, such as heat- and formalin inactivation. 
However, the effect of the inactivation on the spectroscopic fingerprints of mycobacteria 
has not been reported previously.
Here we present the results of the first study on the use of Raman spectroscopy for the 
identification of M. tuberculosis complex- and the most frequently encountered NTM 
species.
The aim of this study is (i) to evaluate the reproducibility of the Raman spectroscopy 
for killed mycobacteria versus viable mycobacteria and (ii) to compare the performance 
of this method with identification on the basis of 16S rRNA sequencing.
MAteriAls AnD MethoDs
strains
In a pilot study, a set of 12 strains representing 6 different, frequently encountered NTM 
species was used to evaluate the effect of two inactivation methods on species discrimina-
tion and spectroscopic reproducibility. The set included M. avium, M. chelonae, M. gor-
donae, M. xenopi, M. kansasii and M. malmoense. Of each species two different strains 
were included. In this pilot study only NTM requiring BSL II precautions were used.
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In the subsequent identification study a collection of 63 Mycobacterium strains, com-
prising 8 different Mycobacterium species, was tested (Table 1). These strains represent a 
variety of the NTM species most frequently isolated from humans in The Netherlands, as 
well as M. tuberculosis. Furthermore, 13 M. lentiflavum strains that were recently isolated 
from patients in Zambia were included (4). All strains were identified to the species level 
by 16S rRNA gene sequencing and RLB-assay (INNO-LiPA Mycobacterium system, Im-
munogenetics, Ghent, Belgium) (8). M. lentiflavum was identified at the species level by 
16S rRNA gene sequencing only. Cultures were stored at –80°C in a 10% glycerol contain-
ing medium until use.
As a reference method for identification we have used the 16S rRNA sequence. This 
method has been found to be very useful for identification and taxonomy of mycobacte-
ria (8) and is applied in many tuberculosis reference laboratories (5,15). In recent years, 
several new Mycobacterium species have been identified by 16S rRNA sequencing which 
could not have been identified by conventional methods. In the recently published new 
diagnostic criteria for nontuberculous mycobacterial diseases by the American Thoracic 
Society, 16S rRNA sequencing of mycobacteria is one of the recommended methods for 
identification (6). Therefore, this method was also used as the gold standard in the pres-
ent study.
Culture
A loop (1 μm) of biomass was taken from a Mycobacterium culture on Middlebrook 
7H10-agar or Löwenstein-Jensen and suspended in a Mycobacteria Growth Indicator 
Tube (MGIT; Becton Dickinson Microbiology Systems, Cockeysville, Md.). The vials 
were incubated in a semi-automated incubation system (BACTEC MGIT 960 system). 
This system continuously measures the oxygen levels in the culture vials and a change 
in the oxygen concentration over a preset threshold is an indication of bacterial growth. 
Vials positive for microbial growth were indicated by the incubation system.
table 1: Mycobacterium strains included in the identification study.
Mycobacterium species Number of isolates
M. tuberculosis  7
M. avium  9
M. chelonae  4
M. gordonae  5
M. kansasii  9
M. malmoense 10
M. xenopi  6
M. lentiflavum 13
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inactivation methods
In the pilot study, two inactivation methods for mycobacteria (heating at 80°C for 20 min 
and suspension in 10% formalin for at least one hour) were compared to direct applica-
tion of Raman spectroscopy to viable mycobacteria. Positive cultures were centrifuged for 
15 min at 3660xg and the sediment was divided into three equal portions. One third of 
the sediment was suspended in 1.0 ml normal saline and stored at 4°C (in case of viable 
mycobacteria); one third was suspended in 1 ml 10% formalin and stored at 4°C; and 
the third part was suspended in 1 ml normal saline and heated for 20 min at 80°C and 
thereafter stored at 4°C. To check whether the bacteria had truly been inactivated, 500 
µl of the heated and formalin-inactivated suspensions was inoculated in a MGIT culture 
tube and incubated at 37°C for 12 weeks.
In the identification study, all Mycobacterium cultures were heat-killed and Raman mea-
surements were performed directly or after storage at 4°C for less than 2 days.
raman spectroscopy
Before Raman measurements were performed, the samples were washed three times with 
aquadest (AD). The sediment was suspended in 10 µl of AD and 4 µl was transferred to a 
fused silica glass slide and air dried, resulting in small pellets of biomass.
Raman spectra were collected using a Model 2500 High Performance Raman Module 
(HPRM) (River Diagnostics BV, Rotterdam, The Netherlands), coupled to a custom-build 
inverted microscope stage, with an automated XY-stage (River Diagnostics) and operated 
using RiverICon software, version 1.63. The microscope contained a custom-designed 
microscope objective with a numerical aperture of 0.7, optimized for Raman experi-
ments in the 750-1000 nm wavelength region, which focused laser light emitted by the 
Model 2500 HPRM in the samples on the fused silica slide. The objective also collected 
Raman scattered light from the samples. Samples were excited using laser light from a 
785 nm diode laser (Sacher Lasertechnik, Marburg, Germany), delivering approximately 
150 mW to the sample. The spectrometer was calibrated according to the manufacturer’s 
guidelines.
Automated data collection and signal pre-treatment was performed using the Riv-
erICon software, requiring approximately 1 minute per sample. Pre-treatment consisted 
of correction for the signal contribution of the fused silica substrate and scaling of all 
spectra using the extended multiplicative signal correction (EMSC) approach described 
by Martens and Stark (12). Briefly, all spectra were fitted to a representative Mycobac-
terium reference spectrum using a 7th order polynomial to correct for varying spectral 
backgrounds.
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identification and hierarchical cluster analysis (hCA)
The similarity between samples was calculated using the squared Pearson’s correlation 
coefficient (R2) between the representative spectra and than multiplied by 100 to be ex-
pressed as percentages.
To evaluate the possibilities for species identification, a leave-one-out approach was 
used. In this approach the similarity of a sample was compared to all other measured 
samples by calculating the R2 values. The predicted species of a sample was assumed to be 
identical to the species of the sample with which the highest correlation occurred. This 
procedure was repeated for all measured samples. HCA on spectra was performed using 
the pair wise similarity matrix as distance matrix in combination with Ward’s cluster 
algorithm.
reproducibility of raman spectroscopic measurements
In the pilot study all strains were cultured three times. The similarity between the spectra 
obtained from these replicates was used to evaluate the reproducibility of the Raman 
procedure compared to the inter-species similarity. Ideally, the intra-strain similarity is 
less than the intra-species similarity. To determine the intra-strain Raman reproducibil-
ity, we used the spectra obtained from the three parallel cultures of one isolate. First the 
pair wise correlation coefficients between these three spectra were calculated (between 
spectrum 1 and 2, between spectrum 1 and 3, between spectrum 2 and 3). The mean of 
these three correlation coefficients is a measure for the intra-strain reproducibility.
To determine the inter-species similarity, we calculated the mean spectrum of the first 
two isolates belonging to the same species. Then the pair wise correlation coefficients 
between this spectrum and the spectra of the other isolates in the pilot study were cal-
culated. The mean value of these correlation coefficients is a measure for the similarity 
between the first species and all other species present in the study.
Data analysis
All data analysis algorithms were programmed using MATLAB version 7.1 (The Math-
works, Natick, MA, USA) and the PLS toolbox 2.0 (Eigenvector Research Inc., Manson, 
WA, USA). To compare the intra-strain and inter-species similarities an unpaired Student 
t-test was used. A p-value of less than 0.05 was considered significant.
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results
1. Pilot study
Comparison of raman spectroscopy spectra for inactivated and viable 
mycobacteria
For biosafety reasons, the inactivation procedures were validated prior to further ex-
periments. None of the heat-killed or formalin-inactivated Mycobacterium suspensions 
revealed growth in a liquid culture after incubation for 12 weeks.
Raman spectra of a M. kansasii isolate after inactivation by formalin or heating in com-
parison to the procedure without inactivation are shown in Fig.1. No significant changes 
in the Raman spectra were seen after inactivation by heating, whereas formalin inactiva-
tion had a major influence on the Raman spectra.
Furthermore, the effects of formalin inactivation on the mycobacteria proved to be 
a source of large spectral variance (data not shown). Therefore, heat inactivation was 
selected as the method of choice for an evaluation of species identification capabilities of 
Raman spectroscopy.
Classification of heat-killed and viable mycobacteria
A HCA of the spectra obtained from the isolates used in the pilot study is shown in figure 
2. This figure represents spectra obtained from viable as well as heat-killed mycobacteria. 
It was possible to obtain good discrimination between the different species used in the 
400 600 800 1000 1200 1400 1600 1800
Ramanshift (cm-1)
native
heated
formalin
figure 1: Raman spectra of M. kansasii after inactivation with formalin and heating in comparison to 
the procedure without inactivation. Shaded areas indicate spectral region in which significant effects of 
formalin inactivation can be observed.
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pilot study. For all isolates spectra obtained from viable and heat-killed samples show 
low dissimilarities, indicating that the overall classification is not influenced by the pre-
treatment.
reproducibility
In Figure 3 the mean intra-strain similarity between replicate cultures of one isolate and 
the mean inter-species similarity between isolates of different species are given for both 
viable and heat-killed mycobacteria. To obtain a reliable discrimination between the dif-
ferent species, the intra-strain similarity should preferably be as high as possible, whereas 
the inter-species similarity should be much lower.
00.511.522.53
M. chelonae 9802083: viable
M. chelonae 9900212: heat-killed
M. chelonae 9900212: viable
M. chelonae 9802083: heat-killed
M. avium 9900001: viable
M. avium 9900056: viable
M. avium 9900001: heat-killed
M. avium 9900056: heat-killed
M. kansasii 9801608: viable
M. kansasii 9801608: heat-killed
M. malmoense 9801004: viable
M. malmoense 9801544: viable
M. malmoense 9801004: heat-killed
M. malmoense 9801544: heat-killed
M. kansasii 9801635: viable
M. kansasii 9801635: heat-killed
M. gordonae 9702180: viable
M. gordonae 9702180: heat-killed
M. gordonae 9801764: viable
M. gordonae 9801764: heat-killed
M. xenopi 9701302: viable
M. xenopi 9900500: viable
M. xenopi 9900500: heat-killed
R2  dissimilarity (%)
M. xenopi 9701302: heat-killed
figure 2: Dendrogram of hierarchical cluster analysis of Raman spectra of the isolates used in the pilot 
study. Numbers refer to isolates of the collection of the national tuberculosis reference laboratory at the 
National Institute for Public Health and the Environment.
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For all isolates the intra-strain similarity was significantly higher than the inter-species 
similarity with a p-value of 0.011 when only the viable samples were included and a p-
value of 0.0015 for the heat-killed samples.
2. identification study
raman spectra of mycobacteria
Representative Raman spectra for the 8 Mycobacterium species used in the identification 
study are shown in Figure 4. Main differences were found in the intensity of the peaks at 
1150 cm-1 and 1520 cm-1, due to carotenoids. Intense peaks were found for M. gordonae, 
M. xenopi and M. lentiflavum due to pigmentation of these species.
Classification of mycobacteria based on raman spectroscopy
Figure 5 shows the dendrogram resulting from HCA performed on the Raman spectra 
in the identification set. The M. tuberculosis, M. gordonae, M. avium and M. chelonae 
isolates formed separate species-specific clusters. For both M. lentiflavum and M. xenopi 
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figure 3: The average intra-strain and inter-species similarities between spectra obtained from native and 
heat-killed suspensions of 6 Mycobacterium strains. The error bar shows the 95% confidence interval.
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two clusters were found. The spectra of M. malmoense and M. kansasii overlap, but sub 
clusters on species level can be found.
identification study
For species identification the R2 value was calculated for each isolate spectrum with every 
other isolate spectrum in the dataset. Each isolate to be classified is matched to the isolate 
in the dataset with the highest R2 value. The species identity of the isolate with which the 
highest R2 occurred determined the species of the tested isolate. The species identification 
obtained by 16S rRNA gene sequencing was used as the gold standard. This leave-one-out 
approach simulates the situation in a diagnostic setting where a new measurement is 
compared to an existing database.
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figure 4: Representative Raman spectra from the 8 Mycobacterium species used in the identification 
study.
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The overall sensitivity of this model was 95.2% (60 out of 63 measurements, table 2). 
The differentiation between M. tuberculosis and NTM was correct for all strains. Within 
the group of NTM isolates three strains were misidentified: M. xenopi misidentified as 
M. malmoense; M. kansasii as M. lentiflavum, and M. gordonae as M. lentiflavum.
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figure 5: Dendrogram resulting from hierarchical cluster analysis of Raman spectra of the isolates used in 
the identification.
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DisCussion
Our Raman measurements indicate that efficient discrimination between Mycobacterium 
species can be made. Isolates belonging to a single species were grouped correctly into 
different clusters, corresponding to M. tuberculosis, the most relevant clinical species of 
NTM and M. lentiflavum. Overall, correct species identification was achieved in 95.2% of 
the samples within three hours of a positive signal of the automated culture system. The 
differentiation between M. tuberculosis and NTM was 100% accurate. As the treatment 
of NTM disease differs significantly from the treatment of TB, both the rapidity and the 
accuracy of this new assay are important assets.
The spectra of the strains inactivated by heat-killing showed minimal differences when 
compared to the spectra of viable mycobacteria. Therefore, identification of mycobacteria 
was possible without biosafety III precautions during Raman measurements.
For 60 out of the 63 Mycobacterium strains analyzed, Raman spectroscopic identification 
corresponded to the molecular identification test. None of the three misidentifications 
can currently be explained. We suggest that although the DNA identification methods 
grouped these bacteria within single species, there still are considerable phenotypic dif-
ferences between strains in a single species. More detailed DNA sequencing of bacteria 
sub-grouped by Raman may confirm this hypothesis. Further Raman studies with Myco-
bacterium isolates may reveal the accuracy of the method in discriminating more species. 
An extended spectral database containing more spectra of other M. tuberculosis complex 
and NTM strains with a larger number of isolates per species has to be established, as was 
already performed for other microorganisms (7,10,11). In addition, in our study only 
seven M. tuberculosis strains were analysed. The Raman spectroscopy correctly classified 
all strains, but larger studies will be necessary to confirm and extend these results.
table 2: Classification of Mycobacterium species by 16S rRNA sequencing and Raman spectroscopy.
16S rRNA 
sequencing
Raman identification
M. tuber-
culosis
M. avium M. che-
lonae
M. gor-
donae
M. kansasii M. mal-
moense
M. xenopi M. lentifla-
vum
Total
M. tuberculosis 7 (100%)  7
M. avium 9 (100%)  9
M. chelonae 4 (100%)  4
M. gordonae 4 (80%)  1 (20%)  5
M. kansasii 8 (88.9%)
 1 
(11.1%)  9
M. malmoense 10 (100%) 10
M. xenopi  1 (16.7%) 5 (83.3%)  6
M. lentiflavum 13 (100%) 13
Total 7 9 4 4 8 11 5 15 63
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Fourier-Transform Infrared microspectroscopy was successfully used recently to differ-
entiate NTM at the species level (14). To our knowledge, however, our data prove for 
the first time that Raman spectroscopy can be used for identification of mycobacteria, 
including M. tuberculosis complex. Apart from enabling rapid identification, vibrational 
spectroscopic techniques require virtually no sample handling or consumables and are, 
therefore, very cost-effective. This is in sharp contrast to other rapid identification tech-
niques. Although regarded as the gold standard, 16S rRNA sequencing is not appropriate 
for routine analysis, due to its complexity and high costs.
We conclude that Raman spectroscopy holds much promise for a rapid, accurate, and easy-
to-use alternative for the identification of clinically relevant Mycobacterium species.
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ABstrACt
Ziehl-Neelsen (ZN) staining for the diagnosis of tuberculosis (TB) is time-consuming and 
operator dependent and lacks sensitivity. A new method is urgently needed. We investi-
gated the potential of an electronic nose (EN) (gas sensor array) comprising 14 conduct-
ing polymers to detect different Mycobacterium spp. and Pseudomonas aeruginosa in the 
headspaces of cultures, spiked sputa, and sputum samples from 330 culture-proven and 
human immunodeficiency virus-tested TB and non-TB patients. The data were analyzed 
using principal-component analysis, discriminant function analysis, and artificial neu-
ral networks. The EN differentiated between different Mycobacterium spp. and between 
mycobacteria and other lung pathogens both in culture and in spiked sputum samples. 
The detection limit in culture and spiked sputa was found to be 1 x 104 mycobacteria 
ml–1. After training of the neural network with 196 sputum samples, 134 samples (55 
M. tuberculosis culture-positive samples and 79 culture-negative samples) were used to 
challenge the model. The EN correctly predicted 89% of culture-positive patients; the six 
false negatives were the four ZN-negative and two ZN-positive patients. The specificity 
and sensitivity of the described method were 91% and 89%, respectively, compared to 
culture. At present, the reasons for the false negatives and false positives are unknown, 
but they could well be due to the nonoptimized system used here. This study has shown 
the ability of an electronic nose to detect M. tuberculosis in clinical specimens and opens 
the way to making this method a rapid and automated system for the early diagnosis of 
respiratory infections.
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introDuCtion
The World Health Organization (WHO) has declared tuberculosis (TB) a global emer-
gency. It is estimated that one-third of the world’s population is infected with Mycobac-
terium tuberculosis. An estimated 8 to 9 million new cases occur each year, with 2 to 3 
million deaths (4). The majority of these new infections and deaths occur in developing 
countries. The human immunodeficiency virus (HIV) epidemic has massively contrib-
uted to the worldwide tuberculosis problem.
The usual method of diagnosing TB in low-income countries is by detection of acid-
fast bacteria in sputum by direct microscopy. When done properly, 60 to 70% of all adults 
with pulmonary TB can be identified using the Ziehl-Neelsen (ZN) staining procedure, 
followed by microscopic examination (11,19). However, in areas of endemicity, labora-
tories are often overloaded with samples for smear examination. Therefore, a new simple 
and rapid diagnostic test should directly replace microscopy with similar specificity and 
sensitivity (19). In the past, research was mainly focused on the development of either 
antibody/antigen detection assays or the development of nucleic acid amplification reac-
tions.
Against this background, we have investigated the potential of a gas sensor array (“elec-
tronic nose” [EN]) to detect M. tuberculosis in culture and sputum. It is well known that 
smell can be used to diagnose diseases, and it has been used by both the Greeks and 
the Chinese since 2,000 BC (12). Electronic nose is the colloquial name for an instru-
ment made up of chemical sensors combined with a pattern recognition system (5). The 
reversible adsorption of volatile organic compounds (VOCs) to the sensor surface leads 
to a change of physical properties (conductivity, resistance, and frequency) of the sensor, 
which is measured. The key function of an EN is to mimic the human olfactory system 
by combining nonspecific gas sensors with a pattern recognition system to analyze and 
characterize complex odors without separation of the mixture into individual compo-
nents. In the EN, the human olfactory receptors have their analogues in chemical sensors 
that produce an electrical signal (similar to nerve cells). Each sensor within the array is 
characterized by partial and overlapping specificities to VOCs. Due to the partial and 
overlapping specificities, a unique response curve is recorded during the measurement 
by each sensor containing the vital information to allow discrimination of the different 
samples. To describe this information, the response curve is described by mathematical 
terms expressed as maximum absorption rate, desorption rate, maximum response (or di-
vergence), and area under the response curve. These mathematical terms are subsequently 
analyzed by pattern recognition software. The pattern recognition software corresponds 
to the cerebral cortex of the brain and is able to classify and memorize odors (1,18).
Electronic noses have been applied mainly in the food industry to characterize the odors 
of beverages (2,17) or olive oil (7). More recently, researchers discovered the potential of 
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electronic noses as a diagnostic tool for the detection of Mycobacterium bovis in badgers 
and cattle (3). A review of medical applications is given elsewhere (15,23).
The aim of this study was to investigate the potential of an electronic nose to detect 
Mycobacterium tuberculosis and other pathogens in both culture and patients’ sputa as a 
first step toward simple breath analysis for the specific, rapid, and noninvasive diagnosis 
of diverse lung infections.
MAteriAls AnD MethoDs
liquid cultures
All bacteria (Mycobacterium tuberculosis, RIVM myc 4514; Mycobacterium avium, RIVM 
myc 3875; Mycobacterium scrofulaceum, RIVM myc 3442; and Pseudomonas aeruginosa, 
AMC 23123) were cultured in Middlebrook 7H9 medium with oleic acid-albumin-dex-
trose-catalase enrichment. The bacteria were incubated at 37°C until an optical density 
(420 nm) of 0.30 (2 x 108 bacteria ml–1) was reached.
sputum samples
The study was approved by the ethics committee of the Academic Medical Center, Am-
sterdam, The Netherlands, and The Saint Francis Hospital in Katete, Zambia. All subjects 
gave written permission for sputum sampling after oral and written information was 
provided.
Sputum samples were collected from 280 patients with suspected TB either from The 
Saint Francis Hospital in Katete, Zambia (n = 80), or from the WHO Sputum Bank (n = 
200) (through the WHO Specimen Bank). In addition, sputum samples were collected at 
the Academic Medical Center, Amsterdam, The Netherlands, from 7 patients with proven 
pneumonia (caused by Streptococcus pneumoniae) and from 50 patients with proven non-
TB (serving as negative controls). All patients were examined by chest X ray, and their 
sputum samples were examined by ZN staining and liquid culture (either by BacT/ALERT 
from bioMérieux, France, or by Bactec MGIT 960 from Becton Dickenson). Culture was 
used as the “gold standard” in this study as both inclusion and exclusion criteria for TB. 
Furthermore, the HIV status and the smoking habits of the suspected TB patients were 
investigated. The collected sputum samples were stored at –70°C until the analysis was 
performed.
spiked sputum samples
A pool of 25 sputum samples (each 1 ml) was made from the above-mentioned non-TB 
patients (n = 50) for spiking purposes. The sputum pool was spiked with various numbers 
of different bacterial isolates, including M. tuberculosis, M. avium, and P. aeruginosa, as 
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well as a mixture (50:50) of M. tuberculosis and P. aeruginosa, which served as a mixed-
infection sample.
sample preparation and headspace analysis
The liquid cultures were cooled to 4°C and allowed to equilibrate for at least 20 min 
to minimize the loss of volatiles during the transfer into smaller-headspace vials. Two 
milliliters of the “cold” culture was transferred into a 5-ml-headspace vial (Macherey and 
Nagel, United Kingdom) and immediately sealed with a silicon/Teflon crimp cap (Jaytee 
Bioscience Ltd., United Kingdom). The headspace was allowed to equilibrate for 45 min 
at 37°C.
The frozen sputum samples were defrosted on ice to minimize the loss of volatiles; 0.5 
ml of “well-mixed” sputum was transferred into a sterile 5-ml-headspace vial, mixed with 
0.5 ml of a 1 M NaCl solution (4°C), and subsequently sealed.
Spiked sputum samples were prepared by mixing 0.5 ml of non-TB sputa (individual 
samples or a pool) with 0.5 ml of “cold and equilibrated” bacterial suspension containing 
1 M NaCl. Negative control samples were prepared by mixing 0.5 ml of individual non-
TB sputum samples with 0.5 ml of a 1 M NaCl solution (4°C). All control samples were 
prepared in 5-ml-headspace vials as described above. All sputum samples were incubated 
at 37°C for 330 min prior to the headspace analysis. Two cycles of freezing and thawing 
had no influence on the results (not shown).
gas-sensing system and headspace sampling
For this study, an electronic nose (Bloodhound BH-114; Bloodhound Sensors, Leeds, Unit-
ed Kingdom) that employed 14 conducting polymers based on polyaniline was used. The 
sensor unit automatically set two calibration points. The first was the baseline, which was 
obtained when activated-carbon-filtered (Carbon Cap 150; Whatman) air was passed over 
the sensor at a flow rate of 4 ml min–1. The second calibration point was a reference point 
obtained from the headspace of a control sample vial containing 9 ml of distilled water.
The interaction of the VOCs with the conducting polymer surface produced a change 
in resistance over time, which was measured and subsequently displayed on a computer 
screen for each sensor. The curve was similar to the classical Langmuir adsorption curve. 
Two sensor parameters were selected to study the sensor response: divergence (maximum 
response) and area under the response curve. The sampling profile was set at 6 seconds of 
absorption and 14 seconds of desorption for the analysis of liquid samples; for the analy-
sis of spiked sputum, we used 7 seconds of absorption and 21 seconds of desorption.
For the analysis of the unknown headspace, the sample vials were connected to the elec-
tronic nose by inserting a needle into the headspaces of the sample vials. The unknown 
headspace was passed over the sensor surface at a flow rate of 20 ml min–1, which was 
automatically set by the sensor unit. Between each pair of measurements, a time delay of 
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2 min was set. The individual samples in each experiment were tested in a randomized, 
blinded fashion.
Data analysis
Principal-component analysis (PCA), discriminant function analysis (DFA), and an ar-
tificial neural network (ANN) were applied to analyze the multivariate data. The sensor 
response was normalized prior to the multivariate data analysis (except for the determi-
nation of the detection limit). To perform these analyses Excel add-in software (XLstat 
version 3.4) was used. Two sensor parameters, namely, the maximum response and the 
area under the response curve (Langmuir adsorption spectrum), were used to perform 
the analysis.
Principal-component analysis is a method aimed at reducing the amount of data when 
there is a correlation present. The idea is to find principal components (PC), which are 
linear combinations of the original variables (sensor responses) describing each speci-
men. In other words, PCA projects the original data matrix from a high-dimensional 
space into a lower-dimensional space (a three-dimensional space or plane) without losing 
essential information (variance). The relationship between samples can be visualized by 
plotting individual principal components against each other (13).
Discriminant function analysis is a supervised classification method aimed at find-
ing a formal decision boundary between classes. The idea is to find linear discriminant 
functions (S1, S2, …, Sn), which are linear combinations of the original variables. The 
classification model (DFA) was built on the first four PC, which normally account for 
over 90% of the variance (information) of the original data matrix. In each case, the DFA 
model was cross-validated as follows. Data from individual samples (culture or sputum) 
were withheld, and a DFA model was built on the remaining data set (training set). The 
data from the withheld samples (testing set) were then inserted into the discriminant 
functions and subsequently assigned to the class for which the centroid had the smallest 
Euclidean distance to the unknown sample. The result could be visualized by plotting the 
individual discriminant functions against each other (13).
Artificial neural networks are attempts to mimic the neurons in the human brain and 
were used here for classification of sputum samples into TB and non-TB. Such networks 
have a number of linked layers of artificial neurons, including input, hidden, and output 
layers. The ANN is trained using a large training set of sputum samples from suspected 
TB patients. In this study, a back propagation network with a sigmoid transfer function 
was applied. During the training period, the weights connecting individual neurons were 
adjusted so that the error between output signal and target signal was minimized (13). 
The performance of the ANN was evaluated using the test set of sputum samples. Only 
the sputum samples from the suspected TB patients (n = 280) and from the proven non-
TB cases (n = 50) were included in the ANN analysis.
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results
specificity of the en
The “smells” of three Mycobacterium sp. cultures (M. tuberculosis, M. avium, and M. scrof-
ulaceum) and one Pseudomonas aeruginosa culture were analyzed and compared to the 
“odor” of blank medium. The raw EN data were analyzed by PCA (data not shown), fol-
lowed by DFA. The DFA model was built on the first four principal components. Figure 1 
shows the results of the DFA analysis. It was possible to distinguish between the different 
bacterial classes using the first two discriminant functions (S1 and S2). The three differ-
ent Mycobacterium spp. were grouped closely together but still allowed discrimination 
(Fig. 1, top). The DFA model was validated by the analysis of 15 “unknown” samples. All 
unknown samples were correctly classified as either one of the three Mycobacterium spp., 
P. aeruginosa, or blank medium.
Similarly, when the negative pooled sputum samples were spiked with M. tuberculosis, 
M. avium, P. aeruginosa, and a mixture of M. tuberculosis and P. aeruginosa (at a final 
concentration of 1 x 108 bacteria ml–1) and analyzed, it was possible to distinguish be-
tween “unspiked” sputum and “spiked” sputum samples (Fig. 1, bottom). Within the 
spiked sputum samples, a difference in smell was observable for the different bacterial 
classes. The DFA model was validated by the analysis of 10 unknown samples. All un-
known samples were correctly identified as unspiked sputum or spiked sputum. Within 
the spiked sputum samples, all unknown samples were correctly assigned to one of the 
four “subclusters” representing the different bacterial classes (Fig. 1, bottom).
Analytical sensitivity of the en
Six different concentrated M. tuberculosis suspensions (1 x 103 mycobacteria ml–1 to 1 x 
108 mycobacteria ml–1) were analyzed and compared to blank medium. The raw EN data 
were analyzed by PCA (data not shown), followed by DFA. The results of the DFA analy-
sis are shown in Fig. 2, top. The DFA model was validated by the analysis of 14 “unknown” 
samples. Two out of 14 unknown samples were incorrectly classified as blank medium 
(Fig. 2, top). Both incorrectly classified samples belonged to the group containing 1 x 103 
mycobacteria ml–1. All other unknown samples were correctly identified. Therefore, the 
detection limit was determined to be as low as 1 x 104 mycobacteria ml–1.
The detection limit for M. tuberculosis in spiked pooled sputum samples was also de-
termined. For this purpose, a sputum pool was divided into two parts. One part was 
spiked with an M. tuberculosis suspension containing 1 x 104 mycobacteria ml–1. The raw 
EN data were analyzed by PCA (data not shown), followed by DFA. The bottom panel 
of Fig. 2 shows that it was possible to distinguish between spiked and unspiked samples. 
The DFA model was validated by the analysis of 12 “unknown” samples. All “unknown” 
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 figure 1: (Top) DFA analysis of liquid cultures of M. tuberculosis (12 samples), M. avium (12 samples), 
M. scrofulaceum (12 samples), and P. aeruginosa (12 samples) and blank medium (12 samples). Cross-
validation: 15 samples (3 from each group) were withheld from building the DFA model but were 
subsequently assigned correctly once the model was built (encircled symbols). S1 and S2, discriminant 
functions 1 and 2. The numbers in parentheses indicate the percentages of the data matrix described by 
the relevant functions. The circles were added by the authors.
(Bottom) DFA analysis of sputum samples spiked with M. tuberculosis (12 samples), M. avium (12 samples), 
P. aeruginosa (12 samples), mixed infection (12 samples), and blank sputum (12 samples). Cross-validation: 
10 samples (2 from each group) were withheld from building the DFA model but were subsequently 
assigned correctly once the model was built (encircled symbols).
77Clinical application of electronic-nose technology to early detection of Mycobacterium tuberculosis
 
-1
-0.5
0
0.5
1
1.5
-1.5 -1 -0.5 0 0.5 1 1.5 2 
S1 (95%)
S2
 (3
%)
 
10^3 CFU/ml 10^4 CFU/ml 10^5 CFU/ml 10^6 CFU/ml 10^7 CFU/ml 10^8 CFU/ml Blank 
Wrongly classified
 
-1.5
-1
-0.5
0
0.5
1
1.5
2
-2.5 -2 -1.5 -1 -0.5 0 0.5 1 1.5 2
S1 (97 %)
Blank Spiked sputum Sputum
  
figure 2: (Top) Determination of the detection limit of the electronic nose for M. tuberculosis in liquid 
culture. Six different concentrations ranging from 1 x 103 to 1 x 108 mycobacteria ml–1 were analyzed 
(seven samples for each concentration and seven blanks). Cross-validation: 14 samples (2 samples 
from each group) were withheld from building the DFA model. Samples containing more than 1 x 104 
mycobacteria ml–1 were correctly assigned (encircled symbols). In contrast, blank medium and samples 
containing 1 x 103 mycobacteria ml–1 could not be distinguished from each other.
(Bottom) Determination of the detection limit of the electronic nose for M. tuberculosis in spiked sputum. 
The sputum was spiked with 1 x 104 mycobacteria ml–1. Twenty replicates were analyzed for each group. 
Cross-validation: 12 samples (4 samples from each group) were withheld from building the DFA model 
but were subsequently assigned correctly once the model was built (encircled symbols).
78 Chapter 4
samples were correctly classified (Fig. 2, bottom). The variability within the unspiked 
samples was higher than within the spiked samples.
Performance of the en using clinical samples
The PCA analysis of 50 positive control samples (i.e., the individual non-TB sputum 
samples spiked with 108 M. tuberculosis cells ml–1), 50 negative non-TB sputum samples 
from The Netherlands, and 280 clinical samples from Africa (Table 1) is shown in Fig. 
3. It was possible to obtain good discrimination between TB and non-TB samples. As 
shown in Fig. 1, TB-negative samples were found on the left-hand side, whereas TB posi-
tive samples were on the right-hand side. Nevertheless, no complete separation could be 
obtained, as indicated by the overlapping circles in Fig. 3. In both groups (TB positive and 
TB negative), a subcluster could be identified. These subclusters contained the samples 
of smoking patients. However, not all smokers were present in this subcluster (89% were 
present). Patients suffering from pneumonia formed a separate cluster.
After training the neural network with 196 of the original samples (133 TB and 63 non-
TB samples), the remaining 134 samples were used to validate the model. Among the 134 
samples were 55 culture-confirmed TB samples, of which 51 were ZN positive and 4 were 
ZN negative. The results from the ANN are summarized in Table 2. The neural network 
was able to predict 49 TB-positive patients out of 55 correctly. Six suspected TB culture-
positive samples gave a false-negative result. Among these six false negatives were four 
ZN-negative and two ZN-positive patients. Three of the four ZN-negative false negatives 
were HIV positive, and one was a smoker. Among the ZN-positive false negatives was one 
HIV-positive patient, who was also a smoker.
The neural network was also able to predict 72 suspected TB-negative patients correctly. 
Seven TB-negative patients gave a false-positive result. One false-positive patient was 
HIV positive and a smoker.
table 1: Details of patients that provided clinical samples, showing TB status (culture), sex, HIV status, and 
smoking habits.
Status Total no. % Males (no.) % HIV+ (no.) % Smokers
TB+ 188 67.0 (126) 53.7 (101) 31.4 (59)
TB- 142 59.2 (84) 29.6 (42)  9.2 (13)
Total 330 63.6 (210) 43.3 (143) 21.8 (72)
table 2: Performance of the electronic-nose-neural-network system in comparison to culture.
Status No. (%) with culture
confirmed TB
No. (%) culture
TB negative
Total
EN positive 49 (89.9)  7 (8.9)  56
EN negative  6 (10.9) 72 (91.1)  78
Total 55 (100) 79 (100) 134
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The sensitivity for the detection of culture-proven TB was 89% (95% confidence inter-
val [CI], 80 to 97%), the specificity was 91% (95% CI, 85 to 97%), and the positive and 
negative predictive values were 88% (95% CI, 78 to 96%) and 92% (95% CI, 86 to 98%), 
respectively.
DisCussion
Current global TB control depends on the diagnosis of cases, followed by adequate treat-
ment. The available laboratory methods for the detection of M. tuberculosis do not fully 
meet the need in environments with high TB and HIV prevalences (19).
This study showed that volatile detection through electronic-nose technology is able to 
identify M. tuberculosis in both cultures and sputum samples. It has long been established 
that smell can be used to diagnose diseases, such as diabetes and uremia (10,20). Pavlou 
and Turner (15) and Pavlou et al. (14,16) were among the first to apply electronic noses 
in medical diagnostics. They showed that different bacteria, such as Helicobacter pylori, 
E. coli, and M. tuberculosis, generate a unique “smell” and can therefore be differenti-
ated from each other, allowing a diagnosis. Recently, the same EN used in this study was 
shown to be able to diagnose M. bovis infection in badgers and cattle (3).
Electronic-nose technology offers certain advantages, such as a low detection limit 
(5 to 0.1 ppm) (21), cost- and time effectiveness, robustness, simplicity, and operator 
 
 
-8.0
-6.0
-4.0
-2.0
0.0
2.0
4.0
6.0
-15.0 -10.0 -5.0 0.0 5.0 10.0 15.0 
PC 1 (83%)
PC 2 (9%) 
Pneumonia 
Smokers 
Pos. Control: 
spiked sputum 1 x 10 
mycobacteria ml 
TB positive 
TB 
negative 
Smokers 
Neg. control
8 
figure 3: PCA plot showing the analysis of negative (Neg.) control samples (50 samples), positive (Pos.) 
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negative; 188 samples, TB positive). PC 1 and PC 2 are the first two principal components; the numbers 
in parentheses represent the percentages of information described by each principal component (circles 
were added by the authors).
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independence, in contrast to molecular or immunologically based assays. Therefore, we 
investigated the ability of an electronic nose to detect Mycobacterium spp. and other lung 
pathogens in culture and sputum. In this study, we showed that Mycobacterium spp. and 
Pseudomonas aeruginosa emit characteristic volatiles, allowing discrimination between 
the different bacterial classes in both culture and sputum (Fig. 1). The intragroup (class) 
variability is greater in sputum than in culture. The reasons for this observation are not 
clear. The volatility of molecules is influenced by parameters such as sample viscosity, 
equilibrium temperature, and concentration (22). Since the incubation parameters for 
liquid and sputum samples were similar, we assume that the higher viscosity, the het-
erogeneity, and/or a stronger background “smell” of sputum might be responsible for 
the variability. As shown in Fig. 1, bottom, and 2, bottom, by adding M. tuberculosis to 
sputum, an additional “odor” was introduced into the sample headspace, leading to a 
reduced intragroup variability. This indicates that mycobacteria release enough volatiles 
into the headspace, even in a complex matrix (sputum), to allow a diagnosis at low con-
centrations (1 x 104 mycobacteria ml–1). This result is of extreme importance for clinical 
diagnosis, where sputum is the usual source for TB detection.
Electronic noses show a linear relationship between sensor response and concentra-
tion (8). This concentration dependency was exploited here to determine the detection 
limit (Fig. 2). This relationship might also reveal relevant clinical information. For the 
treatment itself, it is not important how many bacteria are present in sputum, but the 
number of bacteria present greatly influences the infectiousness of patients. This opens 
the possibility to predict not only the presence of TB, but also the risk for patients to 
transmit the disease.
The sensitivity of the ZN stain compared to culture under field conditions is at most 50 
to 60% (19). With the method presented, we achieved a specificity of 91% and a sensitivity 
of 89% compared to culture (Table 2). The electronic nose was unable to detect four ZN-
negative but culture-positive specimens (false negatives). The bacterial loads in these four 
specimens were most likely below the detection limit of the electronic nose under the 
current setup, but larger numbers of ZN-negative but culture-positive specimens need to 
be tested. The detection limit of the electronic nose for M. tuberculosis in spiked sputum 
was 104 mycobacteria ml–1 (Fig. 2, top). However, the two remaining false-negative speci-
mens had a positive ZN stain (1+) and should therefore contain enough mycobacteria to 
cause a sufficient sensor response. At present, we do not know the reasons for either the 
false negatives or false positives. They could well be due to the nonoptimized system used 
here or to sample degradation during storage.
Clinical specimens are more diverse than spiked samples. It is assumed that the viscos-
ity, the background smell, and especially, the heterogeneity of sputa influence the out-
come of the analysis. Interestingly, smoking itself did not affect the analysis in terms of 
diagnosing TB. However, not all smokers were grouped in the subclusters shown in Fig. 
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3. The individual smoking habits (number of cigarettes per day and last cigarette before 
sample taking) could not be established. We assume that certain smoke ingredients give 
rise to a slightly different sensor response, allowing separation.
Seven cases of pneumonia were among the clinical specimens. As shown in Fig. 3, they 
formed a separate cluster. This indicates that the causative agent (in this case, S. pneumo-
niae) for pneumonia generates a different volatile profile (smell) than mycobacteria. This 
is of clinical importance, showing the potential to differentiate between TB cases and 
cases of other respiratory diseases.
To date, it is unknown which volatile compounds are responsible for the sensor re-
sponse. We assume that the response is caused by the combined effects of (i) microbial 
metabolites and (ii) volatile cellular compounds. In the past, many research groups tried 
to identify volatile substances emitted from microorganism using gas chromatography 
or gas chromatography-mass spectroscopy. Each Mycobacterium species synthesizes a 
unique set of mycolic acids, among other substances, which might allow discrimination 
between different Mycobacterium species (Fig. 1) (9). In contrast, Pseudomonas aerugi-
nosa emits sulfur compounds and esters (6).
The described method is not yet fully optimized for “field” application. Nevertheless, it 
potentially fulfils all requirements for a new diagnostic tool for TB (19), including robust-
ness, simplicity, sensitivity, and cost-effectiveness. Among many advantages are the simple 
sample preparation and its amenability to automation. Together with an appropriate clas-
sification model, this method has the potential to become a rapid and automated system 
for the early diagnosis of respiratory diseases through sputum or even breath analysis. It 
might also be possible to improve or modify currently available sensors toward specific 
M. tuberculosis markers, which would simplify the optimization of such a system.
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ABstrACt
In Africa, the diagnosis of tuberculosis (TB) is almost invariably based on the microscopic 
examination of Ziehl-Neelsen-stained clinical material. However, not only Mycobacte-
rium tuberculosis, but also non-tuberculous mycobacteria (NTM) yield positive results in 
the microscopic detection of acid-fast bacilli (AFB). Furthermore, a significant part of the 
patients, especially HIV-positives, may represent AFB-negative, albeit culture-positive, 
mycobacteriosis.
In Sesheke, Zambia, 64 (both HIV positive and negative) patients, who were chronically 
ill for more than two weeks, were included in a study on the etiology of tuberculosis-like 
disease using modern culture and identification methods. Thirty out of 64 (47%) patients 
yielded positive Mycobacterium cultures that were identified as M. tuberculosis (8 times), 
M. szulgai (7), M. avium-intracellulare (3), M. simiae (1) and M. terrae (1). Ten isolates 
were not suitable for identification due to contamination or re-culture problems. Twelve 
of the 30 (43%) culture-positive patients were also positive in microscopic examination, 
including four patients with NTM isolates. Seven of the 22 NTM isolates belonged to 
M. szulgai. The patients with M. szulgai- positive sputum manifested symptoms extremely 
similar to tuberculosis caused by M. tuberculosis. DNA fingerprinting analysis revealed 
four different patterns among the seven M. szulgai isolates, excluding the possibility of a 
common source of infection or a laboratory cross-contamination. Three out of five pa-
tients with M. szulgai infection responded to anti-tuberculosis treatment.
The contribution of NTM, and especially of M. szulgai, to tuberculosis-like diseases in 
both HIV-positive and negative patients in Africa may be underestimated.
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introDuCtion
Tuberculosis remains an important global public health problem that has been exacer-
bated by the HIV epidemic. In the year 2000 an estimated number of 8-9 million new 
tuberculosis (TB) cases occurred. Worldwide, an estimated 11% of new adult tuberculosis 
was co-infected by HIV, while in Sub-Saharan Africa about 38% of new TB cases were 
attributable to HIV(1).
The clinical presentation of tuberculosis in HIV-infected individuals depends on the se-
verity of suppression of immunological functions. In the early stages of HIV infection, it 
resembles that of HIV-negative individuals with more pulmonary involvement and local-
ized lesions. The clinical presentation tends to be more generalized with the progressive 
suppression of immunological functions. In many Third World countries the diagnosis 
of tuberculosis is based on clinical assessment, a sputum smear, and radiological features. 
Symptoms are often non-specific in HIV-positive patients and a sputum smear is positive 
in only 50-80% of individuals with culture-confirmed cases of pulmonary tuberculosis, 
resulting in the delay or misdiagnosis of tuberculosis in these countries (2).
Furthermore, in developed countries it has been reported that HIV-infected patients 
are susceptible to infections by non-tuberculous mycobacteria (NTM), such as Myco-
bacterium avium complex (3). The isolation of these bacteria generally raises questions 
concerning their clinical significance and the criteria described in a Statement by the 
American Thoracic Society (ATS) are widely used to guide the diagnostic process (4,5). 
The incidence of disseminated Mycobacterium avium complex infections in HIV patients 
in the Western world has decreased significantly with the introduction of more potent 
anti-HIV treatments. In Africa, HIV treatment is not yet widely available. However, the 
isolation of NTM is rarely reported, although the prevalence of HIV infection is high in 
many areas. This may be due to a lack of representative studies and/or more generally to 
the absence of suitable diagnostic tools.
In Yeta District Hospital in Sesheke, Zambia, during the late 1990s an increasing number 
of HIV-positive patients, clinically suspected of pulmonary tuberculosis, had a negative 
sputum smear but reacted positively to tuberculosis treatment. This suggested an increas-
ing prevalence of sputum smear-negative tuberculosis. On the other hand, NTM can 
cause a broad spectrum of diseases, often mimicking tuberculosis, and the contribution 
of NTM to tuberculosis-like diseases in Zambia is unknown.
The aim of this pilot study was to evaluate the role of NTM in the development of tu-
berculosis-like disease in Africa and the confusion that this may cause in the diagnosis 
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of tuberculosis by microscopy. This is especially relevant in the light of the increasing 
prevalence of HIV.
MAteriAls AnD MethoDs
All chronically ill patients admitted to Yeta District Hospital in Sesheke, Zambia, who did 
not respond to anti-malaria treatment or routine antibiotics in the period May to Septem-
ber 2000 were included in this study. Patients were considered chronically ill if they were 
suffering from chronic complaints for more than two weeks. Signs and symptoms in any 
part of the body were considered because tuberculosis can affect all parts of the body. In 
total 64 patients were included who produced sputum for a smear and culture. Most of 
the patients included complained about coughing and/or chest pain (75%) and general 
malaise (19%). The remaining 6% of the patients had lymphadenopathy or abdominal 
complaints.
Informed written consent to participate in the study was obtained from all patients.
The medical officer in charge documented the medical history and a general physical 
examination was performed. A daily follow-up of signs and symptoms was done.
A sputum specimen was cultured for mycobacteria. The sputum was divided into two 
equal parts. One half was decontaminated using 6% sulphuric acid and cultured on Lö-
wenstein-Jensen (LJ) medium and the other half was stored at −20°C in Zambia. In The 
Netherlands the latter half was decontaminated with N-acetyl-l-cysteine (NALC)-NaOH 
and cultured in Mycobacteria Growth Indicator tubes (Becton Dickinson Microbiology 
Systems, Cockeysville, Md.) (6). Serological testing for HIV was performed using a par-
ticle agglutination test (Serodia HIV1/2, Fujirebio Inc., Tokyo, Japan) and the AxSYM 
HIV Ag-Ab Combination Assay (Abbott GmbH Diagnostika, Wiebaden-Delkenheim, 
Germany). Mycobacterial isolates were identified by the Accuprobe culture confirmation 
test for the M. tuberculosis complex (Accuprobe, bioMérieux, Marcy l’Etoile, France) or 
by 16S rRNA gene sequencing (7).
Patients suspected of pulmonary tuberculosis were treated with anti-tuberculosis drugs 
according to the Zambian government policy. The treatment protocol for newly diag-
nosed patients who had smear positive sputum tests for AFB was two months of isoniazid, 
rifampicin, pyrazinamide and ethambutol and six months of isoniazid and ethambutol 
(2HRZE/6EH). In cases of smear negative results the same protocol was applied without 
pyrazinamide in the first two months (2HRE/6EH).
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Drug susceptibility of the mycobacterial isolates was determined using the minimal in-
hibition concentration method (MIC) (8). Series of dilutions of anti-tuberculosis drugs 
were added to melted 7H10 agar and poured into 25-well plates. Ten µl of suspension 
with a turbidity of McFarland 1 were inoculated into each well. As a control also 10 µl of 
a 1:100 diluted suspension was inoculated on 7H10 without additives to determine a 1% 
cut-off. The growth on these wells was compared after 5, 12, and 19 days of incubation. 
The MIC is the concentration at which more than 99% of the growth is inhibited.
Typing of all M. tuberculosis isolates was performed by IS6110 RFLP analysis and the 
seven M. szulgai isolates were subjected to random amplified polymorphic DNA (RAPD) 
analysis using rapd 1, ERIC2, 1749, 1750 and 1752 as primers (9,10). Apart from the 
seven Zambian M. szulgai isolates, two independent M. szulgai isolates from The Nether-
lands were included as controls.
results
The study population consisted of 64 Zambian patients, of which 51 (79%) were HIV-
positive. Thirty-five female and 20 male adults over 15 years of age and nine children 
were included.
Thirty out of 64 (47%) patients yielded positive Mycobacterium cultures of their sputum 
(see Table 1). M. tuberculosis was isolated from eight patients, of whom four patients were 
HIV-positive, and NTM were isolated from 22 patients, of whom 16 were HIV-positive 
and two had an unknown HIV-status. The NTM cultures were identified as M. szulgai (7), 
M. avium-intracellulare (3), M. simiae (1) and M. terrae (1). Ten NTM isolates were not 
suitable for identification due to contamination or failure to re-culture.
The Ziehl-Neelsen smears of sputum were positive in 12 of the 30 culture-positive pa-
tients (40%), of which seven (58%) were HIV-positive. In four patients with a positive 
smear NTM were isolated and in eight patients M. tuberculosis was identified. All smears 
table 1: Positive Mycobacterium cultures.
Ziehl-Neelsen (ZN) Culture result Total
M. tuberculosis NTM
ZN+ 8 (4 HIV+) 4 (3 HIV+) 12
ZN- 0 18 (13 HIV+ and 2 HIV?a) 18
Total 8 22 30
aHIV?: Unknown HIV-status.
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for the patients with a positive M. tuberculosis culture were positive, and of these eight, 
four (50%) were HIV-positive. Of the four patients with a positive smear and NTM in the 
culture, three were HIV-positive.
The NTM isolates could be identified of 12 patients, including nine adults and three 
children.
Nine of these 12 patients were female. The median age of the adult patients was 39.5 
years. The most frequent symptoms were coughing and/or chest pain (10 patients); 
abdominal discomfort with diarrhea and a subcutaneous abscess on the leg were each 
presented by one patient. The four patients with a positive smear and NTM in the culture 
had all respiratory complaints.
Anti-tuberculosis treatment was provided to seven of 12 NTM positive patients and 
comprised isoniazid, rifampicin, pyrazinamide and ethambutol according to the World 
Health Organization’s recommended first-line regimens for tuberculosis treatment (11).
The anti-tuberculosis treatment was started by the physician on the basis of clinical 
symptoms without knowing the culture results. All 12 patients did not improve on two 
courses of empiric antibiotics. Four patients responded clinically in the first 3 months 
and three patients did not respond to the anti-tuberculosis treatment. From three of the 
five patients who did not receive anti-tuberculosis treatment during the study period 
M. avium-intracellulare was isolated from their sputum. The two other patients who did 
not receive anti-tuberculosis treatment had M. szulgai in the sputum culture and were 
HIV-negative.
From seven admitted patients, M. szulgai was cultured from the sputum (see Table 2). 
Six patients complained of a productive cough and/or chest pain without night sweats 
and one patient had an abscess on the leg without pulmonary problems. Two patients 
were HIV-negative; one with respiratory complaints and the other with an abscess on 
her leg. The median duration of complaints was one month. Physical examination was 
consistent with infiltration in three out of the six patients with pulmonary complaints. 
The sputum smear was positive in two patients with respiratory complaints, one of whom 
was HIV-positive and one was negative. All patients were first treated with two courses 
of routine empiric antibiotics without result, where after anti-tuberculosis treatment was 
prescribed to five patients. Three of the five patients, who were HIV-positive, responded 
well. The other two patients, who were HIV-negative, showed no improvement on the 
anti-tuberculosis treatment.
The drug susceptibility of the identified NTM was also determined. The seven M. szul-
gai strains had reduced sensitivity to isoniazid (MIC 11 µg mL-1) and were sensitive to 
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rifampicin, ethambutol, streptomycin, pyrazinamide, protionamide, amikacin, cipro-
floxacin, clofazimine and claritromycin.
To examine the possibility of cross-contamination or a common source of infection, all 
M. tuberculosis and M. szulgai isolates were typed by IS6110 RFLP- and by RAPD typing, 
respectively. The isolated M. tuberculosis strains all showed unique RFLP patterns. RAPD 
on the seven M. szulgai isolates was repeated several times, using two different primer 
sets. Four distinct patterns were found with both primer sets (see Figure 1). The RAPD 
patterns that were found among M. szulgai isolates from Zambia were different from the 
RAPD patterns of strains isolated in the Netherlands (not in Figure 1).
DisCussion
Since the early 1970s, M. szulgai has been recognized as a cause of serious infections 
and cases have been reported in several parts of the world. However, Africa is the only 
continent from which no M. szulgai isolation has been described so far (12,13). In this 
study, 30 out of 64 (47%) patients yielded positive Mycobacterium cultures. These 30 
Mycobacterium cultures were identified in eight cases as M. tuberculosis (27%) and in 
22 cases as NTM (73%). Of the 12 NTM isolates suitable for identification, seven were 
identified as M. szulgai. As far as it is known, these are the first documented cases of 
M. szulgai infection in Africa.
table 2: NTM isolated from sputum in Zambian patients.
Case Isolate
Male /
Female
Age HIV Complaintsa
Durationb
(wks)
ZNc
Two courses of 
antibiotics
Anti-tuberculosis 
treatment
1 M. szulgai female 38 pos resp 4 pos no improvement improvement
2 M. szulgai male 4 neg resp 4 pos no improvement no improvement
3 M. szulgai male 13 pos resp 156 neg no improvement improvement
4 M. szulgai female 22 pos resp 4 neg no improvement no anti-tuberculosis 
treatment during 
study
5 M. szulgai female 29 pos resp 2 neg no improvement improvement
6 M. szulgai female 43 pos resp 8 neg no improvement no anti-tuberculosis 
treatment during 
study
7 M. szulgai female 43 neg leg abscess 20 neg no improvement no improvement
aComplaints = reason for visiting the hospital. Resp = complaints/symptoms of the tractus respiratorius.
bDuration = duration of complaints at the time of visiting a hospital and being included in study.
cZN = Ziehl-Neelsen microscopy of sputum.
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Figure 1: RAPD analysis of Mycobacterium szulgai strains. 
 
 
figure 1: RAPD analysis of Mycobacterium szulgai strains.
Figure 1A shows the RAPD fingerprints generated using the primer RAPD1 (5’-ggttgggtgagaattgcacg), 
figure 1B applying primer ERIC2 (5’-aagtaagtgactggggtgagcg), figure 1C primer 1749 (5’-tgccgggtgg), 
figure 1D primer 1750 (5’-gcgattgggg) and figure 1E primer 1752 (5’-gccgaaccgg).
The M indicates the lane with a molecular marker (λ-DNA cleaved with HindIII). Lane 0 represents a control 
reaction without DNA template. Lanes 1-6 show the RAPD patterns of 6 different M. szulgai isolates. Four 
different RAPD genotypes, marked I-IV, were identified among the 6 isolates.
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Similar to other mycobacteria, M. szulgai is associated with a wide spectrum of diseases. 
The reported cases of human infection caused by M. szulgai revealed that pulmonary 
disease, mimicking tuberculosis, was the commonest type of infection caused by this 
organism (12,13). Nevertheless, skin infection (14,15), olecranon bursitis (12), septic ar-
thritis (16), osteomyelitis (17,18), tenosynovitis (19), cervical adenitis (12), and dissemi-
nated infections (14,20) have also been recorded. Most infections have been described 
in patients with chronic obstructive pulmonary disease (COPD) and healed tuberculosis 
(13,21,22).
Furthermore, M. szulgai is one of the most rarely isolated, known mycobacterial patho-
gens. Although M. szulgai is also seen as an environmental mycobacteria, recovery from 
the environment is exceptional. There are a limited number of reports on isolation of 
M. szulgai from a snail, tropical fish, aquarium water and swimming pool water. (21)(13). 
Most literature on this Mycobacterium suggests that it is an unlikely laboratory contami-
nant; it is unlikely to act as a commensal and should be considered clinically significant 
when isolated (22).
In this study, six of the seven patients from whom M. szulgai was isolated showed pulmo-
nary disease indistinguishable from that caused by M. tuberculosis. Physical examination 
was consistent with infiltration of the lung in three of the six patients. Unfortunately, no 
chest X-ray was available. From these seven patients one sputum was cultured and the 
Ziehl-Neelsen was positive in two cases. Five of the seven patients were HIV-positive. No 
improvement was achieved after two routine empiric antibiotic courses in all patients. In 
contrast, three out of five patients with a M. szulgai infection recovered on anti-tuber-
culosis treatment. An explanation could be that in at least a part of these patients with 
chronic respiratory complaints (cases1, 3 and 5) their lung disease was associated with the 
presence of M. szulgai. However, not all the conditions described in this study completely 
fulfil the ATS criteria regarding NTM pulmonary disease. The diagnosis ‘pulmonary 
disease’ due to NTM instead of colonization according to the ATS is based on a combina-
tion of clinical and radiological observation, exceeding all bacteriological criteria. In the 
African setting it was not possible to perform a bronchial wash. All possible efforts were 
made to prevent laboratory cross-contamination and therefore a single sputum from each 
patient was cultured. The equipment for chest X-rays was unfortunately out of order for 
some time.
In this study the cumulative results of the cultures on Löwenstein-Jensen medium and 
the Mycobacteria Growth Indicator tubes were provided. Therefore, the separate results 
of the two culture methods and the contamination rates could not be deduced. Moreover, 
the number of colonies on the LJ tubes cultured in Zambia were not reported. In fact, a 
single colony on the LJ tube could have indicated colonization. Therefore, the distinction 
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between colonization and infection or disease could not be deduced from the culture re-
sults. In addition, the respective patients could also have represented culture-negative TB 
cases, as the sputum was only subjected to culture and not tested by molecular methods 
for the presence of M. tuberculosis. However, the performance of the nucleic acid am-
plification (NAA) tetst is in general good in clinical respiratory specimens that are AFB 
smear-positive but less in specimens that contain fewer organisms or are AFB-negative. 
The NAA-test would in a part of the cases be better in comparison to culture to detect a 
mixture of NTM and M. tuberculosis.
Although M. szulgai is rarely recovered from the environment, contamination with NTM 
should be considered in all cases of suspected nosocomial infection due to NTM and 
careful surveillance must be applied to identify possible outbreaks. Many species of non-
tuberculous mycobacteria, such as Mycobacterium gordonae, M. xenopi, M. kansasii, and 
M. abscessus, have been reported to cause pseudo-infection (23-26). The isolates causing 
contamination have been traced to a variety of sources, such as PANTA PLUS (Becton 
Dickinson Microbiology Systems, Cockeysville, Md.), the hospital water and ice supplies, 
bronchoscopes, and a variety of laboratory handling errors (24-26). Recently, a M. szulgai 
pseudo-infection originating from hospital water has also been described (27). In this 
study the possibility of a pseudo-infection and a laboratory cross-contamination was 
considered highly unlikely because DNA fingerprinting analysis revealed four different 
patterns among the seven M. szulgai isolates.
In contrast to other NTM, M. szulgai has shown in vitro and in vivo susceptibility to most 
primary anti-tuberculosis drugs. However, several reports describe variable susceptibil-
ity to anti-tuberculosis drugs, probably because standardized protocols for susceptibility 
testing of M. szulgai are lacking. The organism is inherently resistant to pyrazinamide 
and streptomycin. In vitro resistance to isoniazid, rifampicin and ethambutol have been 
shown in some cases (28). Resistance to clarithromycin was observed and susceptibil-
ity to ciprofloxacin was noted (29). In previously reported cases, anti-tuberculosis drugs 
were reported successful when combinations of more than two drugs were used (30). 
Nevertheless, the optimal treatment for M. szulgai infections has not yet been established; 
most authors recommend the use of 3 or 4 drug regimens based on in vitro susceptibility 
for 9-12 months after the culture has become negative (5,30).
In this study the seven M. szulgai strains had reduced sensitivity to isoniazid and 
were sensitive to rifampicin, ethambutol and ciprofloxacin. Five of the seven patients 
were treated with a combination of isoniazid, rifampicin, ethambutol and, in cases of a 
positive smear, also with pyrazinamide, because an infection with M. tuberculosis was 
expected. Three of the five patients, who were HIV-positive, responded well. The other 
two patients, who were HIV-negative, showed no improvement on the anti-tuberculosis 
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treatment. One of these patients had a positive smear and was suspected of pulmonary 
disease. Probably the combination of two in vitro sensitive anti-tuberculosis drugs was 
not optimal. Moreover, the clinical response to anti-tuberculosis treatment of patients 
in this study was evaluated for 3 months and this may have been too short. The other 
patient had an abscess on her leg and no respiratory complaints. The abscess fluid was not 
cultured for mycobacteria. It is most likely that the isolated M. szulgai in the sputum was 
not the etiology of her disease.
The study focused on the seven patients with a positive culture for M. szulgai. In ad-
dition, there were five more patients with an identified NTM in the sputum culture. 
Instead to cultures yielding M. szulgai which have almost always a clinical significance, 
the significance of positive M. simiae or M. terrae cultures is more controversial, as these 
bacteria are uncommon causes of pulmonary disease (5). M. avium-intracellulare is a 
frequently encountered, clinically significant NTM. However, M. avium-intracellulare is 
also common in many environmental sources. Distinguishing between colonization, con-
tamination and disease in case of isolation of these NTM is complicated and can be a real 
challenge. Therefore, in this study we concentrated on the seven patients with M. szulgai 
cultures.
The contribution of NTM, and especially of M. szulgai, to tuberculosis-like diseases in 
both HIV-positive and negative patients in Africa may have been underestimated.
This could have important consequences for the use of various diagnostic methods 
to establish the diagnosis of a mycobacterial infection as well as for the possibilities for 
adequate treatment. In addition, more extended studies are needed to determine the 
magnitude of this problem. To discriminate between colonization and infection or dis-
ease, studies with a control group from the same area should be examined for natural 
prevalence of different NTM and sputum of patients with probable NTM disease should 
also be subjected to a direct molecular test to detect possible presence of M. tuberculosis 
complex.
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ABstrACt
To access the possible role of non-tuberculous mycobacteria (NTM) as a cause of tuber-
culosis-like diseases, 167 chronically ill patients, hospitalised in three hospitals in Katete, 
Sesheke and Chilonga, Zambia, were investigated.
The percentage of patients with a positive culture for M. tuberculosis complex was equal 
in the three geographic locations (19 to 25%). In contrast, the percentage of sputum cul-
tures positive for NTM differed significantly between the villages and ranged from 78% 
in Katete, 65% in Sesheke and 21% in Chilonga. Furthermore, the distribution of NTM 
species was different at the three geographic sites.
Two sputum specimens were cultured from each of in total 101 patients. In 15 patients 
(15%) the same NTM species was found in both sputum specimens. In almost half (7) 
of these there was a basis for a suspicion of NTM-associated disease. In five patients 
M. lentiflavum and in two patients M. intracellulare was isolated twice.
The demographic and clinical characteristics of patients with positive and negative NTM 
cultures were analysed. The odds ratio for an NTM culture positive sputum was signifi-
cantly higher for patients living in Katete and Sesheke. Furthermore, females and patients 
with a chest X-ray suspected of tuberculosis were independently associated with an NTM 
culture positive sputum.
In association with clinical complaints of patients admitted at three different geographic 
sites in Zambia, a high percentage of positive NTM cultures was found. A proportion 
almost fulfilled the criteria of the American Thoracic Society. This finding may be due 
to the extremely high rate of HIV positivity (between 69-79%) among the patients ex-
amined. Although not examined in this study a low CD4+ T-lymphocyte count in HIV 
positives is sometimes associated with NTM infection. More extended studies are needed 
to determine the magnitude and nature of NTM infection on the African continent.
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introDuCtion
Tuberculosis is almost invariably caused by Mycobacterium tuberculosis. However, infec-
tions by some of the non-tuberculous mycobacteria (NTM) can also mimic this disease. 
NTM are distinguished from members of the M. tuberculosis complex by the fact that 
they are not obligate pathogens, but natural inhabitants of a wide variety of environmen-
tal reservoirs, including natural and municipal water, soil, aerosols, protozoans, domestic 
and wild animals, milk and food products (20).
A large geographical variation in the distribution of NTM has been reported. In the Unit-
ed States, NTM lung disease is most commonly attributable to M. avium complex, with 
M. kansasii being the second most important (18). In the United Kingdom, especially in 
England and Wales, M. kansasii is the pathogen most commonly associated with NTM 
lung disease, while M. malmoense is the most commonly encountered NTM in Scotland. 
M. xenopi predominates in Southeast England (2). In Japan, the most common cause of 
NTM pulmonary disease is M. avium complex, followed by M. kansasii (24). However, in 
most parts of the world the distribution of NTM is not yet fully known.
Reported rates of NTM colonization and disease are likely underestimates, with the for-
mer probably less accurate than the latter, given that people without significant symptoms 
will not commonly undergo intensive investigations to detect possible NTM infection. 
Also the lack of systematic reporting of NTM isolation in most nations limits the ability to 
derive accurate estimates of infection. NTM disease is a problem in certain populations, 
including patients with underlying lung disease and individuals with impaired immunity. 
Northern American rates of colonization and disease have been reported to range from 
approximately 1-15 per 100,000 and 0.1-2 per 100,000, respectively. Generally, similar 
rates have been reported in European studies, with the exception of extremely high rates 
in an area of the Czech Republic where mining is the dominant industry (14). These stud-
ies have also shown marked geographic variability in NTM prevalence. Rates in Japan 
and Australia were similar to those reported in Europe and North America.
Most data reporting high rates of infection with NTM come from northern European 
countries or the United States. In African countries, despite the fact that environmental 
exposure to NTM is very high, infection by NTM seem to be rare, even among patients 
with AIDS (16). However, it is not clear whether this is due to a true low prevalence of 
NTM infection or that the magnitude of this problem has not yet been unravelled.
A number of studies on the epidemiology of NTM has been performed in South Africa. 
The results of mycobacterial studies of sputum cultures from large random samples of 
South African native people were reported in two studies (3,11). In 1,196 Zulus examined 
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in Natal, prevalence rates of 750 and 1,400 per 100,000 for M. tuberculosis and NTM 
were found, respectively (3). In the other study, sputum from 2,230 Xhosa people in the 
Transkei region was examined and 69 specimens grew M. tuberculosis and 150 NTM, 
yielding prevalence rates of 4,300 and 6,700 per 100,000, respectively (11). Furthermore, 
two other South African NTM studies focussed on a population of gold miners (8,9). 
Within the framework of one of these projects the records of a cohort of HIV-negative 
gold miners, investigated for suspected pulmonary mycobacterial disease, were reviewed 
(9). Annual rates of NTM infection were found to be 101 per 100,000 with the two 
most common organisms being isolated M. kansasii (66/100,000) and M. scrofulaceum 
(12/100.000), respectively.
A considerable part of the NTM has proven to be to a larger or smaller degree clini-
cally relevant, stimulating interest in these NTM in recent years (22). The criteria set in a 
Statement by the American Thoracic Society (ATS) and those formulated by the British 
Thoracic Society (BTS) may be used to differentiate between true NTM infection, colo-
nization, pseudo-infection and contamination (1,2). This differentiation between NTM 
infection or disease and no NTM infection or disease is made on the basis of clinical, 
radiological and microbiological features.
The goal of this pilot study was to assess the possible role of NTM in tuberculosis-like 
diseases in various geographic locations in Zambia.
MAteriAl AnD MethoDs
Chronically ill patients, hospitalised in three hospitals in different provinces of Zambia 
from March to August 2001, were the subject of this study. The hospitals included were St. 
Francis Hospital in Katete (Eastern Province), Yeta District Hospital in Sesheke (Western 
Province), and Our Lady’s Hospital in Chilonga (Northern Province). St. Francis Hospital 
and Our Lady’s Hospital are referral hospitals and Yeta District Hospital is a first level 
hospital. All the hospitals serve a rural population.
The distance between the hospitals in Katete and Chilonga amounts to approximately 
250 kilometres and both villages are about 950 km apart from Sesheke. All patients above 
the age of 15 years who were chronically ill with complaints of any part of the body for 
more than two weeks and visited the hospital for clinical examination were included in 
this study.
The medical history of the patients was retrieved, and a detailed physical examination 
was performed. Sputa of the patients were examined for the presence of acid-fast bacteria 
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and subjected to culture in Mycobacteria Growth Indicator tubes (Becton Dickinson Mi-
crobiology Systems, Cockeysville, Md.). Decontamination of the sputum was done using 
N-acetyl-l-cysteine (NALC)-NaOH and 6% sulfuric acid after dividing the sputum speci-
men into two equal parts to compare decontamination procedures for the detection of 
mycobacteria (4). In St. Francis Hospital in Katete and Yeta District Hospital in Sesheke, 
sputum from patients was collected and cultured on two consecutive days. In Our Lady’s 
Hospital in Chilonga only a single sputum was collected and cultured because of logistic 
reasons. Serological testing for HIV was performed using a qualitative immunoassay 
(Abbott Determine HIV-1/2) and the Vidas HIV DUO assay (bioMérieux, Marcy l’Etoile, 
France). Chest X-rays were taken and evaluated blind in The Netherlands. The Accuprobe 
culture confirmation test for M. tuberculosis complex (Accuprobe, bioMérieux, Marcy 
l’Etoile, France) and/or 16S rRNA gene sequencing were used to identify mycobacterial 
isolates (13).
Data analysis
Data were entered in SPSS 6 and analysed using STATA vs 8.0 (Stata corporation College 
Station, TX, USA). A student t-test was used to assess different means between groups 
and proportions were compared using chi-square testing.
Univariate odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to as-
sess associations of potential risk factors of participants being NTM-positive. A stepwise 
backward regression approach was used for a multivariate analysis.
results
general characteristics
In total, 167 chronically ill patients were included in the study; 63 in Katete, 51 in Sesheke 
and 53 in Chilonga. The patient characteristics are shown in Table 1. The sex and age dis-
tribution of the patients was comparable between the villages. The ratio of HIV-positive 
patients varied between 69 and 79 percent in the three hospitals. The occupation of the 
majority of patients in Katete and Sesheke was farming; 71% and 61% respectively. In 
Chilonga more variation in the occupation was observed. Nineteen (36%) patients were 
farmers, nine were fulltime housewives, seven were in business, five were teachers, four 
were working in construction and the remaining patients were working as a taxi driver, 
office worker or guard. The minority of patients were smokers and alcohol drinkers in Ka-
tete and Sesheke. Insufficient data on this issue were available from Chilonga. The patients 
with tuberculosis in the past were comparable between the three hospitals, between 19% 
and 29%. In Katete, most patients (52%) retrieved their water from a borehole. In Sesheke 
and Chilonga the main source of water was a nearby river which was used in combination 
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with water from the tap (40 to 45%). Patients who were milk consumers in Katete usu-
ally boiled their milk prior to use. The patients in Sesheke mainly used un-boiled milk. 
No data were available on this item from Chilonga. A relatively high, but not significant 
number of patients (14%), died during the study period in Katete in comparison with 
Sesheke (9%) and Chilonga (2%).
Most of the 167 patients included were complaining of regular coughing and/or chest 
pain (79%). Complaints of the digestion tract was found in 13% of the patients and the 
other 8% of the patients had either skin infections/abscesses, lymphadenopathy, tractus 
urogenitalis or central nervous system complaints.
Culture results
The percentage of patients with a positive culture for M. tuberculosis complex was equal 
in the three locations and varied between 19 and 25% (see Table 2). Moreover, a high 
percentage of positive sputum cultures were found for NTM. The number of patients 
with positive NTM cultures was significantly higher in Katete (78%) and Sesheke (65%) 
in comparison to Chilonga (21%). However, in Chilonga only one sputum specimen was 
cultured, while in Katete and Sesheke two sputum specimens were subjected to culture. 
Taking only the first sputum specimen in Katete and Sesheke into account, the number of 
patients with positive NTM cultures was still significantly higher in Katete and Sesheke in 
comparison with Chilonga. The sputum smear was positive in 19 out of 38 patients (50%) 
table 1: Characteristics of included patients with chronic complaints for at least two weeks in Katete, 
Sesheke and Chilonga.
Katete Sesheke Chilonga p-value All
Number of included patients, n (%) 63 51 53 167
Female, n (%) 37 (59) 26 (51) 19 (36) 0.05  82 (49)
Age, median (range) 36 (18-76) 37 (18-67) 39 (7-74) 0.9  38 (7-76)
HIV, n (%) 48 (79) 38 (76) 34 (69) 0.3 120 (75)
Farmer, n (%) 45 (71) 31 (61) 19 (36) <0.001  95 (57)
Smoking, n (%)  1 (2) 11 (22) -* 0.001  12 (11)
Using alcohol, n (%)  4 (7) 15 (31) -* 0.01  19 (18)
Tuberculosis Rx in past, n (%) 12 (19) 15 (29) 15 (28) 0.4  42 (25)
Water source, n (%)
Well
Borehole
Tap
River
16/60 (27)
31/60 (52)
 5/60 (8)
 8/60 (13)
 7 (14)
 0
21 (41)
23 (45)
5/39 (13)
2/39 (5)
15/39 (40)
16/39 (42) <0.001
 29 (19)
 33 (22)
 41 (27)
 47 (31)
Un-boiled milk, n (%)  1 (2) 35 (69) -* <0.001  36 (33)
Died during study period, n (%)  9 (14)  1 (2) 5 (9) 0.07  15 (9)
*Data on smoking and using alcohol or (un)boiled milk were not available in Chilonga.
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with a sputum culture positive for M. tuberculosis complex and in only 3 out of 76 (4%) 
patients with sputum culture positive for only NTM.
In all three hospitals, the collected sputum specimens were split in two equal parts before 
decontamination and culturing to test the performance of two decontamination meth-
ods. The result below summarizes the sum of both approaches.
In Katete, 217 sputum specimens were cultured from 63 patients (see Table 3). From 
140 of the 217 (65%) sputum specimens mycobacteria were isolated. M. tuberculosis was 
found in 16 of the 217 (7%) cultured sputum specimens and NTM in 124 (57%). The most 
isolated NTM were M. lentiflavum (42) and M. intracellulare (19).
The number of mycobacteria isolated in Sesheke was comparable with the number iso-
lated in Katete. In contrast, no M. lentiflavum was found in Sesheke. Mycobacteria were 
table 2: Patients with positive Mycobacterium cultures in Katete, Sesheke and Chilonga.
Katete, n (%) Sesheke, n (%) Chilonga, n (%) p-value All, n (%)
Number of included patients 63 51 53 167
M. tuberculosis complex 12 (19) 13 (25) 13 (25) 0.7  38 (23)
NTM in any sputum 49 (78) 33 (65) 11 (21) <0.001  93 (56)
NTM only in 1st sputum 42 (67) 25 (49) 11 (21) <0.001  78 (45)
NTM in 1st and 2nd sputum 28 (44) 12 (24)  -* 0.02  40 (35)
Same NTM in both sputa 13 (21)  5 (10)  -* 0.1  18 (16)
NTM and M. tuberculosis  8 (13)  7 (14)  3 (6)  18 (10)
*Only a single sputum specimen per patient was cultured in Chilonga.
table 3: Isolated mycobacteria from sputum specimens in Katete, Sesheke and Chilonga.
Culture result Isolates
Katete, n (%)
Isolates
Sesheke, n (%)
Isolates Chilonga, 
n (%)
Negative  77 (35)  55 (30)  67 (65)
M. tuberculosis  16 (7)  25 (14)  18 (17)
M. avium complex
 M. intracellulare  19 (9)  19 (10)   0
 M. avium   0   0   1 (1)
M. chelonae   8 (4)   0   0
M. lentiflavum  42 (19)   0   0
Various unknown Mycobacterium species  18 (8)  29 (16)   5 (5)
Various other Mycobacterium species*   7 (3)  14 (8)   6 (6)
AFB without identification  30 (14)  42 (23)   6 (6)
Total number of sputum specimens 217 184 103
*Various other Mycobacterium species in Katete include M. mucogenicum, M. elephantis, M. gordonae, 
M. gilvum and M. rhodesia.
Various other Mycobacterium species in Sesheke include M. fortuitum, M. mucogenicum, M. asiaticum, 
M. terrae and M. triplex.
Various other Mycobacterium species in Chilonga include M. mucogenicum, M. triplex, M. obuense and 
M. gordonae.
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isolated in 129 of the 184 (70%) sputum specimens cultured. M. tuberculosis was found 
in 25 of the 184 (14%) cultured sputum specimens and NTM in 104 (57%). The mainly 
isolated NTM in Sesheke was M. intracellulare (19).
In Chilonga mainly one sputum specimen was collected, which was also divided and 
pre-treated in two ways before culturing. From the 53 patients included in the study, 
103 sputum specimens were cultured. In contrast to Katete and Sesheke, only 36 (35%) 
cultures were positive for mycobacteria. M. tuberculosis was found in 18 of the 103 (17%) 
cultured sputum specimens and NTM in the other 18 (17%) specimens. M. intracellulare 
and M. lentiflavum were not isolated in Chilonga. M. avium was isolated only in a single 
culture.
Comparison of patients with and without ntM in their sputum
The demographic and clinical characteristics of patients with positive and negative NTM 
cultures were analysed. The medical history, physical examination and pathology of chest 
X-ray did not show significant differences between these two patient groups (Table 4). 
Table 5 shows the analysis of possible risk factors for patients with NTM in their sputum. 
The odds ratio (OR) for NTM culture positive sputum was significantly higher for pa-
tients living in Katete and Sesheke. Furthermore, females and patients with a chest X-ray 
suspected of TB were independently associated with a NTM culture positive sputum. A 
higher OR, but not significant in the multi-variate analysis, was seen for farming and 
table 4: Medical history, physical examination and chest X-ray of NTM culture-positive and culture-
negative patients.
167 chronically ill patients NTM positive NTM negative p-value All
Number of patients 93 74 - 167
Female sex, n (%) 55 (59) 27 (36) 0.004  82 (49)
Age, median (range) 37 (17-76) 38 (7-74) 0.9  38 (7-76)
HIV-positive, n (%) 71 (79) 49 (70) 0.2 120 (75)
BMI, mean 17.3 17.7 0.6  17.5
Weakness, n (%) 75 (82) 63 (88) 0.3 138 (84)
Vomiting, n (%) 19 (21) 18 (25) 0.5  37 (23)
Diarrhoea, n (%) 20 (22) 15 (21) 0.9  35 (22)
Dysuria, n (%) 10 (11) 13 (18) 0.2  23 (14)
Hepatomegaly, n (%) 19 (22) 13 (22) 0.9  32 (220
Splenomegaly, n (%) 21 (24) 10 (17) 0.3  31 (21)
Lymph nodes, n (%) 52 (56) 44 (60) 0.6  96 (58)
Chest X-ray compatible with TB in the 
absence of M. tuberculosis in culture, n (%)
25 (47) 15 (32) 0.1  40 (40)
Previous TB treatment, n (%) 23 (25)) 19 (26) 0.9  42 (25)
Died, n (%)  8 (9)  7 (9) 0.8  15 (9)
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using water from the borehole. The HIV-status and the influence of un-boiled milk were 
not statistically significant.
repeated isolation of ntM from sputum
The diagnostic criteria for NTM pulmonary disease according to the ATS and BTS in-
clude both imaging findings consisted with pulmonary disease and repeated isolation of 
the same mycobacteria from sputum samples in symptomatic patients.
In this study, two sputum specimens were collected and cultured from a total of 101 
patients. In 21 (21%) of these patients M. tuberculosis and in 66 patients (65%) NTM were 
isolated from at least one sputum specimen. In 10 patients M. tuberculosis in combination 
with NTM were isolated from the sputum specimens.
In 56 patients (55%), NTM (presumably) representing different species were found 
in both sputum specimens. In 29 of these 56 patients the NTM in at least one sputum 
could not be identified. In 15 patients (15%) the same species of NTM was found in both 
sputum specimens and in three more patients the same species of NTM in both sputum 
samples together with a M. tuberculosis were found. (see Table 6 for an overview of all 
18 patients with same species NTM in both sputum samples). Nine of these 15 patients 
with the same species NTM, without M. tuberculosis, in both sputum samples (60%) were 
female and the median age was 41 years (range 25-67). Thirteen patients were visiting the 
table 5: Risk factors for positive NTM culture from sputum.
Univariate analysis,
OR (95% CI)
Multivariate analysis,
OR (95% CI)
Location
 Chilonga
 Sesheke
 Katete
1
7.0 (2.9-16.8)
13.4 (5.5-32.6)
1
4.7 (1.6-13.7)
11.8 (4.5-30.8)
Sex (female) 2.5 (1.5-4.3) 2.0 (1.0-4.5)
Chest X-ray suggesting TB 1.9 (1.0-3.9) 2.5 (1.1-5.9)
Age ≥ 25 0.8 (0.3-2.1) ns
Farmer 2.0 (1.1-3.8) ns
Water (in comparison to tap water = 1):
 Borehole
 Well
 River
3.1 (1.2-8.2)
2.6 (0.9-7.0)
1.2 (0.5-2.8)
ns
Un-boiled milk 1.0 (0.4-2.4) ns
Smoking 0.4 (0.1-1.3) ns
Using alcohol 0.7 (0.2-1.9) ns
M. tuberculosis isolated from sputum 0.6 (0.3-1.2) ns
Tuberculosis Rx in past 1.0 (0.5-1.9) ns
HIV-positive 1.6 (0.8-3.3) ns
Underweight (BMI < 18) 1.0 (0.5-2.1) ns
Definition of abbreviations: ns = not (statistically) significant, OR = odds ratio, CI = confidence interval.
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hospital because of respiratory complaints and two because of complaints of the gastroin-
testinal tract. Six patients (40%) had suffered from tuberculosis in the past, of whom five 
presenting at the time of inclusion in the study had respiratory complaints. Ten of the 14 
tested patients (71%) were HIV-positive. Two of these 15 patients died during the study 
period.
A chest X-ray was made in 10 of these 15 cases (Table 6). In 4 patients, the pathology 
on the chest X-ray suggested tuberculosis. M. lentiflavum was isolated in both sputum 
samples from all 4 patients. The sputum smears were microscopically positive in two 
patients.
In six patients, the chest X-ray showed no signs indicative of tuberculosis. M. lenti-
flavum was isolated from both sputum specimens in three patients, M. intracellulare in 
another two patients and M. chelonae in one patient.
Unfortunately, from five patients no chest X-ray was made. In one patient, M. lentifla-
vum was cultured from the lymph node biopsy and from two sputum samples. In three of 
these five patients M. intracellulare was identified in both sputum specimens. In the last 
patient without an X-ray, mycobacteria were cultured from both sputum specimens but 
could not be identified to the species level. The highest phylogenetic agreement, based 
on rRNA gene sequences, demonstrated a high degree of similarity with M. intracellu-
lare. One of these five patients had a history of tuberculosis and two did start with anti-
tuberculosis treatment.
Case reports of patients suspected of ntM disease
In four of the 166 cases (i.e. four of the ten patients with a chest X-ray of the 15 patients 
with same species NTM in both sputum samples) included in this study, mycobacteria 
were repeatedly and consistently isolated from sputum in addition to lesions on the chest 
X-ray. Patient one was a 50-year-old female who presented herself with a productive 
cough with haemoptysis for 24 weeks. Furthermore, she was having pain passing urine. 
She was not responding to antibiotics. The HIV tests were indifferent. Her body mass 
index (BMI) was 20. The radiographic investigation of the chest revealed a pleural and 
pericardial effusion and an alveolar consolidation. The sputum smear was positive and 
treatment with rifampin, isoniazid, ethambutol and pyrazinamide was started. M. lenti-
flavum was isolated from two consecutive sputum specimens. Also from two consecutive 
urine samples M. lentiflavum was isolated. The patient died three months after the treat-
ment was started.
The second case concerned a 35-year-old HIV-positive man. He complained about a 
cough and night sweats that started 34 weeks earlier. A relative of this patient had been 
found sputum-positive a few months earlier. On physical examination, enlarged axillary 
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and submandibular lymph nodes and an enlarged spleen were found. The temperature 
was 39°C and the BMI 24. He had already been treated with antibiotics without improve-
ment. The chest X-ray did show pleural fluid. The sputum smear was positive. M. lentifla-
vum was isolated from two sputum specimens.
An HIV-positive, 30-year-old woman presented with coughing and vomiting for five 
weeks. She had been treated for tuberculosis in the past, but she interrupted this treat-
ment. On physical examination, enlarged axillary and supra-clavicular lymph nodes and 
an enlarged spleen were found. The temperature was 35.5°C and the BMI 18. She was 
not improving on antibiotics before admission. Pleural effusion, alveolar infiltration, and 
interstitial pathology were seen on the chest X-ray. The patient clearly improved upon 
treatment with rifampin, isoniazid, pyrazinamide, and ethambutol. M. lentiflavum was 
cultured from two sputum specimens.
The last patient was a 25-year-old, HIV-positive woman who complained of a productive 
cough with haemoptysis of one month duration. She was known with asthma. Enlarged 
axillary and submandibular lymph nodes and an enlarged liver were found on physical 
examination. The temperature on admission was 38.5°C. Her chest X-ray showed pleural 
and pericardial effusion. Treatment with antibiotics was started. The culture of the both 
sputum specimens indicated the presence of M. lentiflavum. The patient died nine days 
later.
DisCussion
A high percentage (56%) of patients presenting with a variety of complaints at three Af-
rican hospitals yielded positive NTM sputum cultures. This finding may be due to the 
extremely high rate of HIV positivity (between 69-79%) among the patients examined. 
The group of HIV-negative patients that was found was so relatively small in this study 
that correlations between NTM isolation and HIV status could not be studied adequately. 
Although not examined in this study, a low CD4+ T-lymphocyte count in HIV posi-
tives may be associated with NTM infection, whereas all HIV positives may have a much 
higher chance of being colonized by these bacteria.
The ratio of patients with positive NTM cultures was significantly higher in Katete (78%) 
and Sesheke (65%) in comparison to Chilonga (21%). Therefore, the patient character-
istics of the patient populations at the three sites were compared. In Katete and Sesheke 
more patients were working as a farmer in comparison with Chilonga. In the literature, 
mining and other heavy industries are the environments most frequently cited as risk 
factors for NTM acquisition (10,14). Farming has not yet been mentioned as a risk factor 
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for NTM infections in Africa, but it is conceivable since farmers have an intensive and 
long lasting exposure to NTM in soil, water, and other potential environmental sources. 
Therefore, the observation of a lower percentage of NTM culture-positive patients in 
Chilonga could indeed be the consequence of the lower proportion of farmers among the 
patients in this area.
NTM are natural inhabitants of a wide variety of environmental reservoirs including 
municipal water systems and soil (20,25). Food is also a source of human exposure to 
NTM. Between the three villages also main differences were observed in the water supply 
and the consumption of (un)boiled milk. In Katete most patients (52%) retrieved their 
water from a borehole and in Sesheke and Chilonga a nearby river and water from the 
tap (40 to 45%) were the main source of water supply. Patients who were milk consumers 
in Katete usually boiled their milk prior to consumption, whereas patients in Sesheke 
mainly used un-boiled milk. This suggests that direct contact with the environment may 
be a risk factor for contracting a NTM infection in Zambia.
Alcohol abuse and smoking have also been associated with NTM infection in the lit-
erature (17). Unfortunately, in this study the use of alcohol and smoking was noted in the 
patient history in Katete and Sesheke, but not quantified.
In most NTM studies older males with underlying chronic obstructive pulmonary dis-
ease (COPD) are the predominant patient group. COPD was documented in this study 
but not observed as a risk factor, probably because many patients did not know if they 
had this underlying disease. In addition, studies have also described a patient group of 
elderly woman with no pre-existing pulmonary disease at increased risk of especially 
Myco bacterium avium complex and M. kansasii (7,18). Although other NTM have been 
found in Zambia than those mentioned here, in this study the female sex was also a risk 
factor for NTM culture positive sputum. Traditionally, in Zambia women are more in-
volved in cropping and gardening compared to men. NTM exposure of the female patient 
through farming could be a possibility.
NTM have been found all over the world, although there seems to be a geographic distri-
bution (2,18,24). Mycobacteria such as M. kansasii, M. chelonae, M. fortuitum, M. avium 
and M. intracellulare are responsible for the great majority of the NTM infections. In 
Africa little is known about the most prevalent NTM species. In South African gold min-
ers who were investigated for suspected pulmonary mycobacterial disease, the most com-
mon micro-organisms were M. kansasii and M. scrofulaceum (9). In a study in Nigeria, 
11 out of 102 (11%) mycobacterial isolates from cases with persistent symptoms of lower 
respiratory tract infections were identified as NTM (12). Six were classified as M. avium, 
four as M. kansasii and one as M. fortuitum.
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In Kenyan adults with acute pneumonia, 11 of the 53 positive mycobacterial cultures 
belonged to NTM; M. fortuitum/M. chelonae (3 cultures), M. szulgai (2), M. kansasii (2), 
M. terrae (1), and other NTM (3) (21).
In this study clear geographic differences of isolated NTM species were observed.
In Katete most commonly M. lentiflavum and M. intracellulare were isolated, but in 
Sesheke mainly M. intracellulare was isolated and no M. lentiflavum was found. Neither 
M. intracellulare nor M. lentiflavum were isolated in Chilonga. Interestingly, in all three 
villages not previously identified mycobacteria were found (between 5-16% of the cul-
tured sputum specimens). These data indicate there may be another distribution of my-
cobacteria in Africa compared with the United States and Europe.
The incidence of NTM colonization and disease is almost completely unknown in the 
major part of Africa. North American and European rates of colonization and disease 
have been reported to range from approximately 1-15 per 100,000 and 0.1-2 per 100,000, 
respectively. In two population-based studies in South Africa prevalence rates of NTM 
colonization were 1,400 and 6,700 per 100,000, respectively (3,11).
In a population of South African gold miners annual rates of NTM colonization were 
measured at 101 per 100,000 and rates of disease with the two most common organisms 
were 66 (M. kansasii) and 12 (M. scrofulaceum) per 100,000, respectively (8,9).
In this study NTM were isolated from at least one sputum specimen in 98 of the 167 
(59%) hospitalised and chronically ill patients. Two sputum specimens were collected 
and cultured from 101 patients. In 15 patients the same species NTM was found in both 
sputum specimens. A chest X-ray was made in 10 of these 15 patients (Table 6). The 
chest X-ray was suspected for TB in four patients with repeated M. lentiflavum isolates 
from their sputum, which may indicate pulmonary infection. Chronic respiratory symp-
toms not reacting to antibiotics, radiological features suggesting tuberculosis and also 
two positive sputum cultures are nearly sufficient for fulfillment of the ATS diagnostic 
criteria. In six patients the chest X-ray did not suggest tuberculosis. In five of these 15 pa-
tients no chest X-ray was made because of technical problems with the X-ray equipment. 
At least three patients without a chest X-ray were suspected of pulmonary disease by 
NTM. In one patient M. lentiflavum was isolated from two sputum specimens and from a 
(normally sterile) lymph node. In two other patients with chronic respiratory complaints 
and no response to antibiotics, anti-tuberculosis treatment was started. M. intracellulare 
was isolated from consecutive sputum specimens in both patients. The combination of 
symptoms, together with the positive cultures, is an important indicator of NTM infec-
tion and is suggestive of NTM pulmonary disease.
However, the ATS criteria are not completely fulfilled because two instead of three 
sputum specimens were NTM culture-positive. Furthermore, the sputum of the patients 
suspected for NTM disease were not tested by molecular methods for the possible 
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presence of M. tuberculosis, especially the ZN positive sputa should ideally have been 
subjected to such a test. Culture of the sputum was only done in MGIT tubes and not on 
a solid medium. This liquid culture system has the disadvantage that it does not allow 
the  quantitative detection of colony-forming units (CFUs). A low number of CFUs could 
have been an indication of colonization of specimens by NTM. Therefore, the liquid 
culture was not helpful in discriminating between colonization and infection or disease. 
Moreover, NTM are found ubiquitously in the environment and colonization or infection 
by NTM may result from drinking contaminated water or showering with it. Recently, 
M. lentiflavum was isolated from public water distribution systems (23). Isolation of the 
same NTM from two different sputum specimens collected at consecutive days could 
therefore be a result of colonization with the NTM, because of exposure to drinking water 
contaminated with NTM.
Additionally, disease caused by M. lentiflavum is difficult to treat with standard anti-tu-
berculosis drugs. In most cases clarithromycin is added to the treatment but the manage-
ment of this NTM infection remains difficult (15). The improvement of patient number 
three in our study on anti-tuberculosis treatment without clarithromycin may therefore 
be indicative of disease caused by M. tuberculosis instead of M. lentiflavum.
Overall, for almost half (7 /15) of the patients with the same NTM in both sputum 
specimens there was a basis for the suspicion of NTM-associated disease. In five patients 
M. lentiflavum (cases 1,2,3,4 and 11) and in two patients M. intracellulare (cases 12 and 
14) was isolated twice. Overall, at least in a part of these patients with the same NTM in 
both sputum specimens a NTM associated disease was considered.
In this study the estimated rate of colonization is 58% (59/101) with a striking rate of 
disease of about 7% (7/101). The fact that all patients were presented at the hospitals with 
chronic complaints could partially explain such a high rate. The limited sample size of this 
study lacks the power to generalise these findings to the population as a whole. Moreover, 
the patients were examined over six months of the year and seasonal influences may have 
played a role as well (6,19). The study was performed from March to August during the 
cool and dry (May to August) and warm and rainy (mid-November through to the end of 
April) seasons. Patients were included during six consecutive months and the variation 
during one year or between years could not be measured. The first study was started in 
Katete and the study in Chilonga was the last one finalized. In summary; differences in 
climate could have influenced the number and species of isolated NTM.
Furthermore, differences in the incidence of NTM colonization/disease and geographic 
differences in the isolation of NTM between the three villages could possibly be clarified 
by the variation in geographical characteristics. The three villages of this study are located 
in three different districts in Zambia. Katete and Chilonga are about 250km apart from 
each other and both villages are about 950km apart from Sesheke. Katete and Sesheke 
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are situated at an altitude of between 1000 and 1500m and Chilonga between 1500 and 
2000m. Furthermore, mean annual temperatures are between 19-22°C, reaching their 
maximum annual range in the extreme south-west (14-26°C in Sesheke). The mean an-
nual rainfall decreases from over 1000mm in the North (for instance in Chilonga) to 
less than 700mm in the South. The agricultural potential correlates with these different 
ecological zones.
The ubiquitous presentation of NTM in the environment contributes to the difficulties 
in interpreting positive culture results. NTM can be associated with either colonization, 
serious infection, or with pseudo-outbreaks with a wide variety of presentations (26). 
In this study laboratory cross-contamination was prevented by all possible efforts, in-
cluding that all materials needed for collection and cultivation were imported from The 
Netherlands. All handling was carried out according to standard operating procedures 
that were introduced by experienced staff from The Netherlands. Also the fact that in 
a significant proportion of the cases from consecutive sputa the same NTM were iso-
lated indicates that the quality of NTM isolation was adequate. Furthermore, molecular 
analysis revealed that the mycobacterial isolates represented several evolutionary lineages 
and strain variation (5). In addition, at the three villages the same materials were used, 
while different species NTM were isolated. Therefore, laboratory cross-contamination is 
considered highly unlikely in this study.
High rates of NTM colonization and disease are reported in this study. Furthermore, 
differences in the distribution of specific species of NTM in chronically ill patients in 
three villages in Zambia were observed. So far, only a few studies on the epidemiology 
of NTM have been performed in Africa, mainly South Africa, and benchmark data are 
not available. The current study in the Zambian patient population at least indicates that 
more extended studies are needed to determine the magnitude of NTM infection in the 
African continent.
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ABstrACt
The isolation of nontuberculous mycobacteria (NTM) raises the question of their clinical 
significance, especially in an African setting. We found a high percentage of NTM isolated 
from various specimens, including ones that are normally sterile, among 213 patients 
in Zambia. Because tuberculosis can affect all parts of the body, we decided to include 
patients who had signs and symptoms in any part of the body for more than 2 weeks. 
Most patients had tractus respiratorius (80%) and tractus digestivus (10%) symptoms. 
During three consecutive days, sputum was collected and two separate sputum speci-
mens were cultured for mycobacteria. Depending on the clinical picture, pleural effusion, 
ascites, abscess material, or enlarged lymph nodes were also cultured for mycobacteria. 
A specimen from one sterile body site was collected from 25 patients (60% human im-
munodeficiency virus [HIV] positive). NTM were isolated from 8 of these 25 specimens. 
Mycobacterium lentiflavum was isolated from four patients, and Mycobacterium goodii 
was isolated from one patient. In order to exclude the possibility of laboratory cross-con-
tamination, a novel amplified fragment length polymorphism DNA typing method for 
M. lentiflavum was developed. Genetic variation was detected, rendering the likelihood 
of laboratory contamination unlikely. Clinically relevant infection due to NTM occurs in 
both HIV-positive and HIV-negative patients in Zambia, and their clinical impact seems 
to be underestimated. This is the first report of M. lentiflavum and M. goodii infections 
in Africa.
Isolation of nontuberculous mycobacteria in Zambia: eight case reports 117
introDuCtion
Mycobacterium tuberculosis and human immunodeficiency virus (HIV) co-infections 
are increasingly noted in third-world countries (8). In developed countries, it has been 
reported that HIV-infected patients are susceptible to infections by nontuberculous my-
cobacteria (NTM) (14). The isolation of NTM generally raises questions of their clinical 
significance, especially in an African setting, and assessment of this significance should 
be guided by the diagnostic criteria of the American Thoracic Society (1). According to 
these criteria, the diagnosis of NTM pulmonary disease must be based on solid clinical, 
radiographic, and bacteriologic factors. A culture of a tissue biopsy is one of the bacte-
riologic criteria and is considered positive if there is any growth from a usually sterile 
extra-pulmonary site. Many infections occur without the identification of causal micro-
organisms, especially in African settings. An improved understanding of the aetiology 
of these infections and which microorganisms play a role is of the utmost importance. 
Because only microscopic examination is usually available to confirm the diagnosis of 
tuberculosis in Africa, the involvement of acid-fast NTM in tuberculosis-like syndromes 
might result in the misdiagnosis of tuberculosis.
Mycobacterium avium complex bacteria, as well as other NTM, are widely distributed 
in the environment, and colonization of humans appears to be common (16). However, 
genuine infection by NTM has been reported almost exclusively from developed coun-
tries and not from developing countries, although the prevalence of HIV infection is 
generally much higher in the latter settings (7). Disseminated disease due to M. avium 
complex bacteria does occur in HIV-positive Africans but has been reported more fre-
quently in the United States and Europe (2). This may be due to a lack of attention to this 
phenomenon in Africa, where possibilities for identification of mycobacteria are gener-
ally limited.
During a tuberculosis surveillance study prior to the present study, we regularly iso-
lated NTM from various clinical specimens from 84 Zambian patients with pulmonary 
syndromes. A positive Mycobacterium culture was found in 51% of the included patients 
who were clinically suspect for tuberculosis, and 73% of these mycobacteria were NTM. 
The clinical significance of some of these NTM was questionable, and the aim of the 
present study was to resolve this enigma. To examine the clinical relevance of NTM in 
Zambian patients, eight patients from whom NTM were cultured from sterile body sites 
are described in detail.
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CAse rePorts
Case 1.
A 67-year-old woman who was HIV negative was admitted with a painful abdominal 
swelling on the left side. Pain started a month earlier, after a herpes zoster infection. On 
physical examination, an enlarged axillary lymph node and enlarged liver and spleen, but 
no chest abnormalities, were found. Mycobacterium lentiflavum was cultured from the 
lymph node biopsy and from two sputum samples.
Case 2.
A 37-year-old female HIV-negative patient who was suffering for 2 months with a pain-
fully swollen abdomen was admitted. She was also complaining about night sweats and 
a poor appetite. The chest X ray revealed an enlarged heart and pleural effusion at the 
left and right sites. The ultrasound showed an enlarged liver, ascites, a splenic abscess, 
and pericardial fluid. The splenic abscess and heart failure were treated with metronida-
zole and diuretics. After 2 weeks of treatment, the splenic abscess was reduced in size, 
but the liver seemed to have enlarged further. Treatment with rifampin, isoniazid, and 
pyrazinamide was started. Mycobacteria were cultured from the ascites and subsequently 
identified by 16S rRNA gene sequencing as an unknown Mycobacterium phylogenetically 
related to Mycobacterium gilvum (Fig. 1). One month later, the patient was readmitted 
because of heart failure.
Case 3.
The third case concerns a 38-year-old HIV-negative woman. She complained about chills 
and abdominal distension that started 7 months earlier. She had already been treated 
with diuretics without improvement. The white blood cell count was 6.200/mm3 with 
18% eosinophils. No abnormalities were seen on the chest X ray. The patient was treated 
with antibiotics, anthelminthics, diuretics, and draining of the ascites. M. lentiflavum was 
cultured from the ascites.
Case 4.
A 21-year-old female HIV-positive patient presented herself with a distended abdomen 
and edema of the ankles that started 3 weeks earlier. Furthermore, she was having a pro-
ductive cough and pain passing urine for 4 months. On physical examination, an icteric 
patient was seen with enlarged cervical, supraclavicular, and submandibular lymph nodes 
and abdominal ascites. The chest X ray did not show any abnormality. M. tuberculosis 
was isolated from sputum and urine, and Mycobacterium fortuitum was isolated from the 
ascites. The patient died 4 days later.
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M. tuberculosis
M. parafinicum
M. scrofulaceum
UMS, case 8M. lentfiflavumM. gilvum 
UMS, case 2
M. fortuitum
M. goodii 
figure 1: Phylogenetic tree on the basis of similarity in the 16S rRNA gene sequences and respective 
sequences of the mycobacterial isolates.
UMS = unknown Mycobacterium species.
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Case 5.
The patient was a 36-year-old HIV-positive woman who suffered from recurrent abscesses 
for 2 years. The patient presented with fever and multiple cutaneous abscesses on both 
legs and in the neck area. M. lentiflavum was isolated from the pus and from one of two 
sputum samples.
Case 6.
A 35-year-old HIV-negative woman was admitted previously because of cough and 
left pleural effusion. Symptomatic improvement was achieved with amoxillin. She sub-
sequently presented with a nonproductive cough and left chest pain. The radiographic 
investigation of the chest revealed a pleural effusion and alveolar consolidation on the left 
side. The culture of the pleural effusion proved the presence of M. lentiflavum. The patient 
improved upon treatment with rifampin, isoniazid, pyrazinamide, and ethambutol.
Case 7.
An HIV-negative 66-year-old man presented with a productive cough, chest pain, and 
diarrhea for 3 days. The patient’s medical history showed that he had pneumonia 1 year 
ago which improved with amoxicillin treatment. Pleural effusion, a left alveolar infiltra-
tion, and peribronchial pathology were seen on the chest X ray. Hookworms were found 
in the stool. The culture of the pleural effusion indicated the presence of M. goodii.
Case 8.
The patient was a 26-year-old HIV-positive woman who complained of a productive 
cough with haemoptysis and chest pain of 1-month duration. She had been treated for 
tuberculosis twice in the past. Her chest X ray showed pleural effusion and possible inter-
stitial pathology. Mycobacteria were cultured from the pleural effusion and could not be 
identified to the species level (Fig. 1). The highest phylogenetic similarity, based on rRNA 
gene sequences, was demonstrated with M. parafinicum and M. scrofulaceum.
MAteriAls AnD MethoDs
The study population consisted of 213 Zambian patients, 99 female and 114 male adults 
over 15 years of age. All patients who were admitted with chronic complaints to St. Fran-
cis Hospital in Katete (Eastern province), Yeta District Hospital in Sesheke (Southern 
province), or Our Lady’s Hospital in Chilonga (Northern province) during the period of 
March to August 2001 were included in the study. Because tuberculosis can affect all parts 
of the body, we decided to include patients who had signs and symptoms in any part of 
the body for more than 2 weeks. Most of the included patients had tractus respiratorius 
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(80%) and tractus digestivus (10%) symptoms. The other 10% of the patients had skin 
infections/abscesses, lymphadenopathy, or tractus urogenitalis or central nervous system 
complaints.
The medical history of the patients was retrieved, and detailed physical examination 
was performed. During three consecutive days, sputum was collected from patients with 
a productive cough. The first two sputum specimens were cultured for mycobacteria, 
and the third one was stored at −20°C. Depending on the clinical symptoms, samples of 
pleural effusion, ascites, abscess material, or enlarged lymph nodes were obtained in a 
sterile manner. All specimens were cultured for mycobacteria. Materials needed for col-
lection and cultivation were imported from The Netherlands, and an experienced Dutch 
technician performed the work in the Zambian laboratory. All possible efforts were made 
to prevent laboratory cross-contamination, including the collection of a specimen in a 
container that was not used before and that was imported from The Netherlands. The 
stock of decontamination fluid was sterilized twice a week, and each day a fresh, sterile 
tube or bottle was opened, the samples in the laboratory were processed one by one in 
the absence of other samples, and negative control cultures were included in each batch 
of samples. Microscopic slides were also prepared one at a time. All work associated with 
this project was conducted by the same experienced laboratory technician. All culture 
procedures were performed in a new class I biosafety cabinet.
A specimen from a sterile body site was collected from 25 patients. Ten of these speci-
mens were cultured without decontamination, and 15 specimens were divided into two 
equal parts: one half was decontaminated with N-acetyl-l-cysteine (NALC)-NaOH and 
the other half was decontaminated using 6% sulfuric acid to compare decontamination 
procedures for the detection of mycobacteria (4). The specimens from a sterile body site 
were first cultured without decontamination, but to avoid any confusion in the handling 
of the samples in the laboratory, all collected specimens were decontaminated after the 
first weeks of inclusion. Serological testing for HIV was performed using a qualitative 
immunoassay (Abbott Determine HIV-1/2) and the Vidas HIV DUO assay (bioMérieux, 
Marcy l’Etoile, France). Chest X rays were taken and evaluated in The Netherlands in a 
blinded manner regarding the origin of the pictures and any additional clinical infor-
mation. The specimens were cultured in Mycobacteria Growth Indicator tubes (Becton 
Dickinson Microbiology Systems, Cockeysville, Md.) according to the instructions of 
the manufacturer and the guidelines described previously by Master (17). Mycobacterial 
isolates were identified by the Accuprobe culture confirmation test for the M. tubercu-
losis complex (Accuprobe, bioMérieux, Marcy l’Etoile, France) or by 16S rRNA gene 
sequencing (15).
Molecular analysis of 12 M. lentiflavum isolates was performed by high-throughput 
amplified fragment length polymorphism (AFLP) (htAFLP) analysis according to a 
method described previously by van den Braak et al. (27) and Melles et al. (18). In 
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short, DNA was isolated from pure cultures (28), and htAFLP was performed ac-
cording to standard procedures. One enzyme combination was used to digest the 
mycobacterial DNA: Csp6I/NIaIII. The general primers for preamplification were 5′-
GTAGACTGCGTACCTAC-3′ for Csp6I and 5′-GAGTCCTGAGCATG-3′ for NIaIII 
and eight different sets of primers (+G/AA, +G/AG, +G/AT, +G/CA, +C/AA, +C/AG, 
+C/AT, and +C/CA) suited for selective amplification of subsets of restriction fragments. 
Apart from the 10 Zambian M. lentiflavum isolates, we included two independent iso-
lates from The Netherlands and M. tuberculosis control strain H37Rv (6). Nine isolates 
were tested in duplicate to define the test reproducibility. Banding patterns of coded 
samples were scored visually by an independent observer. DNA fragments from 150 to 
550 bp in length were evaluated.
The study was approved by the research ethical committee of the University of Zambia 
and by the Central Board of Health and the Ministry of Health in Zambia. Informed 
written consent to participate in the study was obtained from all patients. At the time of 
the study, the estimated Zambian HIV seroprevalence was 20%, and the case notification 
rate for tuberculosis was about 500/100,000 (20).
results
Clinical microbiology
Overall, out of 213 patients, 69% were HIV positive. M. tuberculosis was isolated from 
44 patients, 77% of whom were HIV positive, and NTM were isolated from 90 patients. 
Without knowing the results of the study, treatment for tuberculosis was given to 73 pa-
tients, 10 of whom were treated for extra-pulmonary tuberculosis.
A specimen from a sterile body site was collected from 25 patients (60% HIV posi-
tive). Eight of these 25 specimens were positive for NTM (Table 1), while in another five 
specimens, the presence of M. tuberculosis was demonstrated. Twelve specimens were 
culture negative. The Ziehl-Neelsen smears were all negative except for one (case 1). In 
contrast, 21 of the 44 patients with a positive culture for M. tuberculosis had a positive 
Ziehl-Neelsen smear of their sputum. The restriction fragment length polymorphism pat-
terns of the isolated M. tuberculosis strains were all different (data not shown), essentially 
excluding the possibility of laboratory cross-contamination for these strains.
typing of M. lentiflavum
Fifty-five M. lentiflavum isolates were cultured from 149 specimens obtained from 38 
of the 70 patients admitted to St. Francis Hospital in Katete. This mycobacterial spe-
cies has so far been rarely identified from clinical materials (see Discussion). In order 
to exclude the possibility that laboratory cross-contamination was the source of these 
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positive cultures, a random set of 12 of these isolates was subjected to htAFLP analysis. 
The M. lentiflavum strains from cases 1 and 6 were included in this random set (strains 
9, 11, and 13 in Table 2). Evaluation of the DNA fragments resulted in 256 scorable DNA 
markers. Reproducibility of the variable markers as deduced from the duplo analyses 
appeared to be 100% (results not shown), and two strains from two specimens from a 
single patient were indistinguishable.
Although most of the markers were not variable among the M. lentiflavum isolates, 
a part of the AFLP restriction fragments revealed a considerable level of variation. Any 
variable combination of markers received a marker pattern number (I to VII) (Table 2). 
Consequently, a marker pattern is corroborated by various marker fragments, thereby 
constituting a very reliable genotype. M. tuberculosis appeared to yield completely dis-
tinct AFLP patterns (see Fig. 2 for an example of the experimental output). Among the 
12 M. lentiflavum strains, six different types were documented. The types obtained for 
the two Dutch strains (types B and F) were clearly different from those generated for the 
Zambian isolates (types A, C, D, and E) (Table 2).
Type D strains were isolated from six patients (patients 019, 001, 021, 033, 045, and 
062), and the sputum and biopsy isolates from patient 033 yielded the same type. Al-
though other strains from patients visiting the same hospital were genetically distinct, 
table 2: htAFLP results for M. lentiflavum strains isolated from Zambian patients admitted to St. Francis 
Hospital, including Dutch control strainsb.
Strain Strain name Ward Origin of strain
Marker Patterna Overall
htAFLP typeI II III IV V VI VII
1. 037 UA 1 Zambia + − − − − + − A
2. 00-1863 X The Netherlands − + − − − − − B
4. 049 SpA 1 Zambia + − + − − − − C
5. 019 Sp2A 1 Zambia − + − − − − + D
7. 001 SpA 2 Zambia − + − − − − + D
8. 021 Sp2N 3 Zambia − + − − − − + D
9. 033 biopsy 2 Zambia − + − − − − + D
13. 033 Sp2A 2 Zambia − + − − − − + D
10. 011 U2A 4 Zambia − + − + − − + E
11. 045 Plv2A 2 Zambia − + − − − − + D
12. 062 SpN 2 Zambia − + − − − − + D
15. 01-0014 X The Netherlands − + − − + − − F
aFor an example of a marker pattern, see Fig. 2.
bNote that strains 9 and 13 are derived from two specimens obtained from a single patient. Strains 
9, 13, and 11 are derived from cases 1 and 6 as described in this paper. The column denominated 
“Ward”identifies the ward of admission of the patient with “1”indicating the internal medicine ward for 
males, “2”indicating the internal medicine ward for females, “3”indicating the surgery ward for males, 
and “4”indicating the tuberculosis ward. Materials are identified in the strain code, with “U”being urine, 
“Sp”being sputum, “biopsy” being a lymph node biopsy, and “Plv”being pleural effusion.
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ruling out full-blown laboratory contamination, we cannot exclude such an event for the 
six patients infected by a type D strain. On the other hand, this region of Zambia might 
be an area where type D is endemic.
Figure 2: AFLP analysis of M. lentiflavum strains.  
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figure 2: AFLP analysis of M. lentiflavum strains.
Two separate fragment patterns obtained by two amplifications steps with the primers G/AT and G/CA 
are demonstrated. Shown are the fingerprints for all strains listed in Table 2. Some strains are included in 
duplicate. Lane order is (from left to right): 1 = 037 UA, 2 = 00-1863, 3 = 037 UA, 4 = 049 SpA, 5 = 019 Sp2A, 
6 = 049 SpA, 7 = 001 SpA, 8 = 021 Sp2N, 9 = 033 biopsy, 10 = 011 U2A, 12 = 062 SpN, 13 = 033 Sp2A, 14 = 
001 SpA, 15 = 01-0014, 16 = 033 Sp2A, 17 = 00-1863, 18 = 011 U2A, 19 = 033 Sp2A, 20 = 01-0014, 21 = 045 
Plv2A, 22 = M. tuberculosis. Three different types of arrows (pointing up, to the right or left) identify three 
main marker patterns. The marker patterns are mentioned in table 2. The arrow pointing up identifies 
pattern II, the arrow pointing to the right identifies pattern III and the arrow pointing to the left identifies 
pattern I. The boxed regions highlight the pattern belonging to the specific arrow. Molecular weight in bp 
on the right side of the figure.
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DisCussion
NTM are ubiquitously present in the environment and can therefore be associated with 
either colonization, serious infection, or pseudo-outbreaks with a wide variety of presen-
tations (10,22,23,25). NTM should be considered in all cases of nosocomial infection, and 
careful surveillance must be applied to identify possible outbreaks. Presumed nosocomial 
outbreaks of NTM can be investigated by molecular typing of mycobacterial isolates. In 
cases where identical DNA fingerprints are found, laboratory cross-contamination can-
not always be excluded. However, in our study, all possible measures were taken to avoid 
any laboratory cross-contamination. The NTM were cultured from patients with compat-
ible clinical syndromes and were isolated from specimens that do not normally contain 
microorganisms. Molecular analysis revealed that the mycobacterial isolates represented 
several evolutionary lineages and more subtle strain variations. Therefore, in our study, 
laboratory cross-contamination is considered highly unlikely.
On basis of the diagnostic criteria of the American Thoracic Society, the medical rel-
evance of the NTM isolations reported here appears certain for at least half of the cases 
(cases 1, 6, 7, and 8). Their signs and symptoms were compatible with pathology found 
on physical examination or chest X ray, and the NTM were isolated from pleural effusions 
and a lymph node. In the other four cases (cases 2, 3, 4, and 5), NTM were isolated from 
ascites and a cutaneous abscess, and in these cases, it is not completely clear whether these 
mycobacteria were the most important causes of the pathologies. These last patients had 
other conditions that could have explained their nonspecific symptoms and the physical 
findings.
In none of the eight patients diagnosed with NTM infection of normally sterile body 
sites was the diagnosis made before hospital discharge or death. No specific therapy was 
given for the mycobacteria isolated, except for patient 2, who received empirical treat-
ment with rifampin, isoniazid, and pyrazinamide before the results of the culture became 
available. In five of the six specimens of sterile body sites, which were decontaminated 
with sulfuric acid and NALC-NaOH, NTM were cultured only after decontamination 
with sulfuric acid. However, the commonly used decontamination method is the use 
of NALC-NaOH. It has been shown that the decontamination method used affects the 
recovery of NTM (4).
Only a few cases of human disease caused by M. lentiflavum have been reported previ-
ously. The first case, concerning an 85-year-old woman with spondylodiscitis that im-
proved upon anti-tuberculous treatment, was reported in 1996 (24). Four children with 
lymphadenitis due to M. lentiflavum were described between 1997 and 2002 (5,12,26), 
as were cases of disseminated infection in an HIV-infected patient (21) and in a patient 
undergoing steroid therapy (13). Finally, M. lentiflavum was isolated from a patient with 
a chronic pulmonary disease. M. goodii was first described in 1999 and was isolated from 
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patients with traumatic osteomyelitis following iatrogenic infections and from patients 
with respiratory infections (3). Recently, a patient with bursitis due to an M. goodii infec-
tion was described (9). All of these cases occurred in Europe and the United States. To 
our knowledge, here we describe the first cases of M. lentiflavum and M. goodii infection 
in African patients. In fact, no clinically relevant NTM isolations in sub-Saharan Africa 
were reported before the 1990s (11,19).
Our htAFLP-mediated strain-typing method further corroborates the clinical relevance 
of the isolates; genetic diversity was observed among the strains. This degree of strain 
diversity shows that (i) the typing procedure is as adequate as can be expected when small 
numbers of strains are used and (ii) it is not the case that laboratory cross-contamination 
is the source of all of the M. lentiflavum isolates. However, multiple isolates of genotype 
D (Table 2) were identified. Whether this is due to laboratory contamination or a genuine 
NTM outbreak still needs to be resolved. It has to be emphasized that the respective type 
D strains were derived from patients nursed in different wards. The elevated incidence 
of the type D M. lentiflavum isolates (7/10 [70%] of the Zambian isolates) suggests that 
local dissemination of a certain type occurred or that M. lentiflavum as a species is quite 
clonal. The latter hypothesis is not in contradiction with the well-conserved features 
of the htAFLP fingerprints, even when isolates from The Netherlands and Zambia are 
compared (Fig. 2). In addition, both restriction fragment length polymorphism analysis 
and randomly amplified polymorphic DNA analysis performed for a subset of strains 
also revealed additional DNA polymorphisms among M. lentiflavum isolates (results not 
shown).
We conclude from our study that clinically relevant infection due to NTM seems to 
occur in HIV-positive as well as in HIV-negative patients in Zambia. The role of NTM in 
human disease in Africa may well be underestimated and should be examined in more 
detail and on a larger scale. Information is urgently needed with regard to the proper 
diagnostic procedures and the possibilities for adequate treatment of NTM-induced 
disease.
128 Chapter 7
referenCes
 1. American Thoracic Society. 1997. Diagnosis and treatment of disease caused by nontuberculous myco-
bacteria. Am. J. Respir. Crit. Care Med. 156:S1-S25.
 2. Ansari, N. A., A. H. Kombe, T. A. Kenyon, N. M. Hone, J. W. Tappero, S. T. Nyirenda, N. J. Binkin, and 
S. B. Lucas. 2002. Pathology and causes of death in a group of 128 predominantly HIV-positive patients 
in Botswana, 1997-1998. Int. J. Tuberc. Lung Dis. 6:55-63.
 3. Brown, B. A., B. Springer, V. A. Steingrube, R. W. Wilson, G. E. Pfyffer, M. J. Garcia, M. C. Menendez, 
B. Rodriguez-Salgado, K. C. Jost, Jr., S. H. Chiu, G. O. Onyi, E. C. Bottger, and R. J. Wallace, Jr. 1999. 
Mycobacterium wolinskyi sp. nov. and Mycobacterium goodii sp. nov., two new rapidly growing species 
related to Mycobacterium smegmatis and associated with human wound infections: a cooperative study 
from the International Working Group on Mycobacterial Taxonomy. Int. J. Syst. Bacteriol. 49:1493-
1511.
 4. Buijtels P. C. A. M., and P. L. C. Petit. 2005. Comparison of NaOH-N-actetyl cysteine and sulphuric acid 
decontamination methods for recovery of mycobacteria from clinical specimens. J. Microbiol. Methods 
62:83-88.
 5. Cabria, F., M. V. Torres, J. I. Garcia-Cia, M. N. Dominguez-Garrido, J. Esteban, and M. S. Jimenez. 2002. 
Cervical lymphadenitis caused by Mycobacterium lentiflavum. Pediatr. Infect. Dis. J. 21:574-575.
 6. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, 
C. E. Barry III, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, 
K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, and B. G. Barrell. 1998. 
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 
393:537-544.
 7. Corbett, E. L., C. J. Watt, N. Walker, D. Maher, B. G. Williams, M. C. Raviglione, and C. Dye. 2003. The 
growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. 
Med. 163:1009-1021.
 8. Frieden, T. R., T. R. Sterling, S. S. Munsiff, C. J. Watt, and C. Dye. 2003. Tuberculosis. Lancet 362:887-
899.
 9. Friedman, N. D., and D. J. Sexton. 2001. Bursitis due to Mycobacterium goodii, a recently described, 
rapidly growing Mycobacterium. J. Clin. Microbiol. 39:404-405.
 10. Gebo, K. A., A. Srinivasan, T. M. Perl, T. Ross, A. Groth, and W. G. Merz. 2002. Pseudo-outbreak of 
Mycobacterium fortuitum on a human immunodeficiency virus ward: transient respiratory tract coloni-
zation from a contaminated ice machine. Clin. Infect. Dis. 35:32-38.
 11. Githui, W., P. Nunn, E. Juma, F. Karimi, R. Brindle, R. Kamunyi, S. Gathua, C. Gicheha, J. Morris, 
and M. Omwega. 1992. Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: 
comparison of bacteriological results. Tuberc. Lung Dis. 73:203-209.
 12. Haase, G., H. Kentrup, H. Skopnik, B. Springer, and E. C. Bottger. 1997. Mycobacterium lentiflavum: an 
etiologic agent of cervical lymphadenitis. Clin. Infect. Dis. 25:1245-1246.
 13. Ibanez, R., R. Serrano-Heranz, M. Jimenez-Palop, C. Roman, M. Corteguera, and S. Jimenez. 2002. 
Disseminated infection caused by slow-growing Mycobacterium lentiflavum. Eur. J. Clin. Microbiol. 
Infect. Dis. 21:691-692.
 14. Jones, D., and D. V. Havlir. 2002. Nontuberculous mycobacteria in the HIV infected patient. Clin. Chest 
Med. 23:665-674.
 15. Kirschner, P., and E. C. Bottger. 1998. Species identification of mycobacteria using rDNA sequencing. 
Methods Mol. Biol. 101:349-361.
 16. Marras, T. K., and C. L. Daley. 2002. Epidemiology of human pulmonary infection with nontuberculous 
mycobacteria. Clin. Chest Med. 23:553-567.
 17. Master, R. N. 1994. Mycobacteriology, p. 3.0.1-3.16.4. In H. D. Isenberg (ed.), Clinical microbiology 
procedures handbook. American Society for Microbiology, Washington, D.C.
 18. Melles, D. C., R. F. Gorkink, H. A. Boelens, S. V. Snijders, J. K. Peeters, M. J. Moorhouse, P. J. van der 
Spek, W. B. van Leeuwen, G. Simons, H. A. Verbrugh, and A. van Belkum. 2004. Natural population 
dynamics and expansion of pathogenic clones of Staphylococcus aureus. J. Clin. Investig. 114:1732-
1740.
Isolation of nontuberculous mycobacteria in Zambia: eight case reports 129
 19. Morrissey, A. B., T. O. Aisu, J. O. Falkinham III, P. P. Eriki, J. J. Ellner, and T. M. Daniel. 1992. Absence 
of Mycobacterium avium complex disease in patients with AIDS in Uganda. J. Acquir. Immune Defic. 
Syndr. 5:477-478.
 20. Mwaba, P., M. Maboshe, C. Chintu, B. Squire, S. Nyirenda, R. Sunkutu, and A. Zumla. 2003. The re-
lentless spread of tuberculosis in Zambia—trends over the past 37 years (1964-2000). S. Afr. Med. J. 
93:149-152.
 21. Niobe, S. N., C. M. Bebear, M. Clerc, J. L. Pellegrin, C. Bebear, and J. Maugein. 2001. Disseminated 
Mycobacterium lentiflavum infection in a human immunodeficiency virus-infected patient. J. Clin. 
Microbiol. 39:2030-2032.
 22. Oda, G. V., M. M. DeVries, and M. A. Yakrus. 2001. Pseudo-outbreak of Mycobacterium scrofulaceum 
linked to cross-contamination with a laboratory reference strain. Infect. Control Hosp. Epidemiol. 
22:649-651.
 23. Phillips, M. S., and C. F. von Reyn. 2001. Nosocomial infections due to nontuberculous mycobacteria. 
Clin. Infect. Dis. 33:1363-1374.
 24. Springer, B., W. K. Wu, T. Bodmer, G. Haase, G. E. Pfyffer, R. M. Kroppenstedt, K. H. Schroder, S. Emler, 
J. O. Kilburn, P. Kirschner, A. Telenti, M. B. Coyle, and E. C. Bottger. 1996. Isolation and characteriza-
tion of a unique group of slowly growing mycobacteria: description of Mycobacterium lentiflavum sp. 
nov. J. Clin. Microbiol. 34:1100-1107.
 25. Tokars, J. I., M. M. McNeil, O. C. Tablan, K. Chapin-Robertson, J. E. Patterson, S. C. Edberg, and W. R. 
Jarvis. 1990. Mycobacterium gordonae pseudoinfection associated with a contaminated antimicrobial 
solution. J. Clin. Microbiol. 28:2765-2769.
 26. Tortoli, E., C. Piersimoni, P. Kirschner, A. Bartoloni, C. Burrini, C. Lacchini, A. Mantella, G. Muzzi, C. P. 
Tosi, V. Penati, C. Scarparo, M. T. Simonetti, and E. C. Bottger. 1997. Characterization of mycobacterial 
isolates phylogenetically related to, but different from, Mycobacterium simiae. J. Clin. Microbiol. 35:697-
702.
 27. van den Braak, N., G. Simons, R. Gorkink, M. Reijans, K. Eadie, K. Kremers, D. van Soolingen, P. 
Savelkoul, H. Verbrugh, and A. van Belkum. 2004. A new high-throughput AFLP approach for iden-
tification of new genetic polymorphism in the genome of the clonal microorganism Mycobacterium 
tuberculosis. J. Microbiol. Methods 56:49-62.
 28. van Soolingen, D., P. E. de Haas, P. W. Hermans, and J. D. van Embden. 1994. DNA fingerprinting of 
Mycobacterium tuberculosis. Methods Enzymol. 235:196-205.

Chapter 8Chapter 8
Clinical relevance of non-tuberculous 
mycobacteria in Katete, Zambia
P.C.A.M. Buijtels1&2, M.A.B. van der Sande3, C.S. de Graaff4, S. Parkinson5, H.A. 
Verbrugh2, D. van Soolingen6, and P.L.C. Petit7.
1 Medical Centre Rijnmond-Zuid, Department of Medical Microbiology, Rotterdam, 
The Netherlands
2 Erasmus MC, University Medical Center Rotterdam, Department of Medical Microbiology 
and Infectious Diseases, Rotterdam, The Netherlands
3 National Institute of Public Health and the Environment, Centre for Infectious Diseases 
Control, Epidemiology and Surveillance, Bilthoven, The Netherlands
4 Department of Pulmonary Diseases, Medical Centre Alkmaar, Alkmaar, The Netherlands
5 St. Francis Hospital, Katete, Zambia
6 National Institute for Public Health and the Environment, National Mycobacteria Reference 
Laboratory, Bilthoven, The Netherlands
7 Vlietland Hospital, Department of Medical Microbiology, Schiedam, The Netherlands
132 Chapter 8
ABstrACt
Some of the tuberculosis-like syndromes in Africa may be caused by NTM, as is the case 
in Western countries. Due to the spread of HIV, the role of NTM in mycobacterial infec-
tions may be particularly underestimated. In this study, the clinical relevance of the isola-
tion of non-tuberculous mycobacteria (NTM) from HIV-positive as well as HIV-negative 
patients in Zambia with a high prevalence of HIV in the population is evaluated.
The study was performed in 2003 in St. Francis Hospital, which is located in the district of 
Katete in Zambia. One hundred and eighty chronically-ill patients and 385 controls were 
included. From these patients and controls their baseline characteristics were recorded 
and sputum or gargle specimens were cultured for mycobacteria.
The proportion of NTM-positive sputum samples from the patients was significantly 
higher in comparison to the controls, 11 and 6% respectively (p<0.05). The most fre-
quently isolated NTM in the population of patients and controls was the Mycobacterium 
avium complex. However, in both groups also many (32%) not previously identified 
mycobacteria were isolated.
Two consecutive sputum samples were cultured from 29 of the 31 NTM-positive patients. 
In 25 of the 29 patients only a single culture was positive. The remaining 4 NTM-positive 
patients had two positive cultures for NTM of whom one patient had pulmonary disease. 
In two patients M. intracellulare was isolated twice, in one patient M. avium was isolated 
twice and in one patient two different species NTM together with M. tuberculosis were 
isolated. In three more NTM-positive patients one of the two sputum cultures contained 
AFB which could not be identified; two of these patients probably had pulmonary disease 
with M. intracellulare.
In contrast, only one control out of the 61 NTM-only positive controls had two sputum 
or gargle samples positive with (non-identical) NTM.
The 93 patients and controls with NTM cultured from the sputum had significantly differ-
ent clinical and radiological features compared to the 472 patients and controls without 
NTM in the sputum. They were more likely to complain of vomiting and diarrhoea and 
were more often underweight (Body Mass Index < 18). In addition, the chest X-ray had 
more frequently changes consistent with TB.
NTM probably play an important role in the aetiology of mycobacterioses in Zambia. In 
this study two consecutive sputum samples were cultured from 154 patients and 383 con-
trols. The estimated rate of colonization in the patient population was 14/154 (9%) with 
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a rate of disease of 3/154 (about 2%). The estimated rate of colonization in the general 
population was 61/383 (16%). More extended studies, in duration and size, are needed to 
determine the magnitude of NTM infection and colonization in the African population.
introDuCtion
The genus Mycobacterium can be divided into the Mycobacterium tuberculosis complex, 
M. leprae, and the atypical mycobacteria or non-tuberculous mycobacteria (NTM). These 
NTM are also named ‘environmental mycobacteria’, since they are frequently isolated 
from environmental sources, including surface water, tap water, and soil (21).
There are indications that NTM infections in humans are increasing (1,3). In addi-
tion, there appears to be marked geographic variability in the distribution of NTM both 
in terms of the prevalence of NTM lung disease and causative mycobacterial species 
(1,3,27). However, most data reporting high rates of NTM infection come from Northern 
European countries and the United States. In Africa, studies reporting NTM infections 
are rare, despite the fact that environmental exposure to NTM was found to be very high 
(17).
Tuberculosis is a problem of enormous dimension in Africa and M. tuberculosis is the 
most important causative agent. However, it is known that NTM also play a significant 
role in industrialised countries in the aetiology of tuberculosis-like syndromes. In Africa, 
the contribution of NTM to the clinical problem of tuberculosis has so far been examined 
only on a very small scale.
In Zambia, a country with historically high prevalence rates of tuberculosis, patients 
with acid-fast bacilli (AFB)-positive sputum on direct microscopic examination, or those 
displaying chest radiographic findings that suggest active tuberculosis but do not respond 
to antibiotics, are generally presumed to have pulmonary tuberculosis. In principle these 
patients are treated empirically with a combination of anti-tuberculosis drugs for a period 
of six months. Therefore, an inconclusive diagnosis of pulmonary tuberculosis could lead 
to the inappropriate or unnecessary treatment of patients. A number of the tuberculosis-
like syndromes in Africa could be caused by NTM, as is the case in many industrialised 
countries. However, even if NTM are cultured and identified in respiratory specimens, 
NTM lung disease still requires differentiation from contamination or colonization. Thus, 
the detection of AFB in respiratory specimens, or the isolation of NTM, may pose a diag-
nostic problem for the clinician.
A useful guide to the diagnosis of NTM disease in patients with or without HIV co-
infection are the set of criteria set out by the American Thoracic Society (ATS), published 
in a statement in 1997 and the similar guidelines formulated by the British Thoracic 
134 Chapter 8
Society (BTS) (1,3). The diagnostic criteria for NTM pulmonary infections include both 
the imaging findings consistent with pulmonary disease and the repeated isolation of the 
same mycobacteria from sputum or bronchial wash in a symptomatic patient.
In a pilot study performed in three different hospitals in Zambia in 2001, high rates of 
NTM culture positive sputa were observed (7). Therefore, in the present study, the clinical 
relevance of the isolation of NTM from HIV-positive as well as HIV-negative patients in 
Zambia is examined in detail.
MAteriAl AnD MethoDs
The study was performed in St. Francis Hospital, which is located in the district of Katete 
in Zambia, from August 2002 to March 2003. It serves a rural population of over 200,000 
within a 60 km radius and receives specialist referrals from all over the Eastern Province 
(about 1.5 million residents).
The study population comprised of adults (≥15 years old) with chronic (defined as ≥ 
two weeks) complaints and a productive cough who were admitted to the department 
of internal medicine of the hospital. Most of the included patients had respiratory tract 
symptoms (96%). The other 4% of the patients had skin infections/abscesses or lymph 
adenopathy.
For each eligible admitted patient who consented to participate in the study, two healthy 
community controls were recruited randomly from the neighbouring community. These 
controls were not adjusted regarding age or other characteristics of the patients.
On enrolment, each patient and control was interviewed in their own language, and their 
medical records were reviewed using a standard form. A detailed physical examination 
was performed. Chest X-rays were evaluated blind in The Netherlands without any ad-
ditional clinical information. Films were scored for mediastinal adenopathy, cavitation, 
pleural and pericardial fluid, miliary pathology, alveolar infiltration, interstitial pathol-
ogy, pathology other than mentioned, or no pathology. The conclusions of the scoring 
system were chest X-rays labelled with no pathology, pathology not suggestive of TB, and 
pathology consistent for TB. Over three consecutive days, sputum was collected from 
patients with a productive cough. The controls were asked to gargle with normal saline if 
they could not produce sputum. The first two sputum or gargle specimens were cultured 
for mycobacteria, and the third one was stored at −20°C.
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The study was approved by the research ethical committee of the University of Zambia, 
the Central Board of Health, and the Ministry of Health in Zambia. Informed consent 
was obtained from all patients and controls before recruitment.
laboratory methods
Sputum or gargle specimens were divided into two equal parts: one half was decontami-
nated with N-acetyl-l-cysteine (NALC)-NaOH and the other half was decontaminated 
using 6% sulfuric acid in order to compare decontamination procedures for the culture 
of mycobacteria (6). The specimens were cultured in Mycobacteria Growth Indicator 
tubes (Becton Dickinson Microbiology Systems, Cockeysville, Md., US) according to 
the manufacturer’s instructions and the guidelines described previously by Master (16). 
Mycobacterial isolates were identified by the Accuprobe culture confirmation test for the 
M. tuberculosis complex (Accuprobe, bioMérieux, Marcy l’Etoile, France) or by 16S rRNA 
gene sequencing (14). Serological testing for HIV was performed using a qualitative im-
munoassay (Abbott Determine HIV-1/2) and the Vidas HIV DUO assay (bioMérieux, 
Marcy l’Etoile, France).
Materials needed for collection and culture were imported from The Netherlands, and 
an experienced Dutch technician performed the work in the Zambian laboratory. All 
possible efforts were made to prevent laboratory cross-contamination, including the col-
lection of a sputum specimen in a brand-new container imported from The Netherlands. 
The stock of decontamination fluid was sterilized twice a week, and each day a fresh, 
sterile tube or bottle was opened. The samples in the laboratory were processed one by 
one, away from other samples, and negative control cultures were included in each batch 
of samples. Microscopic slides were also prepared one at a time. All work associated with 
this project was conducted by the same experienced laboratory technician. All culture 
procedures were performed in a new class I biosafety cabinet.
Data analysis
Data were entered in SPSS 6 and analysed using STATA vs 8.0 (Stata Corporation College 
Station, TX, USA). Student t-tests were used to assess different means between groups; 
proportions were compared using chi-square testing. Univariate odds ratios (OR) with 
95% confidence intervals (CI) were calculated to assess the associations of potential risk 
factors of participants being NTM-positive. A stepwise backward regression approach 
was used for a multivariate analysis.
Body Mass Index (BMI) was calculated as weight in kg divided by squared height in 
meters. Underweight was defined as a BMI of less than 18.
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Clinical significance of isolated ntM: disease, infection, colonization
The Diagnostic Criteria for NTM Lung Disease were issued in 1997 by the American 
Thoracic Society (ATS) (1). In the year 2000, the British Thoracic Society (BTS) pub-
lished its guidelines for the management of NTM lung disease (3). According to the Brit-
ish Thoracic Society guidelines, NTM lung disease is indicated when positive cultures 
develop from specimens of sputum obtained at least seven days apart in a patient whose 
chest radiograph suggests mycobacterial infection and who may or may not manifest 
symptoms or signs. The American Thoracic Society guidelines include diagnostic criteria 
that are stricter than those of the British Thoracic Society statement. The BTS criteria 
include symptomatic patients with infiltrate, nodular, or cavitary disease, who have had 
three positive sputum/bronchial wash cultures with negative AFB smears, or two positive 
cultures and one positive AFB smear, in the last 12 months.
However, in developing countries the criteria of the ATS or BTS may need some modi-
fication in order to be implementable, because the collection, examination and culturing 
of three consecutive samples within a certain time period is hampered by major logistic 
problems. In this study patients were therefore diagnosed as having NTM lung disease 
if they exhibited respiratory symptoms, abnormal chest radiography suggestive of my-
cobacterial infection and two positive sputum cultures with the same NTM. Patients or 
controls with positive NTM cultures who did not meet these criteria were considered 
colonized.
results
Between August 2002 and February 2003, 180 patients and 385 controls were included 
in the study. Two sputum samples were cultured from a total of 154 patients and 383 
controls. The median age of the patients and controls was 35 (range 16-80) and 30 (range 
15-78), respectively. Females represented 55% (99/180) of the patient group and 69% 
(265/385) of the control group. Of the patients, 128 (71%) were HIV-positive and of the 
controls 87 (23%).
Culture results of patients
Of the 180 patients, 60 (33%) with exclusively M. tuberculosis were isolated from the spu-
tum samples, 12 (7%) yielded both M. tuberculosis and NTM, and 19 (11%) only NTM 
(see Table 1). The Ziehl-Neelsen smear microscopy of the sputum sample was positive in 
46 of the 69 (67%) patients with M. tuberculosis and in one patient with a NTM-positive 
culture.
Clinical relevance of non-tuberculous mycobacteria in Katete, Zambia 137
Two consecutive sputum samples were cultured from 29 of the 31 NTM-positive patients. 
In 25 of the 29 patients only a single culture was positive. The remaining 4 NTM-positive 
patients had two positive cultures for NTM of whom one had pulmonary disease. In 
two patients M. intracellulare was isolated twice, in one patient M. avium was isolated 
twice and in one patient two different species NTM together with M. tuberculosis were 
isolated.
In three more NTM-positive patients one of the two sputum cultures contained AFB 
which could not be identified. Two patients had M. intracellulare in one sputum sample 
and from one patient M. porcinum was isolated.
Case reports for patients suspected of ntM disease
The characteristics of the patients with NTM in both sputum samples and NTM together 
with AFB which could not be identified are shown in Table 2. In three (cases 1, 2 and 
4) there was a solid basis for the suspicion of NTM-associated disease because of the 
combination of symptoms, positive cultures and pathology on the chest X-ray consistent 
with TB. However, only Case 1 fulfilled the criteria of this study for NTM lung disease. In 
all three of these patients M. intracellulare was isolated.
One patient (Case 4) was a 32-year-old HIV-positive man who complained of a pro-
ductive cough with haemoptysis of 17 weeks’ duration. Furthermore, he was vomiting 
and had diarrhoea. The BMI was 15. He had been treated for tuberculosis in the past. 
The chest X-ray was consistent with TB and showed alveolar infiltration and interstitial 
table 1: Culture results of patients and controls.
Culture results Patients Controls
Number 180 385
Culture exclusively M. tuberculosis 60 (33%) 2 (0.5%)
Culture M. tuberculosis and NTM 12 (7%) 1 (0.3%)
Culture exclusively NTMa 19 (11%) 61 (16%)
Culture NTM 31 (17%) 62 (16%)
Two sputum or gargle samples cultured 154 383
Two sputum or gargle samples cultured in NTM 
positive person
29 (of 31 NTM-positive 
patients)
62 (of 62 NTM-positive 
controls)
Single NTM positive culture in NTM positive person 
with two samples cultured
25 (of 29 NTM-positive 
patients)
61 (of 62 NTM-positive 
controls)
Two NTM positive cultures in NTM positive person 
with two samples cultured
4 (of 29 NTM-positive 
patients)
1 (of 62 NTM-positive 
controls)
Two NTM positive cultures in persons with two 
samples culturedb
4 (of 154 patients with 
two samples cultured)
1 (of 383 controls with 
two samples cultured)
aThe proportion of patients with exclusively NTM was comparable with the controls (p=0.2).
bSignificantly more patients in comparison to controls had two sputum or gargle cultures positive with 
NTM (p<0.05).
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pathology. He did not improve on antibiotics and started for the second time with an 
anti-tuberculosis treatment. Mycobacteria were cultured from both sputum samples and 
identified as M. intracellulare. He died five weeks later.
Another patient (Case 1), suffering from M. intracellulare pulmonary disease, was a 55-
year-old man who was HIV-positive. He was admitted with a productive cough with hae-
moptysis that he had had for 17 weeks. Diarrhoea was also present and his BMI was 17. 
He had been receiving anti-tuberculosis treatment for four months. The sputum obtained 
before treatment was started was AFB negative. The radiographic investigation of the 
chest revealed cavities and alveolar consolidation. No improvement was achieved while 
on antibiotics. The sputum was examined again and the smear this time was positive 
for AFB. The first sputum culture revealed M. intracellulare and, unfortunately, in the 
second sputum culture the mycobacteria could not be identified due to logistic reasons. 
The patient died three weeks later.
The last patient (Case 2) with M. intracellulare pulmonary disease was an HIV-positive 
45-year-old woman who presented with respiratory complaints that she had had for 
more than one year. She was known to have asthma. On physical examination enlarged 
submandibular, supraclavicular and axillary lymph nodes were found. Her BMI was 20. 
Alveolar infiltration was seen on the chest X-ray. The culture of the first sputum indicated 
the presence of mycobacteria which could not be identified; in the second sputum M. in-
tracellulare was identified.
Culture results of controls
In three of the 385 (0.8%) controls, M. tuberculosis was cultured from the sputum or gargle 
specimen, and NTM was also isolated from one of these three patients (see Table 1). In 
61 (16%) controls exclusively NTM were isolated and this number was comparable with 
the proportion of patients among whom exclusively NTM were isolated (11%, p=0.2). 
In 61 out of 62 NTM positive controls, only one sputum or gargle specimen was culture 
positive for NTM. In one control, who was HIV-negative, two different mycobacteria, 
M. porcinum and an unknown Mycobacterium, were isolated. No chest X-rays suggestive 
of tuberculosis were observed in any of the controls.
From 383 controls, two sputum or gargle samples were subjected to Mycobacterium 
culture. Significantly more patients in comparison to these controls had two sputum or 
gargle cultures positive for NTM, four out of 154 patients and one out of the 383 controls 
(p<0.05).
isolated Mycobacterium species
The collected sputum or gargle samples from all patients and controls were split in two equal 
parts before decontamination in order to compare the influence of the decontamination 
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method on the yield of mycobacteria (6). From the 180 patients included, a total of 635 
sputum samples were cultured and in total 1,532 sputum or gargle samples were analysed 
from the 385 controls. The results of the cultures are depicted in Table 3. The relative 
number of NTM (72) isolated from the 635 sputum samples of patients was significantly 
more in comparison with the number of NTM (99) isolated from 1,532 sputum or gargle 
samples from the controls: 11 and 6 percent, respectively (p<0.001).
From 273 (43%) of the 635 sputum samples of patients, mycobacteria were isolated. 
M. tuberculosis was found in 201 of the 273 (74%) positive sputum specimens and NTM 
in 72 (26%). The most frequently isolated NTM was M. intracellulare (12).
Mycobacteria were isolated from 104 of the 1,532 (6.8%) sputum or gargle samples cul-
tured from the controls. M. tuberculosis was found in 5 of the 104 (4.8%) positive cultures 
and NTM in 99 (95%). The predominant NTM isolated from the controls were M. avium 
(5), M. goodii (4) and M. peregrinum (4).
In both groups also many (55 of the 171 NTM = 32%) mycobacteria not previously 
identified were found.
Comparison of persons with and without ntM in their sputum or gargle sample
The 93 patients and controls with NTM-positive cultures had significantly different clini-
cal and radiological features compared to the 472 patients and controls without NTM in 
the sputum (Table 4). They were more likely to report vomiting and diarrhoea. Further-
more, they were more often underweight (BMI < 18). Overall, a clinical picture of general 
table 3: Culture results of sputum of patients and controls.
Culture result Patients Controls
Negative 362 (57%) 1428 (93%)
M. tuberculosis 201 (32%)    5 (0.3%)
M. avium complex  15 (2%)    5 (0.3%)
 M. intracellulare  12 (2%)    0
 M. avium   3 (0.5%)    5 (0.3%)
M. gordonae   4 (0.6%)    0
M. peregrinum   2 (0.3%)    4 (0.3%)
M. goodii   1 (0.2%)    4 (0.3%)
M. porcinum   1 (0.2%)    3 (0.2%)
M. lentiflavum   1 (0.2%)    0
Various unknown Mycobacterium species  13 (2%)   42 (3%)
Various other Mycobacterium species*   3 (0.5%)    7 (0.5%)
Unidentified AFB  32 (5%)   34 (2%)
Total number of sputum samples 635 1532
*Various other Mycobacterium species in the patients include M. fortuitum, M. neoaurum, and M. simiae.
Various other Mycobacterium species in the controls include M. fortuitum, M. asiaticum, M. aurum, and 
M. conspicuum.
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malaise was more often observed in the NTM-positive person. In addition, the chest 
X-ray more frequently revealed changes consistent with TB, such as consolidation and 
interstitial pathology. The HIV-status and the presence of M. tuberculosis in the sputum 
culture was not significantly different between the NTM culture positive and negative 
persons. Moreover, there were no significant differences in age (mean 36.7 versus 34.8 
yrs; p=0.2), sex, smoking habits, alcohol, and previous tuberculosis treatment between 
the groups (Table 5). The percentage of farmers, source of water supply and the use of 
(un)boiled milk were comparable. A subgroup analysis, restricted to patients with NTM 
versus patients without NTM in the sputum, yielded broadly similar results (data not 
shown).
table 4: Clinical features of NTM-positive and negative persons.
Any sample NTM-
positive
NTM-negative p-value All
Subjects, n (%) 93 (16.5) 472 (83.5) - 565
HIV-positive, n (%) 41 (45.6) 174 (38.5) 0.2 215 (39.7)
M. tuberculosis, n (%) 13 (14.0)  62 (13.1) 0.8  75 (13.3)
BMI, mean (sd) 20.2 (4.2)  20.8 (3.7) 0.2  20.7 (3.8)
Underweight, n (%) 26 (29.6)  92 (20.6) 0.06 118 (22.1)
Vomit, n (%)  8 (8.6)  18 (3.8) 0.04  26 (4.6)
Diarrhoea, n (%) 12 (12.9)  11 (2.3) <0.001  23 (4.7)
Lymph nodes, n (%) 21 (22.8) 146 (30.9) 0.1 167 (29.6)
Chest X-ray compatible with 
TB but culture negative for 
M. tuberculosis, n (%)
 5 (26.3)  28 (7.1) 0.003
 33 (8.0)
Died, n (%)  9 (9.7)  26 (5.5) 0.1  35 (6.2)
table 5: Background characteristics of NTM-positive and negative persons.
NTM-positive, n (%) NTM-negative, n (%) p-value All, n (%)
Subjects 93 (16.5) 472 (83.7) - 565
Female 61 (65.6) 303 (64.2) 0.8 364 (64.4)
Age (mean, sd) 36.7 (13.1)  34.8 (14.6) 0.2  35.1 (14.4)
Farmer 48 (51.6) 245 (51.9) 1.0 293 (51.9)
Water
  Well
  Borehole
  Tap
  River
  Swamp
27 (29.4)
40 (43.5)
23 (25.0)
 1 (1.1)
 1 (1.1)
158 (33.6)
235 (49.9)
 62 (13.2)
  9 (1.9)
  7 (1.5) 0.1
185 (32.9)
275 (48.9)
 85 (15.1)
 10 (1.8)
  8 (1.4)
Un-boiled milk 15 (16.1)  62 (13.1) 0.4  77 (13.6)
Smoker  5 (5.7)  41 (8.9) 0.3  46 (8.4)
Alcohol  9 (10.3)  51 (11.2) 0.8  60 (11.0)
Hospitalised 31 (33.3) 149 (31.6) 0.7 180 (31.9)
Previous TB treatment  9 (9.7)  28 (5.9) 0.2  37 (6.6)
142 Chapter 8
The independent risk factors for NTM culture positive sputum were determined using 
multivariate analysis. Two factors, underweight (BMI<18) and water supply from the 
tap, were independently associated with having a NTM-positive sputum culture (see 
Table 6).
DisCussion
The purpose of this study was to compare the prevalence of NTM in sputum between 
hospitalised, chronically-ill patients and community controls and to determine the clini-
cal significance of the isolation of NTM.
The proportion of patients and controls with a positive sputum or gargle culture for NTM 
were comparable, 11 and 15%, respectively. However, the proportion of NTM-positive 
sputum samples from the patients was significantly higher in comparison to the controls, 
11 and 6% respectively. This suggests persistent NTM are associated with the chronic 
complaints of these patients.
Gargle is not the same as a normal sputum sample and it is not well known whether cul-
ture results are influenced by these different ways of obtaining specimens. In a specimen 
obtained by gargle especially the flora of the oropharyngeal mucosa is obtained, while 
sputum also represents the flora of the lower airways. In the patient group more subjects 
table 6: Crude and adjusted risk factors (OR, 95% CI) for NTM isolated from sputum.
Univariate analysis, OR 
(95% CI)
Multivariate analysis, OR 
(95% CI)*
Hospitalised 1.1 (0.7-1.7) ns
Age >=25 1.3 (0.8-2.5) ns
Sex (female) 1.1 (0.7-1.7) ns
Underweight (BMI < 18) 1.6 (1.0-2.7) 1.7 (1.0-2.9)
M. tuberculosis 1.1 (0.6-2.0) ns
Previous TB treatment 1.7 (0.8-3.7) ns
HIV-positive 1.3 (0.8-2.1) ns
Tap water to other sources of water supply 2.2 (1.3-3.8) 2.0 (1.1-3.5)
Alcohol 0.9 (0.4-1.9) ns
Smoking 0.6 (0.2-1.6) ns
Un-boiled milk 1.3 (0.7-2.3) ns
Farmer 1.0 (0.6-1.5) ns
Chest X-ray compatible with TB but culture 
negative for M. tuberculosis, n (%)
4.7 (1.6-13.9) ns
*stepwise backward elimination.
Definition of abbreviations: ns = not (statistically) significant, OR = odds ratio, CI = confidence interval.
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were capable of producing sputum and this may have influenced the yield of positive 
NTM cultures.
In the literature, many risk factors for NTM have been determined. These risk factors can 
be divided in underlying medical conditions, the living and working environment, and 
demographic features. Patients with cystic fibrosis and HIV-positives are two important 
high-risk groups (15,18). Other important factors includes the following: underlying 
chronic lung disease, working in the mining industry, advanced age, and being male 
(5,12,15,22). Studies in immune competent patients recognised two patient profiles as 
being at increased risk of NTM: ‘elderly females’ and ‘middle-aged males’ (9,19). In this 
study, in an African setting, HIV, sex and age were not determined as risk factors. In fact, 
the only two true risk factors for a positive NTM culture were being underweight and 
consuming of tap water. It is known from the literature that NTM are natural inhabitants 
of municipal water systems and soil. However, the demographic figures in Africa may not 
be comparable to that in the industrialised world.
It became clear in this study that patients and controls with NTM in the sputum or 
gargle sample had more frequent symptoms and signs of general malaise and that the 
chest X-rays in these NTM-positive persons more frequently showed pathology in com-
parison with NTM culture-negative persons. Clinical symptoms caused by NTM can be 
distinguished in four main categories: pulmonary disease, superficial lymphadenitis, skin 
and soft tissue infection, and disseminated disease. Pulmonary disease accounts for up 
to 90% of all cases. Because one of the inclusion criteria for this study concerned chronic 
complaints with a productive cough, it is conceivable that most of the included patients 
were having respiratory symptoms. However, besides the respiratory symptoms and signs, 
patients with a positive NTM culture also more frequently revealed a clinical picture of 
general malaise, including diarrhoea, vomiting, and being underweight. These symptoms 
and signs may not be specific for NTM infection, but may reflect the poor health of the 
patient more generally.
Differences in the geographic distribution of NTM species have been reported (3,19,25). 
The most commonly encountered NTM from clinical specimens in the industrialised 
world are M. avium complex (MAC) and M. kansasii. In Africa limited studies have been 
performed and the distribution of NTM is not fully known. In the literature, MAC is less 
frequently isolated from clinical specimens (11,17).
In contrast, in this study, the most isolated NTM in the population of patients and 
controls was MAC. However, in both groups a part (32%) of the NTM found in Zam-
bia have not yet been identified on a species level and named in other countries. This 
study indicates that the distribution of NTM in Africa may be different from Europe and 
the United States of America. The not-yet identified NTM at least cause colonization in 
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Africans and in some patients they also cause disease. The magnitude of this problem, in 
addition to the problem of tuberculosis, is unknown at the moment, but deserves more 
attention.
In a former study in Katete during the end of the warm and rainy season in 2001, a high 
rate of M. lentiflavum among patients was reported (7). However, in the present study, 
performed during the cool and dry season as well as in the warm and rainy season, there 
was only one patient from whom M. lentiflavum was isolated. It is known from the lit-
erature that several factors influence the occurrence of mycobacteria in the environment. 
Soil and geologic factors such as chemical composition of the substrates and pH play an 
important role in the distribution of mycobacteria, in general, and of each mycobacterial 
species, in particular. Furthermore, seasonal variations in the composition of the myco-
bacterial flora are linked to climatic conditions and rates of recovery of mycobacteria in 
the environment are higher in the dry than in the wet season (8,20). Another possible 
explanation for the differences in the number of M. lentiflavum isolated in the two studies 
may be found in man-made artificial environments of NTM. NTM such as M. avium, 
M. kansasii and M. xenopi have frequently been isolated from drinking and hospital wa-
ter distribution systems and also M. lentiflavum was isolated from these water systems 
(24,26). In the year 2001 an environmental reservoir contaminated with M. lentiflavum 
may have resulted in colonization of the respiratory or digestive tract of the patients and, 
hence, have caused disease in a part of them.
Also the rates of NTM colonization and disease that have been reported seem to be vari-
able in different geographic areas. In North America and Europe, rates of colonization 
and disease in the general population range from about 1-15 per 100,000 and 0.1-2 per 
100,000, respectively. In the major part of Africa these rates are largely unknown. In 
South Africa, prevalence rates of NTM colonization in the population of between 1,400 
and 6,700 per 100,000 have been reported (4,13). In South Africa gold miners’ rates of 
NTM colonization were calculated at 101 per 100,000 and rates of disease were reported 
as 66 and 12 per 100,000 for M. kansasii and M. scrofulaceum, respectively (10,11).
In this study two sputum samples were collected and cultured from 154 of the 180 
chronically-ill patients included.
NTM were isolated from at least one sputum sample in 29 patients. In four of these 29 
patients NTM was isolated in both sputum samples. In three more NTM-positive patients 
one of the two sputum cultures contained AFB which could not be identified (Table 1).
NTM lung disease was definitely diagnosed in one and probably in three patients (cases 
1, 2 and 4). From the sputum samples of these HIV-positive patients M. intracellulare 
was isolated. These patients presented with respiratory complaints and the chest X-ray 
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showed pathology compatible with tuberculosis. Unfortunately, in two patients one of 
two sputum samples with mycobacteria could not be identified due to contamination 
and re-culture problems. The combination of symptoms, positive cultures and pathology 
on the chest X-ray are significant characteristics of NTM infection and are suggestive of 
NTM pulmonary disease.
However, the ATS criteria are not completely fulfilled because two instead of three 
sputum samples were cultured on consecutive days. Furthermore, two of these patients 
suspected for NTM lung disease were treated for tuberculosis in the past. The sputum 
specimens of these patients were cultured twice in liquid medium after splitting each 
specimen for decontamination with two different methods. These sputa were not tested 
with molecular amplification techniques for the possible presence of M. tuberculosis and 
for the presence of multi-drug resistant M. tuberculosis which should have been excluded 
(2,23). However, the performance of these nucleic acid amplification (NAA) tests is in 
general good in clinical respiratory specimens that are AFB smear-positive but less in 
specimens that contain fewer organisms or are AFB-negative. The NAA-test would in 
a part of the cases be better in comparison to culture to detect a mixture of NTM and 
M. tuberculosis. Moreover, sputum specimens were not cultured on a solid medium and 
therefore it was not possible to count the number of colony-forming units to distinguish 
between colonization and infection or disease.
The estimated rate of colonization in this study in the patient population was 14/154 (9%) 
with a rate of disease of 3/154 (about 2%).
From 383 controls, two sputum or gargle specimens were collected and cultured. NTM 
were isolated from both specimens in one of the 61 controls with at least one sample 
being NTM culture positive. The control was not suspected of NTM pulmonary disease. 
The estimated rate of colonization in the general population on the basis of this figure is 
61/383 (16%).
NTM probably play an important role in the aetiology of mycobacterioses in Zambia. 
More extended studies, both in terms of duration and size, will be needed to determine 
the extension of NTM infection in the African continent.
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ABstrACt
Diagnosis of tuberculosis (TB) in resource-poor countries is almost exclusively based 
on microscopy of Ziehl-Neelsen stained (ZN) sputum smears; in some settings supple-
mented by chest X-ray. The aim of this study was to determine the accuracy of this diag-
nosis of TB in Zambia in the era of increasing HIV prevalence. By applying MGIT liquid 
culture technique, this study distinguished between (i) TB cases confirmed by positive 
Mycobacterium tuberculosis cultures, (ii) mycobacteriosis caused by non-tuberculous 
mycobacteria (NTM) and, (iii) tuberculosis-like disease caused by organisms other than 
mycobacteria.
Patients (15 years and above) who had been diagnosed with TB on the basis of: respira-
tory complaints lasting two or more weeks, failure to improve on two courses of routine 
empiric antibiotics, a positive ZN sputum smear and/or findings on the chest X-ray 
consistent with TB were included in this study. Sputum of the diagnosed TB cases was 
additionally subjected to MGIT liquid culture. Mycobacterium isolates were identified 
using a nucleic acid amplification method and 16S DNA sequencing.
Only in 47% of the 187 diagnosed TB cases M. tuberculosis was cultured. In another 
19% of the cases, exclusively NTM were cultured, whereas from 12% of the TB cases a 
combination of M. tuberculosis and NTM was isolated. In the remaining 29% of cases in 
which TB was diagnosed, no mycobacteria were cultivable. HIV positivity was signifi-
cantly correlated with the isolation of NTM from sputum and inversely associated with 
the isolation of exclusively M. tuberculosis from sputum (p<0.05).
Basing the diagnosis of tuberculosis on symptoms, sputum smear and/or chest X-ray 
may lead to significant numbers of false-positive cases of tuberculosis in Zambia, due to 
the increased prevalence of HIV.
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introDuCtion
The increase in tuberculosis (TB) rates is closely associated with the spread of the HIV 
epidemic throughout sub-Saharan Africa. The clinical presentation of TB in HIV-infected 
individuals various with the degree of immunosuppression, and TB symptoms in HIV 
infected persons are often non-specific, resulting in a delayed- or misdiagnosis.
Sputum smear examination for acid-fast bacteria (AFB) is still the cornerstone of di-
agnosis of pulmonary TB in low-income countries. Smear examination by experienced 
technicians can result in the diagnosis of at most 50-60% of TB cases. However, in these 
high-prevalence settings considerably lower rates of AFB detection in TB patients are 
observed because of poor access to good quality microscopes, the shortage of trained staff 
and the work load. Moreover, the sputum smears of HIV-positive patients often present 
as Ziehl-Neelsen (ZN) negative. Unfortunately, although sputum culture remains the 
‘gold standard’ for the diagnosis of pulmonary TB, this diagnostic tool is rarely available 
in low-income countries. Moreover, the traditional solid medium culture of AFB takes 
3-8 weeks, limiting the usefulness of the culture as a first-line diagnostic test. In the last 
decade, liquid culture methods have become available in the industrialized world, with a 
shorter turn-around time of 1-3 weeks (2,16).
According to the International Standards for Tuberculosis Care, all persons with an unex-
plained productive cough lasting two to three weeks or more should be evaluated for TB 
(10). These patients should submit at least two, and preferably three, sputum specimens 
for microscopic examination. If such patients have a sputum smear positive for acid fast 
bacilli, they are officially diagnosed with TB. The diagnosis of sputum smear-negative 
pulmonary TB is based on at least three negative sputum smears, chest radiography find-
ings consistent with TB, and lack of response to broad-spectrum antimicrobial agents.
However, in areas with a high prevalence of HIV and tuberculosis infection, the diag-
nosis of smear-negative TB is problematic, given the atypical presentation of pulmonary 
TB in HIV-infected patients. Furthermore, smear-negative patients can also present with 
normal or only slightly abnormal chest X-rays. Moreover, in low income countries, ac-
cess to high quality radiography and interpretation is often limited (14). The accurate 
diagnosis of smear-negative pulmonary TB may therefore be complicated when reliance 
is just placed on clinical and radiological features.
Patients for whom there is a strong clinical suspicion of TB are often treated empiri-
cally with a combination of anti-tuberculosis drugs for six to nine months. Therefore, the 
inaccurate diagnosis of tuberculosis leads to unnecessary treatment of patients, diverting 
assets and personnel from true TB cases.
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The aim of this study was to determine the accuracy of the clinical diagnosis of TB, based 
on sputum smears and chest X-ray in Zambia in the era of increasing HIV prevalence. 
Using a modern liquid culture technique a distinction was made between (i) TB cases 
confirmed by positive Mycobacterium tuberculosis cultures, (ii) mycobacterioses caused 
by non-tuberculous mycobacteria (NTM) and, (iii) tuberculosis-like diseases caused by 
pathogens other than mycobacteria.
MAteriAl AnD MethoDs
This study was conducted in St. Francis Hospital in Katete, Yeta District Hospital in Ses-
heke and Our Lady’s Hospital in Chilonga. Ethical approval for the study was provided by 
the research ethical committee of the University of Zambia, the Central Board of Health, 
and the Ministry of Health in Zambia.
All adults aged 15 years and more, admitted to the internal medicine ward with chronic 
complaints lasting two or more weeks, were screened for TB and HIV after informed 
consent had been obtained. The study was performed between 2001 and 2003 during 
consecutive time periods of several months.
The medical history of the patients was retrieved, and detailed physical examination was 
performed. During three consecutive days, sputum was collected from patients with a 
productive cough. The first two sputum specimens were cultured for mycobacteria, and 
the third one was stored at −20°C. Sputa specimens were examined in the normal routine 
flow of the hospital by microscopy for the presence of acid-fast bacteria after Ziehl-Neels-
en staining and all were subjected to culture in Mycobacteria Growth Indicator tubes 
(Becton Dickinson Microbiology Systems, Cockeysville, Md., US). Decontamination of 
the sputum was done using N-acetyl-l-cysteine (NALC)-NaOH and 6% sulfuric acid 
after dividing the sputum specimen into two equal parts to compare decontamination 
procedures for the detection of mycobacteria (7).
Chest X-rays were evaluated in the Netherlands on a blinded manner without any ad-
ditional clinical information. Films were scored for mediastinal adenopathy, cavitation, 
pleural and pericardial fluid, miliary pathology, alveolar infiltration, interstitial pathol-
ogy, pathology other than mentioned, or no pathology. The conclusions of the scoring 
system were defined as: chest X-rays labelled with no pathology, pathology not consistent 
with TB, or pathology consistent with TB.
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Serological testing for HIV was performed using a qualitative immunoassay (Abbott De-
termine HIV-1/2) and the Vidas HIV DUO assay (Biomérieux, Marcy l’Etoile, France). 
The Accuprobe culture confirmation test for M. tuberculosis complex (Accuprobe, bio-
Mérieux, Marcy l’Etoile, France) and/or 16S rRNA gene sequencing were used to identify 
mycobacterial isolates (12).
results
In this study, 320 chronically ill patients were enrolled. The median age of the population 
was 36 (range 16-80) and 52% were female. Of these patients 313 were HIV-tested and 
75% of them were HIV-positive. The median duration of their complaints before admis-
sion to the hospital was eight weeks.
From the 320 patients, 187 were diagnosed as having TB on the basis of: respiratory 
complaints lasting two or more weeks, no improvement on two courses of routine empiric 
antibiotics (e.g. chloramphenicol, cotrimoxazole), a positive ZN sputum smear and/or 
abnormalities on the chest X-ray consistent with TB. At least two sputum smears for AFB 
were microscopically examined in 170 (91%) patients and at least two sputum specimens 
were cultured from 151 (81%) patients. In this cohort in the group of patients diagnosed 
having TB, the HIV-positivity, median duration of complaints and the median age were 
all comparable with that in the whole study group.
Of the 187 patients diagnosed with TB on the basis of sputum smears and chest X-ray, 72 
(39%) had a positive ZN smear and 174 (95%) had a chest X-ray consistent with TB (Table 
1 and 2). In 47% (88) of these 187 patients M. tuberculosis was isolated from one of the 
at least two sputum specimens. In another 19% (36) of these 187 cases, exclusively NTM 
were cultured, whereas from 12% (23) of the TB cases a combination of M. tuberculosis 
and NTM was isolated. In the remaining 29% (54) cases in which TB was diagnosed, 
the culture for mycobacteria remained negative. In five patients diagnosed with TB and 
having a positive ZN sputum microscopy, only NTM were isolated. However, most of the 
patients who were diagnosed as TB and from whom only NTM were cultured from the 
sputum had a negative ZN.
Of the 187 diagnosed TB patients, 183 were tested for HIV and 134 (73%) were HIV-
positive (Table 2). Significantly more HIV-positive patient had a positive culture for NTM 
in comparison with HIV-negative patients; 38% (50/134) and 18% (9/49) respectively 
(p<0.05). Furthermore, 30% (40/134) of the HIV-positive TB patients had a positive 
culture for exclusively M. tuberculosis, in comparison to 51% (25/49) of the HIV-negative 
TB patients (p<0.05).
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Anti-tuberculosis treatment was initiated in 134 of the 187 (72%) patients in the research 
group diagnosed with TB on the basis of a positive sputum smear or a chest X-ray con-
sistent with TB (Table 2). Of the 88 patients with M. tuberculosis positive sputa, 83 (94%) 
were treated. However, also 18 of the 36 (51%) of the patients with only NTM in their 
sputum and 29 of the 54 (54%) patients with a negative culture for mycobacteria were 
also treated.
In three of the 72 patients with a positive ZN sputum smear no anti-tuberculosis treat-
ment was started. In the first patient, therapy was withheld because only one of the three 
smears was positive and very few AFB were seen. Also the chest X-ray of this patient 
table 1: Ziehl-Neelsen (ZN) of sputum, chest X-ray, culture results and HIV status of diagnosed TB patients.
ZN sputum Chest X-ray Culture result Total
negative M. tuberculosis M. tuberculosis 
and NTM
NTM 
only
AFB
not 
identified
Negative Consistent 
with TB
53 (39 
HIV+ and 
3 HIV? a)
18 (16 HIV+)  6 (5 HIV+) 31 (24 
HIV+)
7 (5 HIV+
and 1 
HIV? a)
115
Positive No 
abnormalities
 1 (HIV-)  5 (4 HIV+)  2 (2 HIV+)  0 1 (HIV-)   9
Consistent 
with TB
 0 41 (20 HIV+) 14 (13 HIV+)  3b (3 
HIV+)
1 (HIV-)  59
No chest X-ray  0  1 (HIV-)  1 (HIV+)  2c (2 
HIV+)
0   4
Total 54 (29%) 65 (35%) 23 (12%) 36 (19%) 9 (5%) 187
aHIV? = HIV status not known.
bTwo of these three patients with a sputum positive ZN and only NTM isolated from the sputum were 
receiving anti-tuberculosis treatment.
cOne of these two patients with a sputum positive ZN and only NTM isolated from the sputum was 
receiving anti-tuberculosis treatment.
table 2: Culture results, HIV status and whether was started with or without anti-tuberculosis treatment 
of diagnosed TB patients.
Culture result Patients, n (%) HIV status, n (%) Anti-tuberculosis 
treatment, n (%)
Positive Negative Yes No
Negative for mycobacteria  54 (29)  39 (29) 12 (25)  29 (22) 25 (47)
M. tuberculosis only  65 (35)  40 (30) 25 (51)  60 (45)  5 (9)
M. tuberculosis and NTM  23 (12)  21 (16)  2 (4)  23 (17)  0
NTM only  36 (19)  29 (22)  7 (14)  18 (13) 18 (34)
AFB not identified   9 (5)   5 (3)  3 (6)   4 (3)  5 (9.5)
Subtotal 134 (73) 49 (27) 134 (72) 53 (28)
Total 187 183 187
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was read as normal. Sputum cultures were all negative. The second untreated patient was 
infected by HIV, received several courses of antibiotics without improvement, and the 
chest X-ray was consistent with tuberculosis. However, only one of the smears was micro-
scopically weakly positive, and culture of the sputum specimens yielded in both sputum 
specimens M. lentiflavum. The last patient who was not treated for TB had one sputum 
smear positive for AFB and the culture yielded only M. gordonae. This patient, who was 
HIV-positive, died a few days after admission.
In five patients with a positive sputum smear who were treated with anti-tuberculosis treat-
ment, no M. tuberculosis was isolated. In three of these patients only NTM were recovered, 
and in two patients the acid fast organisms could not be identified to the species level. The 
first patient treated with anti-tuberculosis treatment from whom only NTM were cultured 
from the ZN-positive sputa was infected with HIV and had suffered from TB in the past. 
The chest X-ray was consistent with tuberculosis. The NTM were identified as M. intracel-
lulare and also a not yet identified Mycobacterium was isolated. The second patient, who 
was also HIV-positive, was receiving anti-tuberculosis treatment for four months without 
improvement. She was already treated for TB in the past. The sputum culture revealed 
M. lentiflavum, M. intracellulare and AFB which could not be identified. This patient died 
one week after admission. The third patient treated for TB with a positive smear for AFB 
from which only NTM were cultured from the sputum was also infected with HIV. The 
chest X-ray was consistent with tuberculosis and the sputum culture yielded M. intracel-
lulare and other AFB which could not be identified to species level. The patient died three 
weeks after admission. In the last two patients with a positive sputum smear and treated for 
TB the cultured yielded acid fast bacilli which could not be identified. Both patient were 
HIV-negative and were treated for TB in the past. One of these patients had a chest X-ray 
consistent with tuberculosis and the chest X-ray of the other patient was read as normal.
There were in total 99 patients diagnosed with TB on basis of the sputum smear and/or 
chest X-ray without a positive culture of M. tuberculosis (Table 3). The culture was nega-
tive for mycobacteria in 54 (55%) of these patients and in the remaining 55 patients NTM 
were isolated. Eight (8%) of these patients had a positive ZN of the sputum and 95 (96%) 
had abnormalities on the chest X-ray consistent with tuberculosis. The HIV-positivity as 
well as the median duration of complaints, the median age and percentage of women in 
this patient group were comparable with the 187 patients diagnosed with TB in the whole 
study group. A history of TB was documented in 29 (29%) of the patients which was also 
similar to the entire group of TB patients diagnosed. However, significantly more patients 
died in the group of patients diagnosed with TB and a negative culture for M. tuberculosis 
in comparison with the whole group of 187 patients diagnosed with TB, 28% and 16% 
respectively (p<0.05).
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There were significant differences between patients with M. tuberculosis and NTM in 
their culture regarding presence of history of TB and the proportion of patients that died 
during the study period (see Table 4). Ten percent (9/88) of the patients with M. tuber-
culosis isolated from the sputum died during the study period compared to 28% (10/36) 
of the patients with exclusively NTM in their sputum and 19% (10/54) of the patients 
with a negative culture for mycobacteria (p<0.05). A history of tuberculosis was observed 
in 13% (11/88) of the M. tuberculosis culture-positive patients. In the patients with only 
NTM isolated from the sputum and a negative culture for mycobacteria these percentages 
were 33 (12/36) and 20 (11/54), respectively (p<0.05).
The collected sputum samples from all patients were split in two equal parts before de-
contamination in order to compare the influence of the decontamination method on the 
yield of mycobacteria (7). From the 187 diagnosed TB patients, a total of 670 sputum 
samples were cultured. The results of the cultures are depicted in Table 5. From 382 (57%) 
of the 670 sputum samples of patients, mycobacteria were isolated. M. tuberculosis was 
found in 236 of the 382 (62%) positive sputum specimens and NTM in 146 (38%). The 
most frequently encountered NTM were M. lentiflavum (21) and M. intracellulare (18).
table 3: Characteristics of 99 patients diagnosed with TB and a negative M. tuberculosis culture.
Culture result ZN 
pos
Chest X-ray 
TBa
HIV positive TB 
treatmentb
TB in 
pastc
Died Total
Negative 1 53
39 (and 3 
? d)
29 11 10 54 (55%)
Single NTM 
positive culture
2 20 (and 1 ? d) 16  8  7  6 21 (21%)
Different NTM in 
both sputa
2  9 (and 1 ? d)  8  7  3  9 10 (10%)
Same NTM in 
both sputa
1  5  5  3  2  2  5 (5%)
AFB not identified 2  8  5 (and 1?)  4  6  1  9 (9%)
Total 8 (8%) 95 (96%) 73 (74%) 51 (52%) 29 (29%) 28 (28%) 99
aChest X-ray consistent with tuberculosis.
bAnti-tuberculosis treatment started by clinician without knowing culture results.
cHistory of tuberculosis.
d? = Chest X-ray or HIV status unknown.
table 4: History of TB and patients who died during study period in patients with culture positive for 
M. tuberculosis, NTM, and negative culture.
Culture p-value
M. tuberculosis (88) NTM (36) Negative (54)
Died, n (%)  9 (10%) 10 (28%) 10 (19%) <0.05
History of TB, n (%) 11 (13%) 12 (33%) 11 (20%) <0.05
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In 59 of the 187 (32%) diagnosed TB patients NTM were isolated from the sputum; 36 
(61%) with exclusively NTM and 23 (39%) with cultures yielding a combination of M. tu-
berculosis and NTM (Table 6). Two consecutive sputum samples were cultured from 52 of 
the 59 NTM-positive patients. In 33 of the 52 patients only a single culture was positive. 
The remaining 19 NTM-positive patients had two positive cultures for NTM; 11 patients 
had different NTM species in the sputum samples and eight patients had the same NTM 
in both sputum samples. In four of the eight patients with same NTM in both sputum 
samples M. lentiflavum was isolated and in one patient M. intracellulare. In the remain-
ing three patients M. lentiflavum (2) and M. chelonae were isolated twice together with 
M. tuberculosis.
In five of the 187 cases diagnosed with TB, only NTM were repeatedly and consistently 
isolated from sputum in addition to the finding of lesions on the chest X-ray (Table 7). 
table 5: Isolated mycobacteria from sputum of patients diagnosed with TB.
Culture result Isolates
Negative 288 (43%)
M. tuberculosis 236 (35%)
M. lentiflavum  21 (3%)
M. avium complex  20 (3%)
 M. intracellulare  18 (3%)
 M. avium   2 (0.3%)
M. gordonae   5 (0.7%)
M. chelonae   4 (0.6%)
M. fortuitum   2 (0.3%)
M. mucogenicum   2 (0.3%)
Various unknown Mycobacterium species  32 (5%)
Various other Mycobacterium species*   5 (0.7%)
Unidentified AFB  55 (8%)
Total number of sputum samples 670
*Various other Mycobacterium species include M. goodii, M. terrae, M. neoaurum, M. peregrinum, and 
M. obuense.
table 6: Patients with positive NTM culture(s) from whom two consecutive sputum samples were cultured.
Culture result Total (%)
M. tuberculosis and NTM NTM only
Single NTM positive culture 17 16 33 (63)
Different NTM in both sputa  1 10 11 (21)
Same NTM in both sputa  3a  5b  8 (15)
Total 21 31 52
aNTM identified as M. lentiflavum (2x) and M. chelonae.
bNTM identified as M. lentiflavum (4x) and M. intracellulare.
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Patient one was a 50-year-old female who presented herself with a productive cough with 
haemoptysis for 24 weeks. Furthermore, she was having pain passing urine. She was not 
responding to antibiotics. The HIV tests were indifferent. Her body mass index (BMI) 
was 20. The radiographic investigation of the chest revealed a pleural and pericardial ef-
fusion and an alveolar consolidation. The sputum smear was positive and treatment with 
rifampin, isoniazid, ethambutol and pyrazinamide was started. M. lentiflavum was iso-
lated from two consecutive sputum specimens. Also from two consecutive urine samples 
the same bacterium was isolated. The patient died three months after the treatment was 
started.
The second case with the same NTM in both sputum samples concerned a 35-year-old 
HIV-positive man. He complained about a cough and night sweats that started 34 weeks 
earlier. A relative of this patient had been found sputum-positive a few months earlier. 
On physical examination, enlarged axillary and sub-mandibular lymph nodes and an 
enlarged spleen were found. The temperature was 39°C and the BMI 24. He had already 
been treated with antibiotics without improvement. The chest X-ray revealed pleural 
fluid. The sputum smear was positive and M. lentiflavum was isolated from two sputum 
specimens.
The third patient was an HIV-positive, 30-year-old woman presenting with coughing 
and vomiting for five weeks. She had been treated for tuberculosis in the past, but she in-
terrupted this treatment. On physical examination, enlarged axillary and supra-clavicular 
lymph nodes as well as an enlarged spleen were found. The temperature was 35.5°C and 
the BMI 18. She was not improving on antibiotics before admission. Pleural effusion, 
alveolar infiltration, and interstitial pathology were seen on the chest X-ray. The patient 
clearly improved upon treatment with rifampin, isoniazid, pyrazinamide, and ethambu-
tol. M. lentiflavum was cultured from two sputum specimens.
The fourth patient with in consecutive sputum samples exclusively the same NTM 
was a 25-year-old, HIV-positive woman who complained of a productive cough with 
haemoptysis with one month duration. She was known with asthma. Enlarged axillary 
and sub-mandibular lymph nodes and an enlarged liver were found on physical examina-
tion. The temperature on admission was 38.5°C. The chest X-ray showed pleural and 
pericardial effusion. Treatment with antibiotics was started. The culture of both sputum 
specimens revealed M. lentiflavum. The patient died nine days later.
The last patient was a 32-year-old HIV-positive man who complained of a productive 
cough with haemoptysis of 17 weeks’ duration. Furthermore, he was vomiting and suf-
fered from diarrhoea. The BMI was 15. He had been treated for tuberculosis in the past. 
The chest X-ray was consistent with TB and showed alveolar infiltration and interstitial 
pathology. He did not improve on antibiotics and started with anti-tuberculosis treat-
ment. Mycobacteria were cultured from both sputum samples and identified as M. intra-
cellulare. He died five weeks later.
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From the above described data it can be deduced that the positive predictive value of 
the algorithm for diagnosing TB on the basis of: respiratory complaints for two or more 
weeks, not improving on two courses of routine empiric antibiotics, a positive sputum 
smear and/or pathology on the chest X-ray consistent with TB was 47% (88/187) in this 
study (Table 8). However, it included 72 patients who had respiratory complaints lasting 
two or more weeks, had not improved on two courses of routine empiric antibiotics, 
had negative sputum smears and a chest X-ray without pathology. Of these 72 patients, 
five had a culture positive for M. tuberculosis (with or without NTM) which makes the 
negative predictive value of this algorithm 93%. The sensitivity and specificity were 95% 
(88/93) and 40% (67/166), respectively.
DisCussion
The results of this study show that M. tuberculosis was not cultured from the sputum of 
53% of the patients diagnosed with TB on the basis of ZN microscopy and chest X-ray 
results in Zambia. In 48% of the cases exclusively NTM or a negative culture for myco-
bacteria was observed and in the remaining 5% acid fast organisms, which could not be 
identified to the species level, were found. Among the patients diagnosed with TB, ir-
respective of the Mycobacterium culture results, an extremely high rate of HIV positivity 
was observed: 73%.
The spectrum of HIV-related morbidity in adults in sub-Saharan Africa shows some dif-
ferences to that observed in Europe and north America. This includes a greater incidence 
of tuberculosis, a greater incidence of bacterial diseases in general, but a probably lower 
incidence of Pneumocystis jirovecii pneumonia (5,6). However, less is known about the 
table 8: Performance of algorithm for diagnosing TB on basis of Ziehl-Neelsen sputum smear and/or 
chest X-ray.
M. tuberculosis culture-positive M. tuberculosis culture-negative Total
ZN+ and/or X-ray +a 88  99 187
ZN- and X-ray -b  5  67  72
Total 93 166 259
Sensitivity 88/93 = 95%
Specificity 67/166 = 40%
Positive predictive value 88/187 = 47%
Negative predictive value 67/72 = 93%
a72 patients who had respiratory complaints lasting two or more weeks, had not improved on two courses 
of routine empiric antibiotics but had negative sputum smears and a chest X-ray without pathology.
b187 patients who had respiratory complaints lasting two or more weeks, had not improved on two 
courses of routine empiric antibiotics but had a positive sputum smear and/or chest X-ray suspected for TB.
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effect of HIV on NTM disease in developing countries. There are only a few, controversial 
reports from developing countries on NTM from HIV/AIDS patients. However, the re-
sults in this study indicate that these opportunistic bacteria may be important pathogens 
regarding the diagnosis and perhaps the aetiology of tuberculosis-like infections in Zam-
bia. HIV positivity was found to be significantly correlated with the isolation of NTM 
from sputum. In the patients diagnosed with TB the culture was exclusively positive for 
NTM in 19% of the cases. In 32% of the cases NTM (together with or without M. tuber-
culosis) was isolated. Therefore, the role of NTM in tuberculosis-like disease should be 
considered in smear-negative and smear-positive patients and seems more relevant than 
considered so far in Zambia.
NTM can cause both colonization and clinical disease in humans. To guide the diagnosis 
in a patient from whom NTM has been isolated from a specimen, the recently published 
new diagnostic criteria for non-tuberculous mycobacterial diseases by the American Tho-
racic Society will provide support (11). This is especially important because the treatment 
of NTM disease is generally not directly analogous to the treatment of TB. Drug therapy 
of NTM infection involves multiple drugs, most of the time including a newer macrolide 
(e.g. azithromycin, clarithromycin) (11). In this study probably five patients would meet 
the criteria for NTM pulmonary disease (Table 7). From two consecutive sputum samples 
of these HIV-positive patients M. lentiflavum and M. intracellulare were isolated. These 
patients presented with respiratory complaints and the chest X-ray showed abnormali-
ties compatible with tuberculosis. According to criteria of the ATS for diagnosing NTM 
lung disease these patients suffice. However, these sputa were not additionally tested with 
molecular amplification techniques for the possible presence of M. tuberculosis. Further-
more, it was not possible to count the number of colony-forming units cultured from the 
sputum to discriminate colonization and infection/disease, because the sputum samples 
were not cultured on a solid medium.
The presentation of NTM infections typically mimic TB, confounding the diagnosis of 
TB. In this study, in five of the 72 (7%) patients with a positive sputum smear only NTM 
was isolated. In the light of this, methods for distinguishing M. tuberculosis and NTM in 
clinical material should be implemented on a broader scale in Africa. The direct detection 
and identification of M. tuberculosis in clinical specimens are made possible by methods 
using nucleic acid amplification (NAA) techniques (3,9). However, the performance of 
the test is good in clinical respiratory specimens that are AFB smear-positive (sensitivity 
95% and specificity 98%) but far less in specimens that contain fewer organisms, or are 
AFB-negative (sensitivity 50% and specificity 95%) (1). Fortunately, recent development 
of an ‘enhanced’ nucleic acid amplification test in patients who are clinically suspected of 
having TB (AFB smear-positive and negative) showed a higher sensitivity (8). The NAA-
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tests may provide a reliable way of increasing the specficity of the TB diagnosis (ruling 
in disease) in this algorythm. The challenge to overcome is the implementation of such 
delicate techniques in an African setting.
NTM are widely distributed all over the world, although there seems to be a geographic 
distribution (4,11,15,18). M. avium complex (MAC) is the most common NTM species 
causing disease, but many other NTM species have been found associated to severe infec-
tions. In Africa little is known on the prevalence of different NTM species. In this study, 
the most isolated NTM in the population of patients diagnosed as TB were M. lentiflavum 
and MAC. Interestingly, a part (22%) of the NTM found in Zambia has not yet been 
identified on a species level. This suggests the distribution of NTM in Africa may be dif-
ferent from Europe and the United States of America and the evolutionary divergence of 
phylogenetic sub-lineages of bacteria with in species may merit more detailed taxonomic 
studies.
In this study 29% of the patients diagnosed with TB had a culture negative for mycobac-
teria. Causative micro-organisms of respiratory illness in HIV-positive and negative pa-
tients besides M. tuberculosis may also be either bacterial (most commonly Streptococcus 
pneumoniae and Haemophilus influenzae), viral or Pneumocystis jirovecii. No diagnostic 
methods in this study were used to demonstrate these micro-organisms because the goal 
of this study was not to determine all the causes of tuberculosis-like diseases in Zambia. 
However, in a follow-up study a broader microbiological diagnostic approach would be 
interesting.
Another reason for negative cultures may be found in the lack of sensitivity of culture. For 
mycobacteria this amounts 80-85% (with a specificity of approximately 98%) (13,17). As 
a result, for a limited number of the patients no indications were collected regarding the 
possible causative agent.
Anti-tuberculosis treatment was initiated by the clinician in 134 of the 187 (72%) patients 
diagnosed with TB. In almost all patients (94%) who were M. tuberculosis culture positive, 
treatment was started in comparison to approximately half of the patients with positive 
NTM cultures (51%) or the ones with a negative culture for mycobacteria (54%). The 
clinicians’ diagnosis of TB and the decision to treat often deviated from the protocol used 
in Zambia, especially for the patients with NTM or a negative culture for mycobacteria. 
Probably more factors play a role in the decision of the clinician to start with an anti-
tuberculosis treatment in a patient suspected of TB than the official algorithm. In this 
study differences in the history of TB and mortality were observed between the group 
of patients with a culture positive for M. tuberculosis and the patients yielding a positive 
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NTM culture. In the study period significantly more patients with a positive NTM culture 
died in comparison with patients with a positive M. tuberculosis culture. Probably treat-
ment could not be started because the patient died before the diagnosis had been made 
due to immunosuppression because of HIV/AIDS. Moreover, significantly more patients 
with a positive culture for NTM instead of M. tuberculosis had a history of TB. It is likely 
that the knowledge that the patient had TB in the past discouraged the clinician from 
re-starting the antituberculosis treatment.
We conclude that the traditionally-defined diagnosis of tuberculosis has become highly 
inaccurate in Zambia, due to the increased prevalence of HIV. Misdiagnosis of TB can 
be reduced by the introduction of new diagnostic techniques in addition to AFB micros-
copy, and this would also favour the diagnosis of NTM-causes pulmonary disorders. A 
logical next step is the introduction of knowledge in Africa to treat NTM infections in an 
accurate way.
Al in all, with the changing situation in Africa diagnostic scoring systems and algo-
rithms should be developed and validated to assist clinicians working in resource-poor 
settings with a high prevalence of HIV.
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ABstrACt
Single nucleotide polymorphisms (SNPs) in genes encoding monocyte chemoattractant 
protein 1 (MCP-1), mannose-binding lectin (MBL), tumor necrosis factor (TNF)-α, and 
interferon (IFN)-γ were examined in 46 tuberculosis patients and 119 healthy tuberculin-
positive controls in Zambia. The odds of having tuberculosis was 2.7-fold higher in car-
riers of MCP-1 genotype AG than in those carrying the homozygous genotype AA (95% 
confidence interval (CI): 1.3-5.5). This association was maintained among human immu-
nodeficiency virus-negative patients and controls (Odds ratio 3.0 (95% CI 1.0-8.7)). In 
contrast, none of the MBL, TNF-α, and INF-γ variant alleles or genotypes were associated 
with tuberculosis susceptibility. The MCP-1 gene is one of the relevant genes influencing 
susceptibility to tuberculosis in African people.
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introDuCtion
Tuberculosis (TB), which is mainly caused by Mycobacterium tuberculosis, is a major 
cause of morbidity and mortality worldwide, and a recent World Health Organization 
report estimated that there were 8.8 million new cases of clinical TB diagnosed in the year 
2005, with 1.6 million deaths directly attributable to this disease (30).
Progression to clinical disease is far from being an inevitable consequence of infec-
tion, and it is generally accepted that 90% of M. tuberculosis infected subjects will never 
develop TB. One-in-two people of the remaining 10% will progress to disease during the 
first two years after infection (6).
The factors determining an individual’s risk of infection and breakdown to active disease 
are multi-factorial and involve host-pathogen interactions and environmental conditions. 
Recent evidence supports the role of multiple host genetic factors in susceptibility to TB. 
For instance, the mannose-binding lectin (MBL) is an important factor in the innate im-
mune response and acts in concert with the complement system to opsonize and facilitate 
phagocytosis of microorganisms (26). In mycobacteria, MBL binds to mannose residues 
in the lipoarabinomannan membrane (LAM), covering the bacteria (7). Three structural 
variants of the MBL gene, located separately at codons 52, 54, and 57 of exon 1, have been 
shown to produce variant (amounts of) MBL proteins. Several studies have indicated a 
partial protective effect of heterozygosity for MBL variant alleles against TB (8,10,11), 
whereas others have pointed toward an increased susceptibility for TB for homozygous 
carriers of MBL variant alleles (24). Low serum MBL levels, due to heterozygosity for 
MBL variant alleles, may be protective against TB by limiting complement activation and 
uptake of bacilli by complement receptors (25).
In addition, host protective immunity to mycobacterial infection is dependent on the 
precise coordination of T-lymphocyte sensitisation and monocyte recruitment. Several 
cytokine and chemokine signals play crucial roles in the normal immune response to 
TB, thereby contributing to the initial protection against infection. These factors include 
pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interferon (IFN)-γ, 
and chemokines with selective chemotactic properties for leukocytes such as Monocyte 
Chemoattractant protein 1 (MCP-1) (1).
TNF-α is involved in the recruitment of cells forming a protective granuloma. A TNF-
independent production of chemokines result in a dysregulated inflammatory response 
unable to contain M. tuberculosis. Reactivation of clinical tuberculosis was observed in 
patients undergoing treatment for rheumatoid arthritis or Crohn disease with a human-
ized monoclonal antibody to TNF (13). Polymorphism in the TNF-α promoter region, 
single nucleotide polymorphisms (SNP) located at nucleotides -238, -308, and –376, were 
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found to be associated with susceptibility to several diseases including cerebral malaria, 
mucocutaneous leishmaniasis, asthma and leprosy (2,17,18,22).
Macrophage activation by IFN-γ is essential for protective immunity, as mice and hu-
mans that lack components of the IFN-γ signalling pathway are highly susceptible to 
tuberculosis. A genetic defect in the production of IFN-γ in individuals homozygous for 
the +874 A allele contributed to an increased risk of developing tuberculosis (15,21).
Chemokines are key signal molecules that direct leukocyte subsets to sites of inflamma-
tion. The regulated interaction of chemokines with their respective receptors is thought 
to mediate the controlled recruitment of specific leukocyte subpopulations specifically 
required during local host defense at the site of infection (9). MCP-1 is a prototypic 
chemokine and is a chemoattractant for monocytes and T-lymfocytes. In an unmatched 
case-control study it was found that the G allele of the MCP-1 promoter region was strongly 
associated with increased odds of developing active pulmonary tuberculosis in Mexicans 
and Koreans (5). Furthermore, individuals with the –2518G variant expressed higher 
levels of MCP-1 which inhibited IL12p40 production in response to M. tuberculosis and 
increased the likelihood of TB infection progressing to active disease. Therefore, in the 
present study the MCP-1 promoter gene polymorphisms in association with susceptibil-
ity to develop tuberculosis was investigated in Zambia. In addition, the influence of SNPs 
in the TNF-α gene, IFN-γ and MBL gene on manifestation of TB were examined.
MAteriAl AnD MethoDs
subjects
During an unmatched case-control study in Zambia, tuberculosis patients (between 
15 and 78 yr of age) were recruited at St. Francis Hospital in Katete (Eastern province 
of Zambia). Unrelated, healthy persons of the same age and living in a neighbouring 
community were recruited as controls. Demographic data, previous history of TB and/
or previous contact wit individuals with TB, and the presence or absence of a scar char-
acteristic of bacilli Calmette-Guérin (BCG) vaccination was recorded. Documented 
socio-economic status features included smoking cigarettes, drinking alcohol and being 
employed. Furthermore, the body mass index (BMI) and HIV-status for each included 
person were determined.
Tuberculosis was confirmed by at least two consecutive sputum smears positive for acid-
fast bacilli and/or a positive sputum culture for M. tuberculosis. Patients were subjected 
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to an extensive clinical examination, and an anterior-posterior chest radiograph was pro-
duced for each individual included in the study.
Controls were healthy adults who had at least two gargle specimens with normal saline 
or sputum specimens negative for acid-fast bacteria (AFB) in the smear, together with a 
negative culture for M. tuberculosis. Furthermore, the chest radiographic findings of the 
included controls were without abnormalities indicative of tuberculosis. A tuberculin skin 
test was administered to all controls, using the Mantoux method to deliver 5 tuberculin 
Units of purified protein derivative RT/23 (Statens Serum Institute, Copenhagen, Den-
mark) intradermally. The diameter of induration was measured 48 h after inoculation. All 
included tuberculin reactor controls had tuberculin reactions of ≥ 5 mm of induration.
The study was approved by the research ethical committee of the University of Zambia, 
the Central Board of Health, and the Ministry of Health in Zambia, and all participants 
gave written consent.
genotyping
Genomic DNA was purified from peripheral blood leukocytes. The sequence containing 
the –2518 G to A transition locus in the MCP-1 promoter region was amplified from 100 
ng of genomic DNA using the forward primer (5’-GCTCCGGGCCCAGTATCT-3’) and 
reverse primer (5’-ACAGGGAAGGTGAAGGGTATGA-3’) and a Hot Start PCR (Ap-
plied Biosystems) according to Flores-Villanueva et al. (5). Restriction fragment length 
polymorphism after PCR was used for the identification of MCP-1 alleles. The allele G 
creates a PvuII restriction site yielding two fragments of 182 and 54 bp, respectively. The 
allele A was identified by the presence of a 236 bp undigested fragment. Genotyping of the 
–308 and –238 TNF-α, +874 INF-γ and MBL codons 54 and 57 positions were performed 
according to cited references (16,29,31,32). Restriction enzymes were obtained from New 
England Biolabs (Leusden, The Netherlands) or Fermentas (St. Leon-rot, Germany). All 
restriction endonucleases were used as recommended by the manufacturer.
statistical analyses
Analysis was done with SPPS version 11.0 (SPSS, Inc., Chicago, IL) and STATA version 8.0 
(Stata corporation College Station, TX, USA). Controls were tested for Hardy-Weinberg 
equilibrium (HWE) by use of a 3 x 2 χ2 test with 1 degree of freedom. Associations of 
genotype with disease were tested using χ2 test. Univariate odds ratio’s were calculated by 
logistic regression.
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results AnD DisCussion
Demographic and clinical features
We recruited 46 tuberculosis patients and 119 healthy controls (Table 1). A positive 
sputum smear was found in 33 of these 46 (72%) patients, the remaining ones were diag-
nosed by a positive culture with M. tuberculosis. Chest radiographs were consistent with 
tuberculosis in 41 (89%) of the tuberculosis patients. Genotyping was successful in all 
patients and controls. The group of patients and controls were similar in demographics, 
being employed, having a BCG-scar, consumption of alcohol and smoking of cigarettes. 
However, the percentage of HIV-positivity (65%) was significantly higher in the group of 
tuberculosis patients (p<0.001). In addition, a lower BMI was observed in the patients 
with tuberculosis (p<0.001) and a history of tuberculosis was more frequently docu-
mented among patients.
table 1: Demographic and clinical features of tuberculosis cases and controls.
Parameter TB casesa
(n=46)
Healthy PPD+b
(n=119)
p-value
Female, n (%) 28 (61) 89 (75) 0.08
Age (yr), mean ±SD 37 ± 13 33 ± 15 0.1
BMI (kg/m2) 17.5 (SD 2.1) 21.9 (SD 3.8) <0.001
TB in past, n (%)  6 (13)  4 (3) 0.02
HIV-positive, n (%) 30 (65) 17 (14) <0.001
Smokers, n (%)  1/42 (2)  6 (5) 0.5
Alcohol use, n (%)  2 (5)  8 (7) 0.6
Employed, n (%)  7 (15) 13 (11) 0.4
BCG-scar, n (%) 37/44 (84) 98/117 (84) 1.0
Contact with TB patient, n (%) 17 (37) 53 (45) 1.0
aTB cases: cases of pulmonary tuberculosis, culture positive for M. tuberculosis.
bHealthy PPD+: healthy controls, tuberculin positive.
the –2518 MCP-1 promoter polymorphism
In Zambian control subjects, genotypes of the MCP-1, TNF-α, INF-γ and MBL gene 
were in Hardy-Weinberg equilibrium, but none of the TNF-α, INF-γ and MBL vari-
ants or genotypes were associated with tuberculosis (see Table 2 and 3 for overview). 
In contrast, allele G of the MCP-1 gene was associated with tuberculosis compared with 
healthy tuberculin reactors (p=0.04). Carriers of the MCP-1 genotypes AA were signifi-
cantly over-represented among healthy tuberculin reactors. The genotypes AA and AG 
were equally distributed in the tuberculosis cases. The genotype GG was rarely observed 
in both groups. The odds ratio (OR) for heterozygous AG in tuberculosis cases versus 
tuberculin-positive controls was 2.7.
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MCP-1 polymorphism in hiv-negative patients and controls
In the patient group, a high percentage of HIV-positivity was observed. Therefore, 
analyses of the HIV-negative subpopulation were performed. In total 16 patients and 102 
healthy tuberculin reactors were HIV-negative. Similar (but not significant) results were 
found; carriers of MCP-1 genotypes AA were again more often found in the controls and 
the genotypes AA and AG were equally distributed in the tuberculosis cases. The OR for 
the heterozygous AG type in the HIV-negative tuberculosis cases versus HIV-negative 
tuberculin-positive controls was 3.0 (95% CI 1.0-8.7). Furthermore, no association be-
tween HIV-status and MCP-1 genotypes was observed. Again, none of the TNF-α, INF-γ 
and MBL alleles or genotypes were associated with tuberculosis in these HIV-negative 
persons.
table 2: The genotype frequencies of various MBL, MCP-1, TNF-α, and INF-γ polymorphisms.
Gene and genotypea TB casesb
(n=46) n (%)
Healthy PPD+c
(n=119) n (%)
HWEd p-value OR (95% CI)e
MBL
54 ww 46 (100) 119 (100) - - -
wm 0 0 -
mm 0 0 -
57 ww 33 (71.7) 77 (64.7) 0.45 0.7 1
wm 12 (26.1) 39 (32.8) 0.7 (0.3-1.5)
mm 1 (2.2) 3 (2.5) 0.8 (0.1-7.8)
MCP-1
-2518 AA 22 (47.8) 83 (69.7) 0.66 0.02 1
AG 23 (50.0) 32 (26.9) 2.7 (1.3 - 5.5)
GG 1 (2.2) 4 (3.4) 0.9 (0.1-8.9)
TNF-α
-238 GG 42 (91.3) 103 (86.6) 0.08 0.6 1
GA 4 (8.7) 14 (11.8) 0.7 (0.2-2.3),
AA 0 2 (1.7) -
-308 GG 38 (82.6) 104 (87.4) 0.49 0.4 1
GA 8 (17.4) 15 (12.6) 1.5 (0.6-3.7)
AA 0 0 -
INF-γ
874 AA 32 (69.6) 93 (78.2) 0.29 0.5 1
AT 13 (28.3) 23 (19.3) 1.6 (0.7-3.6)
TT 1 (2.2) 3 (2.5) 1.0 (0.1-9.6)
aw/w = wild/wild, w/m = wild/mutant and m/m =  mutant/mutant.
bTB cases: cases of pulmonary tuberculosis, culture positive for M. tuberculosis.
cHealthy PPD+: healthy controls, tuberculin positive.
dHWE: Hardy-Weinberg equilibrium.
eOR (95% CI): Odds ratio with 95% confidence interval.
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Our results are similar to those of Flores-Villanueva et al., who examined tuberculosis 
patients and healthy controls in Mexico and Korea (5). In this study 435 and 129 patients 
and 510 and 162 controls were included, respectively. The odds of developing tuberculosis 
were 2.3- and 5.8-fold higher in carriers of MCP-1 genotypes AG as compared to homozy-
gous AA. Although a smaller number of patients and controls were included in the pres-
ent cohort, already a significant association was disclosed of susceptibility to TB and the 
AG polymorphism in this gene. Furthermore, the G allele was dominant in patients with 
TB, which emphasizes the power and reliability of the observed association. In contrast, 
Jamieson et al. found no association of the MCP-1 –2518 allele G with susceptibility to 
tuberculosis in a study of cases and controls derived from families in Brazil (12).
Various studies have looked at the correlation between serum MBL concentrations, MBL 
gene polymorphisms and susceptibility to infections. Infections by intracellular agents 
seem to occur more frequently in patients with increased MBL levels (8,11,25). The se-
rum MBL level was not measured in the present study and the promotor haplotype was 
not assessed, limiting the reliability of the interpretation of our current results.
Inconsistent results in the literature have been found for polymorphisms in the TNF-α 
associated with susceptibility to tuberculosis in different populations (4,20,23,27). In 
table 3: The allele frequency of the various MBL, MCP-1, TNF-α, and INF-γ polymorphisms.
Gene Allelea TB casesb
(92 alleles) n (%)
Healthy PPD+c
(238 alleles) n (%)
p-value
MBL
54 w 92 (100) 238 (100) -
m 0 0
57 w 78 (84.8) 193 (81.1) 0.42
m 13 (14.1) 45 (18.9)
MCP-1
-2518 A 67 (72.8) 198 (83.2) 0.04
G 25 (27.2) 40 (16.8)
TNF-α
-238 G 88 (95.7) 220 (92.4) 0.46
A 4 (4.3) 18 (7.6)
-308 G 84 (91.3) 223 (93.7) 0.47
A 8 (8.7) 15 (6.3)
INF-γ
874 A 77 (83.7) 209 (87.8) 0.37
T 15 (16.3) 29 (12.2)
aw = wild and m = mutant.
aTB cases: cases of pulmonary tuberculosis, culture positive for M. tuberculosis.
bHealthy PPD+: healthy controls, tuberculin positive.
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addition, data suggest that the more common polymorphism at position +874 of the 
IFN-γ gene is associated with the risk of tuberculosis in several populations (3,14,15,21). 
However, results of the present and other studies suggest that the IFN-γ +874T/A muta-
tion has no association with TB susceptibility (19,28). The comparison of the production 
of IFN-γ with the genotypes needs to be studied more extensively (15,28). Functional 
variation in the closely linked alleles of the INF-γ gene may also influence the cytokine 
production.
Our data were also analyzed for a subgroup of patients suffering from non-tuberculous 
mycobacterial (NTM) infections versus the controls. Numbers of NTM infected patients 
turned out to be too low to perform reliable analyses (data not shown).
To evaluate genetic factors associated with susceptibility to tuberculosis, we selected new 
sputum smear-positive and/or culture-confirmed tuberculosis patients.
As controls, healthy tuberculin reactors were selected. Of these controls 82% were vac-
cinated with BCG and 53% had been in recent contact with a tuberculosis patient. The 
positive Mantoux-test could have been a consequence of an infection with M. tuberculosis 
or the BCG vaccination. On the other hand, these Zambian controls were more likely 
exposed to M. tuberculosis, given that they are living in a country with an estimated TB 
incidence of 650 per 100.000. To exclude the possibility of tuberculosis disease in the 
controls, the smear and culture of two sputum or gargle specimens had to be negative for 
AFB and M. tuberculosis, and the chest radiograph without findings consistent with tu-
berculosis. However, we were not fully confident that the controls were in no case infected 
with M. tuberculosis. In any case, we made sure they were not suffering from pulmonary 
tuberculosis. Moreover, if there would have been cases of active TB among the controls, 
the correlations between polymorphism in susceptibility genes in the TB patients and 
manifestation of the disease would even be stronger than recorded in this study.
To our knowledge, this is the first study investigating the polymorphism of the MCP-1 
gene in African people; and this may be a first indication that especially this gene may 
play a crucial role in increased susceptibility to this infectious disease in particular human 
populations. Further studies with sufficient statistical power are required to compare the 
true contribution of the MCP-1 gene to the susceptibility to develop tuberculosis among 
Africans and populations in other geographic regions.
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Tuberculosis, especially due to the high prevalence of HIV, remains a problem of large di-
mension in Africa and Mycobacterium tuberculosis is the most important causative agent. 
However, it is known that in developed countries also nontuberculous mycobacteria 
(NTM) play a significant role in the aetiology of tuberculosis-like syndromes, especially 
in HIV-positive patients. In Africa, the contribution of NTM to the problem of tubercu-
losis has hardly been examined.
Southern Africa is the most affected sub-region in Africa concerning HIV/AIDS, where 
HIV prevalence rates have stabilized at high levels, exceeding 25% in some countries, 
while in other African countries, the epidemic is still growing. In Zambia the estimated 
adult (15-49 yrs) prevalence of HIV/AIDS amounted 13.5-20% in 2003 (61).
NTM disease was one of the major AIDS-defining diseases in industrialized countries 
before the era of highly active antiretroviral therapy (HAART). Such infections have 
been thought to be less frequent in sub-Saharan Africa, but with the remaining doubt 
that the unavailability of the laboratory facilities and sophisticated radiological tools 
required to diagnose such disease may lead to underestimating of their true frequency 
(9,12,24,27,37,41,47). Whereas an international prospective study showed that NTM 
prevalence for disease was five to 10-fold lower in Kenya than in the United States of 
America or Northern Europe (24), a few hospital-based studies have reported a differ-
ent prevalence for disease than reported in Kenya (9,12,27,37,41,47). For an overview of 
the literature on prevalence/incidence rates of colonization/infection/disease of NTM in 
Africa see Table 1 in the introduction of this thesis.
Because the clinical relevance of the isolation of NTM in HIV-positive as well as in 
HIV-negative patients in Africa may be underestimated in this study, the meaning of 
NTM was examined in more detail in Zambia.
While progress in tuberculosis diagnostics has been made in developed countries, in the 
rest of the world the techniques used for diagnosing tuberculosis have remained relatively 
unchanged for the past one hundred years. Since the discovery of tuberculosis, the basis 
for its definitive diagnosis has been the detection of the bacillus in clinical specimens. 
Following microscopic detection of the organism in 1882, technical advances have al-
lowed the detection of fewer and fewer organisms in a specimen. Unfortunately, however, 
the level of sophistication and cost associated with more sensitive techniques has, to date, 
made their general applicability unfeasible in developing countries. Microscopic detec-
tion is simply but cumbersome, while the newer tools are still expensive and too complex 
for wide scale implementation in poor resource settings.
Therefore, the basis for tuberculosis diagnosis in developing countries has continued 
to be microscopy of stained smear of expectorated sputum to visualize acid-fast bacteria 
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(AFB). Fortunately, this technique detects most infectious patients. According to the In-
ternational Standards for Tuberculosis Care all patients suspected of having pulmonary 
tuberculosis should have at least two, and preferably three, sputum specimens examined by 
microscopy. When possible, at least one early morning specimen should be included (23).
Smear examination by experienced technicians can result in the detection of 50-60% of 
the tuberculosis cases. However, in low-income countries often much lower rates of AFB 
detection in tuberculosis patients are observed because of poor access to good quality 
microscopes, heavy workload, and shortage of trained staff. Moreover, microscopy is usu-
ally negative in cases with less advanced disease and certain groups of patients, such as 
those with HIV co-infection and patients with extra-pulmonary disease. The proportion 
of cases detected by microscopy is often as low as 20-30% of all cases (20,36,48).
In the absence of positive sputum smears for AFB and no improvement to treatment 
with broad-spectrum empiric antibiotics, most cases of pulmonary tuberculosis in low-
income countries are diagnosed on the basis of clinical and radiological features.
Various criteria, clinical scoring systems, tools, and algorithms have been developed to 
facilitate the diagnosis of pulmonary tuberculosis in people with suspected tuberculosis 
who have repeated negative sputum smears (8,30,49-51,59).
All persons with unexplained productive cough lasting for two-three weeks or more 
should be evaluated for tuberculosis, according to current evidence and WHO guide-
lines. The diagnosis of sputum smear-negative pulmonary tuberculosis should be based 
on at least three negative sputum smears, chest radiography findings consistent with 
tuberculosis, and lack of response to a trial of broad-spectrum anti-microbial agents. 
However, in areas with high prevalence of HIV and tuberculosis infection, the diagnosis 
of smear-negative tuberculosis is complicated, given the atypical presentation of pulmo-
nary tuberculosis in HIV-infected patients.
For instance, clinicians are less likely to find typical radiological signs of pulmonary 
tuberculosis in areas with high prevalence of HIV infection than in those with lower 
rates, as patients with HIV and smear-negative tuberculosis are less likely to reveal 
cavities on the chest X-ray than patients with smear-positive tuberculosis. Furthermore, 
smear-negative patients can also present with normal or only slightly abnormal chest 
X-rays. Numerous studies have shown that no radiographic pattern is fully characteristic 
of tuberculosis (7,20,30,32,43). To establish the tubercular aetiology of an abnormality 
on the chest X-ray further examination is necessary. The experience of many decades of 
data collection and analysis indicate that chest radiography for diagnosis or follow-up of 
pulmonary tuberculosis cases, with or without HIV co-infection, is unreliable (31).
The accurate diagnosis of smear-negative pulmonary tuberculosis may even be 
more complicated when reliance is solely placed on clinical and radiological features. 
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Furthermore, the involvement of acid-fast NTM in tuberculosis-like syndromes might 
result in the misdiagnosis of tuberculosis. To guide the diagnosis in a patient from whom 
NTM is isolated from a specimen, the diagnostic criteria for nontuberculous mycobacte-
rial diseases by the American Thoracic Society (ATS) can provide support (29). The key 
difference between the former and new (2007) diagnostic ATS criteria lies in the more 
lenient bacteriological criteria, single NTM culture from bronchial washing fluid or two 
positive sputum cultures, in a symptomatic patient with nodular or cavitary opacities in 
chest radiograph, now suffice. More patients tend to meet the new criteria, which may 
result in increasing numbers of patients receiving anti-mycobacterial treatment. Its au-
thors, however, repeatedly state that meeting these criteria does not, per se, necessitate 
the institution of therapy. Noteworthy is the exclusion of positive smear(s) of sputum or 
bronchial wash and the exclusion of extra-pulmonary NTM isolates from the diagnostic 
criteria. The consequences of these new diagnostic criteria are that difficulties may arise 
regarding the eventual decision to start treatment in patients and the clinical significance 
of the isolation of NTM, especially from extra-pulmonary samples.
In this light methods for the distinction of M. tuberculosis and NTM in clinical mate-
rial should be implemented on a broader scale in Africa. Nucleic acid amplification tests 
can enhance diagnostic certainty and the LiPA Rif-B test allows to detect M. tuberculosis 
complex bacilli as well as resistance to rifampicin (1,22,28,58). Furthermore, the knowl-
edge on treatment of NTM infections and the basis underlying the decision to initiate the 
treatment should be widely implemented.
PArt i: DiAgnosis of tuBerCulosis
Culture is considered the gold standard for the diagnosis of tuberculosis, but most clinical 
sputum samples contain a variety of micro-organisms that may overgrow M. tuberculosis. 
Decontamination of these samples is therefore crucial in preventing contamination of the 
mycobacterial culture. However, decontamination inhibits the recovery of mycobacteria. 
In the study described in Chapter 2, we compared the effect of two decontamination 
procedures, NaOH-N-actetyl cysteine (NaOH-NALC) and sulphuric acid, on the sen-
sitivity to detect M. tuberculosis complex and NTM in sputum samples. The recovery 
of NTM in the sulphuric acid group was significant higher than in the NaOH-NALC 
group (p = 0.001). In contrast, no significant difference was found for the recovery of 
M. tuberculosis.
The choice of the decontamination method applied definitely influences the recovery 
of mycobacteria and this has clear consequences for the quality of both microbiological 
diagnosis and treatment of patients. In the light of the results obtained in this study it 
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seems best to decontaminate specimens of patients suspected of NTM lung disease with a 
sulphuric acid instead of NaOH-NALC to optimise the detection of NTM.
Unfortunately, although sputum culture is still the gold standard for the diagnosis 
of pulmonary tuberculosis, the application of this diagnostic tool in most hospitals 
in low-income countries is not standard practise. Moreover, classical solid culture for 
mycobacteria requires 3-8 weeks, which limits the usefulness of culture as a first-line 
diagnostic test. In the last decade, liquid culture methods have become available in the 
Western world, with a shorter turn-around time of 1-3 weeks. However, liquid culture 
systems have hardly been applied in Africa because of the costs and maintenance of the 
equipment involved (5,38,39). In addition, culture of mycobacteria requires specialized 
personnel and a dependable supply of water and electricity.
A number of rapid diagnostic tests have been developed in an effort to improve the 
diagnostic accuracy for tuberculosis and to speed presumptive identification prior to 
the report on the cultures. Molecular amplification is the most prominent among these 
new tools. Amplification tests, such as the Amplified Mycobacterium tuberculosis Direct 
Test (MTD) (Gen-Probe, San Diego, California) and the Amplicor Mycobacterium tu-
berculosis Test (Amplicor) (Roche Diagnostic Systems, Inc., Branchburg, New Jersey), 
are promising because they have a high sensitivity and potential for good specificity 
and can be applied directly to clinical specimens such as sputum (2,17). The specificity 
of amplification test can be 98-100% and the sensitivity is higher than 95% in sputum 
that is AFB smear-positive and 60-70% in smear-negative, culture positive specimens 
(4,16,60). Recently developed molecular amplification tests may have better sensitivity 
in smear-negative specimens while retaining the same high degree of specificity (13,35). 
Furthermore, these tests are promising for materials other than sputum (blood, lymph, 
bone marrow, gastric aspirate, cerebrospinal fluid, urine, bronchial aspirate and lavage) 
altough results have considerable variability (45,46). Perhaps the application of molecular 
amplification methods to multiple samples, as is common practise for culture since de-
cades, will sufficiently increase the sensitivity of these tests in comparison to culture.
In any cases, at the moment, the high cost of equipment and material, complexity in 
use, and low specificity under field conditions make them inappropriate for resource-
poor settings.
One of the genomic regions often used for Mycobacterium species identification is the 16S 
ribosomal RNA (rRNA) gene and at present sequencing of this gene is the gold standard. 
The micro-organism is identified by comparison of the nucleotide sequence with refer-
ence sequences in several internet databases. Despite its accuracy, 16S rRNA gene se-
quence analysis lacks widespread use beyond the large and reference laboratories because 
of technical and cost considerations. An additional problem may be that the bacteria 
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of Mycobacterium species in Third world setting presumably have another evolutionary 
development than the ones in the Western world. This implies new data bases are needed, 
specific for high prevalence areas, containing genetic information of the local population 
of mycobacteria to facilitate an adequate and accurate identification.
Another method for the identification of Mycobacterium species is based on line probe 
hybridization, e.g. the Inno-Lipa Mycobacterium system (Innogenetics, Ghent, Belgium), 
which targets the 16S-23S rRNA gene spacer region or the GenoType Mycobacterium 
CM/AS (Hain Lifescience GmbH, Nehren, Germany) which targets the 23S gen regio. 
This method is currenty used for the identification of positive cultures but has potential 
to be used to identify Mycobacterium species directly in clinical specimens. However, also 
this method is currently based on the most frequently encountered species in the Europe 
and perhaps an African version of this method should be produced.
In view of these limitations, there is a need for fast, less complicated tests that are in prin-
ciple directly applicable to bacteria in clinical material and have the flexibility to detect 
any micro-organism, especially in poor resource settings.
It is expected that in the coming years molecular diagnosis of tuberculosis will slowly be 
introduced in Africa. There are already nucleic acid amplification methods that amplify 
DNA without thermal cycling, all reactions can be conducted under isothermal condi-
tions ranging from 60 to 65°C by using only one type of enzyme.
Loop-mediated isothermal amplification (LAMP) is a novel nucleic acid amplification 
method in which reagents react under isothermal conditions with high specificity, effi-
ciency, and rapidity. LAMP was used for detection of M. tuberculosis complex, M. avium, 
and M. intracellulare directly in sputum specimens as well as for identification of culture 
isolates grown in a liquid medium or on a solid medium.
Due to the easy operation of LAMP without sophisticated equipment, it will be simple 
enough to use in small-scale hospitals, primary care facilities, and clinical laboratories 
in developing countries if the remaining issues such as sample preparation, nucleic acid 
extraction, and cross-contamination controls are addressed (11,34).
A new and promising diagnostic tool for the rapid identification of mycobacteria is Ra-
man spectroscopy, described in Chapter 3. The results obtained clearly show the pos-
sibility to discriminate between 63 different Mycobacterium strains and to group them 
correctly into 8 clusters corresponding to M. tuberculosis, the most relevant clinical 
species of NTM in the Netherlands and M. lentiflavum. Moreover, the spectra of the vi-
able (and infectious) strains and strains inactivated by heat-killing were compared and 
showed minimal differences. Therefore, identification of mycobacteria was being possible 
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without biosafety level III precautions. Raman spectroscopy is an optical method, provid-
ing spectroscopic fingerprints from samples in a few seconds. The produced fingerprints 
represent the molecular composition of a sample and are therefore suited for identifica-
tion of micro-organism at both the species- and strain level. Important features of these 
methods are the relative ease with which measurements can be performed, the limited 
amount of sample handling involved, the little amount of biomass required and the high 
reproducibility. In the future, Raman analysis of clinical specimens may be applicable. 
In the past several years there has been a remarkable progress in lowering the costs of 
Raman systems, the equipment has become smaller and less vulnerable and therefore 
application in Africa could become reality in the future.
The electronic nose (gas sensor array) also shows potential for the direct detection 
of mycobacteria in clinical samples. In Chapter 4 we evaluated the electronic nose 
(EN), comprising 14 conducting polymers, to detect different Mycobacterium spp. and 
Pseudomonas aeruginosa in the headspaces of cultures, spiked sputa, and sputum samples 
from 330 culture-proven and human immunodeficiency virus-tested tuberculosis and 
non-tuberculosis patients. The EN differentiated between different Mycobacterium spe-
cies and between mycobacteria and other lung pathogens both in culture and in spiked 
sputum samples. The specificity and sensitivity of the described method were 91% and 
89%, respectively, compared to culture. The detection limit in culture and spiked sputa 
was found to be 1 × 104 mycobacteria ml−1.
This study has shown the potential of an electronic nose to detect M. tuberculosis in 
clinical specimens and opens the way to make this method a rapid and automated sys-
tem for the early diagnosis of respiratory infections. Therefore, this method in principle 
can become a cheap and wide-spread screening method for large populations in poor-
resource settings.
PArt ii: CliniCAl relevAnCe of ntM
Most data reporting high rates of NTM infections come from Northern European coun-
tries and the United States. In African countries, despite the fact that environmental 
exposure to NTM is very high, infection by NTM seems to be rare, even among patients 
with AIDS (42). However, it is not clear whether this is due to a true low prevalence of 
NTM infection or that the magnitude of this problem has not yet been unravelled. In 
Africa the contribution of NTM to the clinical problem of tuberculosis has so far only 
been examined at a very small scale.
A number of studies on the epidemiology of NTM has been performed in South Af-
rica. The results of sputum cultures from a large random sample of South African native 
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people were reported in two studies (6,25). Prevalence rates of NTM colonization/infec-
tion amounted; 1,400 and 6,700 per 100,000, respectively.
Furthermore, two other South African NTM studies focussed on a specific popula-
tion of gold miners, investigated for suspected pulmonary mycobacterial disease (18,19). 
Annual rates of NTM infection/disease were found to be 101 per 100,000 with the two 
most common organisms isolated being M. kansasii (66/100,000) and M. scrofulaceum 
(12/100,000), respectively.
In Yeta District Hospital in Sesheke, which is located in the Western Province of Zambia, 
during the late 1990s an increasing number of HIV-positive patients, clinically suspected 
of pulmonary tuberculosis, had a negative sputum smear but reacted positively to tu-
berculosis treatment. This suggested an increasing prevalence of sputum smear-negative 
tuberculosis. On the other hand, the contribution of NTM to tuberculosis-like diseases in 
Zambia had not been investigated previously.
The aim of the first pilot study described in Chapter 5 was to evaluate the role of NTM in 
the development of tuberculosis-like disease in Zambia and the confusion this may cause 
in the diagnosis of tuberculosis by microscopy. In Sesheke, 64 (both HIV positive and 
negative) patients, who were chronically ill for more than two weeks, were investigated 
using modern liquid culture and identification methods. Thirty out of 64 (47%) patients 
yielded positive Mycobacterium cultures that were identified as M. tuberculosis (8 times), 
M. szulgai (7), M. avium-intracellulare (3), M. simiae (1) and M. terrae (1). Ten isolates 
were not suitable for identification due to contamination or re-culture problems. Twelve 
of the 30 (43%) culture-positive patients were also positive in microscopic examination, 
including four patients with NTM isolates. Seven of the 22 NTM isolates belonged to 
M. szulgai. The patients with M. szulgai- positive sputum manifested symptoms extremely 
similar to tuberculosis caused by M. tuberculosis. DNA fingerprinting analysis revealed 
four different patterns among the seven M. szulgai isolates, excluding the possibility of a 
common source of infection or a laboratory cross-contamination. Three out of five pa-
tients with M. szulgai infection responded to anti-tuberculosis treatment. This suggests 
that in at least a part of the patients with chronic respiratory complaints their lung disease 
was caused by M. szulgai.
In several parts of the world M. szulgai has been recognized as a cause of serious infections 
in humans. However, Africa is the only continent from which no M. szulgai isolation has 
been described so far. Recovery of M. szulgai from the environment is exceptional and 
most literature on this Mycobacterium suggests that it is an unlikely laboratory contami-
nant (3,56). Therefore, M. szulgai should be considered clinically significant when iso-
lated (10). Similar to other mycobacteria, M. szulgai is associated with a wide spectrum 
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of diseases. The reported cases of human infection caused by M. szulgai revealed that 
pulmonary disease, mimicking tuberculosis, was the commonest type of infection caused 
by this micro-organism (54,56).
Because the contribution of NTM, and especially of M. szulgai, to tuberculosis-like 
diseases in both HIV-positive and negative patients in Sesheke seemed to be underesti-
mated (chapter 5) the subsequently pilot study was to assess the possible role of NTM in 
tuberculosis-like diseases in various geographic locations in Zambia, Chapter 6. In 2001, 
in three hospitals in Katete, Sesheke and Chilonga 167 hospitalised chronically ill patients 
were investigated. An extremely high rate of HIV positivity (between 69-79%) among 
the patients was observed. The percentage of patients with a positive sputum culture for 
M. tuberculosis complex was equal in the three geographic locations (19 to 25%). In con-
trast, the percentage of sputum cultures positive for NTM differed significantly between 
the villages and ranged from 78% in Katete, 65% in Sesheke and 21% in Chilonga. Fur-
thermore, the distribution of NTM species was different at the three geographic sites.
Nearly half (7/15) of the patients almost fulfilled the criteria of the American Thoracic 
Society for NTM disease and had the same NTM species isolated from both sputum 
specimens.
In the study described in chapter 6 we did not only find a high percentage of patients 
with positive NTM isolates from sputum specimens but also from specimens that are 
normally sterile, like lymph nodes and pleural effusion. Eight patients from whom NTM 
were cultured from normally sterile body sites are described in detail in Chapter 7. From 
chronically ill patients who had signs and symptoms in any part of the body for more 
than two weeks, pleural effusion, ascites, abscess material, or enlarged lymph nodes were 
cultured for mycobacteria. A specimen from one sterile body site was collected from 
25 patients (60% HIV-positive); NTM were isolated from eight of these 25 specimens. 
M. lentiflavum was isolated from four patients, and M. goodii was isolated from one 
patient. In order to exclude the possibility of a laboratory cross-contamination, a novel 
amplified fragment length polymorphism DNA typing method for M. lentiflavum was 
developed. Genetic variation was detected, rendering the likelihood of laboratory cross-
contamination unlikely. To our knowledge, we describe the first cases of M. lentiflavum 
and M. goodii infection in African patients.
M. lentiflavum is a slowly growing acid-fast bacillus that has biochemical characteristics 
identical to those of organisms belonging to the Mycobacterium avium complex and my-
colic acid and fatty acid chromatography patterns very similar to those of Mycobacterium 
simiae, so genetic analysis is necessary for conclusive identification (53). This organism 
has been isolated from normally sterile clinical samples in Italy, Switzerland, Germany, 
France and Spain and from sputum samples in Brazil and Italy (21,33,40,44,53,57). Cases 
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of human disease have been reported, including chronic pulmonary disease, cervical 
lymphadenitis, liver abscess and fatal disseminated infection (15,33,40,55). In addition, 
M. lentiflavum was isolated from two patients co-infected with M. avium (54).
In the initial microbiological report of M. goodii, most of the 28 isolates were recovered 
from non-pulmonary sources, including skin and soft tissue infections and osteomyelitis 
following penetrating trauma or surgery (14). Additional isolates were associated with 
nosocomial infection (catheter-related sepsis, pacemaker site infection, and other sur-
gical wounds), and other isolates were from patients with lipoid pneumonia or other 
types of pulmonary infection. The next report on M. goodii describes a case of olecranon 
bursitis in a patient with type 2 diabetes mellitus and benign monoclonal gammopa-
thy (26). The patient did not have any history of penetrating trauma, but the possibility 
of bacterial introduction with intrabursal injections or subsequent surgery was raised. 
Recently, a patient with an abdominal wall abscess after an inguinal hernia repair was 
described. He presented with abdominal wall- and preperitoneal abscesses three weeks 
after surgery (52).
High rates of NTM culture positive specimens were observed in the pilot study in Zam-
bia, described in chapter 5 and 6. Therefore, the clinical relevance of isolation of NTM 
from HIV-positive as well as HIV-negative patients was examined in detail in the study 
described in Chapter 8. In 2003, in St. Francis Hospital, 180 chronically ill patients and 
385 controls were included in the study. The proportion of NTM positive sputum samples 
from the patients was significantly higher in comparison to the controls, 11% and 6% 
respectively (p<0.05). In both groups, many (55 of the 171 NTM = 32%) not previously 
identified mycobacteria were isolated.
From 154 patients and 383 controls two consecutive sputum samples were cultured. 
Four patients had two positive cultures for NTM of whom one had pulmonary disease 
caused by M. intracellulare. In three more NTM-positive patients one of the two sputum 
cultures contained AFB which could not be identified of whom two had probable pulmo-
nary disease caused by M. intracellulare. In contrast, only one control had two sputum 
samples positive for (none identical) NTM. Significantly more patients in comparison to 
controls had two sputum cultures positive for NTM (p<0.05).
NTM probably play an important role in aetiology of tuberculosis-like disease in 
Zambia. In our study the estimated rate of colonization in the patient population was 
14/154 (9%) with a rate of disease of 3/154 (about 2%). The estimated rate of colonization 
in the general population was 61/383 (16%). In addition, it became clear in this study 
that patients and controls with NTM in the sputum were more often having symptoms 
and signs of general malaise and that the chest X-rays in these NTM-positive persons 
more frequently showed pathology in comparison with NTM culture-negative persons. 
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Moreover, patients with a positive NTM culture also more frequently revealed a clinical 
picture of general malaise (including diarrhoea, vomiting) and underweight (BMI < 18).
Finally, in Chapter 9, the accuracy of clinical diagnosis of tuberculosis in Zambia in the 
era of increasing HIV prevalence is summarized. In Zambia patients are diagnosed with 
tuberculosis on basis of respiratory complaints for two or more weeks, no improvement on 
two courses of routine empiric antibiotics, a positive Ziehl-Neelsen (ZN) sputum smear 
and/or pathology on the chest X-ray consistent with tuberculosis. Within the frame work 
of this study, sputum of the diagnosed tuberculosis cases were additionally subjected to 
MGIT liquid culture to distinguish between (1) tuberculosis cases confirmed by positive 
M. tuberculosis cultures, (2) mycobacteriosis caused by non-tuberculous mycobacteria 
and, (3) tuberculosis-like disease caused by of organisms other than mycobacteria. Only 
in 47% of the 187 diagnosed tuberculosis cases, M. tuberculosis was cultured. In another 
19% of the cases, exclusively NTM were cultured, whereas from 12% of the tuberculosis 
cases a combination of M. tuberculosis and NTM was isolated. In the remaining 29% of 
cases in which tuberculosis was diagnosed clinically, no mycobacteria were cultivable. 
HIV positivity was found significantly correlated with the isolation of NTM from sputum 
and inversely correlated with the isolation of exclusively M. tuberculosis from the sputum 
(p<0.05). Basing the diagnosis of tuberculosis on symptoms, sputum smear and/or chest 
X-ray may lead to significant numbers of clinically-defined false-positive cases of tuber-
culosis in Zambia, due to the increased prevalence of HIV.
A critical approach has to be made to the clinical relevance of the NTM isolated in the 
patients described in chapter 5, 6, 8 and 9. Not all the conditions described in these 
studies completely fulfilled the ATS criteria regarding NTM pulmonary disease because 
of reasons related to the African conditions of work. Moreover, the number of colonies 
on the solid medium tubes cultured in Zambia were not reported or culturing was only 
performed in liquid medium. A low number of colony-forming units could have been 
an indication of colonization of specimens by NTM. Therefore, the distinction between 
colonization and infection or disease could not be deduced from the culture results; some 
patients could also have represented culture negative TB cases.
Sputum of suspected cases was only subjected to culture and not tested by a nucleic acid 
amplifications (NAA) test or for instance the LiPA-Rif TB test on direct sputum to detect 
the presence of M. tuberculosis or multi-drug resistant M. tuberculosis (1,58). However, 
the performance of the NAA-test is good in clinical respiratory specimens that are AFB 
smear-positive (sensitivity 95% and specificity 98%) but less in specimens that contain 
fewer organisms or are AFB-negative (sensitivity 50% and specificity 95%). The NAA-test 
would be in a part of the cases be better in comparison to culture to detect a mixture of 
NTM and M. tuberculosis.
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In addition, no studies in this thesis were performed on environmental mycobacteria 
isolated from natural and artificial (e.g. tap water) sources in areas where patients and 
controls were living.
The factors determining an individual’s risk of infection and development of active 
disease are multi-factorial and involve host-pathogen interactions and environmental 
components. Substantial epidemiological evidence supports the role of host genetic 
factors in susceptibility to tuberculosis and mycobacteriosis. Host protective immunity 
to mycobacterial infection is dependent on the precise coordination of T-lymphocyte 
sensitisation and monocyte recruitment. Several cytokine and chemokine signals play 
crucial roles in the immune response to tuberculosis, by contributing to the initial control 
of the infection. One of these factors is monocyte chemoattractant protein-1, MCP-1, 
a chemokine strongly involved in the inflammatory process. In the study described in 
Chapter 10, the MCP-1 promotor gene polymorphism in association with susceptibility 
to development of tuberculosis after infection was investigated in Zambian people. The 
allele G of the MCP-1 promotor-enhancing region was found associated with increased 
odds of developing active pulmonary tuberculosis after infection. Persons with the 
MCP-1 genotype AG were 2.7-fold more likely to develop tuberculosis than those with 
the AA genotype.
Although a small number of patients and controls were included in this study, already 
a significant association was disclosed of susceptibility to tuberculosis and a particular 
polymorphism in this gene. To our knowledge, this is the first study investigating the 
polymorphism of the MCP-1 gene in African people, and this may be a first indication 
that especially this gene may play a crucial role in increased susceptibility to this in-
fectious disease in particular human populations. Further studies with sufficient power 
are needed to compare the true contribution of the MCP-1 gene to the susceptibility to 
develop tuberculosis among Africans and populations in other geographic regions.
DireCtions for future reseArCh
High rates of NTM colonization and NTM disease in Zambia are reported in this the-
sis. Furthermore, differences in the distribution of specific species of NTM in chroni-
cally ill patients in three villages in Zambia were observed. So far, only a few studies 
on the epidemiology of NTM have been performed in Africa, mainly South Africa, and 
benchmark data are barely available. More extensive studies; in duration and size, will 
be needed to determine the true magnitude of NTM colonization and infection on the 
African continent. Furthermore, studies on the environmental flora of areas were patients 
and controls are living will be needed. The limited sample size of our studies lacks the 
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power to generalise findings across the population as a whole. Moreover, patients were 
examined during certain months of the year and seasonal influences may have played a 
role as well.
Consistent data of patients have to be collected and the minimum data required should 
include the criteria of the ATS for evaluation of a patient suspected for NTM disease: 
(1) chest radiograph with nodular or cavitary opacities, or an high-resolution computed 
tomography (HRCT) scan that shows multi-focal bronchiectasis with multiple small 
nodules, (2) three or more sputum specimens for AFB analysis and (3) exclusion of other 
disorders, such as tuberculosis. The preferred staining procedure is the fluorochrome 
microscopy and specimens should be cultured on both liquid and solid media. It is dif-
ficult to determine the clinical significance of the isolate without species identification 
and therefore NTM should be identified to the species level. Introduction of diagnostic 
tools, adequate laboratory facilities and training of laboratory technicians will therefore 
be mandatory in Africa. It is advisable to use a nucleic acid amplification method directly 
on clinical specimens from TB suspected patients, in addition to sputum smear micros-
copy and culture, to investigate the possibility of being a true TB case despite the absence 
of positive culture for M. tuberculosis.
To further investigate the occurrence of NTM by culture, the use of MGIT tubes in 
combination with a solid medium is recommended. This would provide the number of 
colonies grown on solid medium and would help to deduce the clinical relevance of a 
positive culture. At least one advanced reference laboratory is required in each country 
and preferable should have an affiliation with a laboratory in the industrialized world.
In general NTM infections in Africa are not treated at this moment and indications have 
been found that at least a part of the NTM isolated in African patients is clinically relevant. 
Patients diagnosed with NTM disease should be evaluated for the initiation of therapy 
and outcome should be critically followed for extended time periods. Furthermore, 
patients suspected of having NTM lung disease but not meeting the diagnostic criteria 
should be followed until the diagnosis is established or excluded. The treatment of NTM 
disease is generally not directly analogous to the treatment of tuberculosis. Multi-drug 
regimes include most of the time a newer macrolide (azithromycin, clarithromycin) (29). 
In vitro susceptibilities for many NTM do not correlate well with clinical response to anti-
mycobacterial drugs but recommendations for routine in vitro susceptibility testing of 
NTM isolates are limited. The duration of therapy for most pulmonary NTM pathogens 
is at least one year until sputum cultures are consecutively negative while on therapy.
Certain conditions like HIV infection tend to facilitate NTM infection and patients with 
such risk factors in future research deserve special attention. In HIV positive patients, 
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disseminated NTM infections typically occurs only after the CD4+ T-lymphocyte num-
ber has fallen below 50/µl. Lung disease due to NTM occurs commonly in structural 
lung disease, such as chronic obstructive pulmonary disease (COPD), bronchiectasis, CF, 
pneumoconiosis, and previous tuberculosis. NTM lung disease also occurs in women 
without clearly recognized predisposing factors. Additional, extended case control stud-
ies to identify possible risk factors for NTM colonization and infection would be a logical 
next step.
In conclusion, tuberculosis classically defined on basis of ZN-smear of sputum and chest 
X-ray may increasingly be over-diagnosed in Zambia, due to the increased prevalence of 
HIV and inaccuracies in the diagnosis of tuberculosis, as described in this thesis. Fur-
thermore, a part of the tuberculosis-like syndromes in Africa is probably caused by NTM 
and the treatment of such infections should be considered. Misdiagnosis of tuberculosis 
can be reduced by the introduction of new diagnostic techniques in addition to AFB mi-
croscopy, which incorporate the diagnosis of NTM pulmonary disorders. Furthermore, 
diagnostic scoring systems and algorithms must be developed and validated to assist 
clinicians working in resource-poor settings with high prevalence of HIV.
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Tuberculose (TB) behoort met HIV/AIDS en malaria tot één van de belangrijkste doods-
oorzaken ter wereld. Deze drie infectieziekten samen zijn namelijk verantwoordelijk 
voor ongeveer 10 procent van alle sterfte in de wereld, die zich voor het overgrote deel 
manifesteert in ontwikkelingslanden. Het afgelopen decennium is het aantal tuberculo-
sepatiënten sterk toegenomen in Afrika als gevolg van de HIV-epidemie en de daarmee 
gepaard gaande immuunsuppressie.
Wereldwijd is één derde van de wereldbevolking, twee miljard mensen, latent geïnfecteerd 
met tuberculose. Slechts 1 op de 10 geïnfecteerde mensen krijgt actieve tuberculose en 
wordt ziek. Jaarlijks ontwikkelen wereldwijd naar schatting zo’n negen miljoen mensen 
daadwerkelijk de ziekte tuberculose.Tuberculose eist bijna twee miljoen doden per jaar, 
hetgeen betekent dat elke dag ongeveer vijfduizend mensen aan tuberculose sterven, 
ondanks het feit dat tuberculose te genezen is. Bijna alle sterfgevallen aan tuberculose, 98 
procent, komen voor in de ontwikkelingslanden.
Tuberculose is de belangrijkste doodsoorzaak onder mensen met een verzwakt immuun-
systeem door een HIV-infectie. Wereldwijd zijn ongeveer 34 miljoen mensen geïnfecteerd 
met HIV/AIDS. Hiervan kent Afrika het hoogste aantal geïnfecteerde mensen. In som-
mige landen heeft één op de vijf volwassenen HIV/AIDS. Een kwart miljoen patiënten 
die per jaar aan tuberculose sterven is HIV-geïnfecteerd of ook AIDS-patiënt. De meeste 
van hen wonen in Afrika. HIV is de voornaamste oorzaak van de dramatische toename 
van tuberculose in Afrika gedurende de afgelopen vijftien jaren. In sommige delen van 
Afrika heeft wel tachtig procent van de tuberculosepatiënten een HIV-infectie.
Tuberculose, in de volksmond ook ‘tering’ of ‘witte pest’ genoemd, is een infectieziekte die 
meestal wordt veroorzaakt door de tuberculosebacterie, Mycobacterium tuberculosis. Ech-
ter in de Westerse wereld is bekend dat ook atypische mycobacteriën, non-tuberculeuze 
mycobacteriën (NTM), een oorzakelijke rol spelen in tuberculose-achtige ziektebeelden. 
Normaliter maken deze NTM de mens niet ziek. Echter, in geval van een slechte afweer 
zoals bij AIDS kunnen sommige NTM wel ziekte veroorzaken. In Afrika is de bijdrage 
van NTM aan het tuberculose probleem nog nauwelijks onderzocht. De gedachte was dat 
deze infectie weinig in sub-Sahara Afrika voorkomt. Uitgebreide laboratorium facilitei-
ten en radiologische apparatuur die nodig zijn om de ziekte te diagnosticeren ontbreken 
echter vrijwel overal in Afrika, waardoor een onderschatting van het werkelijke probleem 
is ontstaan.
In Zambia heeft naar schatting 13,5-20% van de volwassen (15-49 jaar) HIV/AIDS. 
Daarom werd juist in dit land de klinische relevantie van NTM in zowel in HIV-positieve 
als HIV-negatieve patiënten onderzocht.
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De afgelopen jaren zijn in de Westerse landen aanzienlijke vorderingen gemaakt in de 
tuberculose diagnostiek. Helaas zijn juist in gebieden waar heel veel TB voorkomt, zoals 
Afrika, de technieken om tuberculose te diagnosticeren vrijwel onveranderd gebleven in 
de afgelopen eeuw. In 1882 werd de tuberkelbacil voor het eerst microscopisch aangetoond 
als zuurvaste staaf in een sputumuitstrijk gekleurd volgens Ziehl-Neelsen. Deze Ziehl-
Neelsen microscopie is in Afrika en in veel andere ontwikkelingsgebieden nog steeds de 
basis van de diagnose van tuberculose. Helaas zijn gevoeligere technieken zoals kweek 
en DNA/RNA amplificatie zo complex en duur dat ze in het algemeen niet toegepast 
worden in ontwikkelingslanden. De basis voor TB diagnostiek in ontwikkelingslanden 
is daarom nog steeds het microscopisch onderzoek naar de zuurvaste staven (mycobac-
teriën) in sputum. Volgens internationale standaarden, zoals International Standards for 
Tuberculosis Care, zouden van alle verdachte tuberculose patiënten twee, en bij voorkeur 
drie, sputum specimens microscopisch op tuberkelbacillen onderzocht moeten worden, 
indien mogelijk inclusief een ochtendsputum.
Een ervaren analist vindt 50-60% van de tuberculose patiënten door middel van 
microscopisch onderzoek van sputum. In ontwikkelingslanden ligt dit percentage veel 
lager omdat de kwaliteit van de microscopen slechter is, de werkdruk hoger ligt en er een 
tekort is aan getraind personeel. Verder is de microscopie vaak negatief in patiënten met 
recente tuberculose en bepaalde groepen patiënten zoals die met een HIV co-infectie en 
patiënten met extra-pulmonale TB. Het percentage TB patiënten dat door middel van 
microscopie wordt gediagnosticeerd kan daardoor teruglopen tot 20-30%.
Indien sprake is van een negatief microscopisch onderzoek van het sputum en geen reac-
tie op breedspectrum antibiotica wordt waargenomen worden de meeste patiënten met 
pulmonale TB in ontwikkelingslanden op basis van klinische en radiologische kenmer-
ken gediagnosticeerd.
Volgens huidige richtlijnen moeten alle personen met een onverklaarde productieve 
hoest die 2-3 weken of langer duurt op TB onderzocht worden. De diagnose sputum-
uitstrijk-negatieve pulmonale TB wordt gebaseerd op tenminste drie keer een negatief 
microscopisch onderzoek op zuurvaste staven, radiologische afwijkingen passend bij TB 
en geen reactie op een kuur breedspectrum antibiotica.
Echter, de diagnose ‘sputumuitstrijk negatieve pulmonale TB’ is in gebieden met hoge 
prevalentie HIV en TB infectie gecompliceerd ten gevolge van de atypische presentatie 
van pulmonale TB in HIV-geïnfecteerde patiënten. Typische radiologische afwijkingen, 
passend bij pulmonale TB, zijn minder vaak te vinden in gebieden met een hoge HIV 
prevalentie. Verder presenteren HIV positieve en sputumuitstrijk-negatieve TB patiënten 
zichzelf minder vaak met caviteiten in de longen. Tevens kunnen sputumuitstrijk-nega-
tieve patiënten zichzelf ook presenteren met een normale of minimaal afwijkende thorax 
foto. Om vervolgens de etiologie van de afwijkende thorax foto te achterhalen is verder 
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onderzoek noodzakelijk, omdat uit jarenlang onderzoek is gebleken dat radiologisch 
onderzoek voor de diagnose of follow-up van pulmonale TB niet betrouwbaar is.
Een bijkomend probleem is dat het voorkomen van zuurvaste NTM bij patiënten met 
tuberculose-achtige ziektebeelden kunnen resulteren in het misdiagnosticeren van TB. 
De recentelijk gepubliceerde diagnostische criteria voor NTM ziekte van de American 
Thoracic Society (ATS) kunnen de diagnose ondersteunen indien bij een patiënt NTM 
uit een specimen wordt geïsoleerd. Het grootste verschil tussen de oude en nieuwe di-
agnostische ATS criteria ligt in de minder harde bacteriologische criteria. Een enkele 
positieve bronchusspoelselkweek voor NTM, of twee positieve sputumkweken in een 
symptomatische patiënt met nodulaire of cavitaire afwijkingen op de thorax foto, zijn nu 
voldoende om een NTM infectie vast te stellen. Waarschijnlijk zullen nu meer patiënten 
dan voorheen aan de ATS criteria voor een echte NTM infectie voldoen, waardoor een 
toename verwacht wordt van het aantal patiënten dat voor een anti-mycobacteriële be-
handeling in aanmerking komt. Door de auteurs van de nieuwe ATS criteria wordt wel 
duidelijk naar voren gebracht dat patiënten die aan de criteria voldoen niet per se met 
behandeling hoeven te beginnen. Het klinisch beeld blijft van belang. Noemenswaardig is 
ook de exclusie van een positieve sputumuitstrijk of bronchusspoelsel en de exclusie van 
extra-pulomonale NTM isolaten in de diagnostische criteria. De consequenties van deze 
nieuwe criteria zijn waarschijnlijk dat er moeilijkheden gaan ontstaan betreffende initi-
atie van therapie en vaststellen van de klinische significantie van de geïsoleerde NTM, 
met name afkomstig uit een extra-pulmonaal specimen.
In dit kader zouden er in Afrika op korte termijn methoden geïntroduceerd moeten 
worden die onderscheid kunnen maken tussen M. tuberculosis en NTM in klinische ma-
terialen. Wel blijft de gevoeligheid van dergelijke testen bij directe toepassing op klinische 
materialen een punt van zorg.
Met de huidige kennis lijkt onderzoek naar de diagnostiek en behandeling van 
NTM infecties in Afrika van belang te zijn, zeker in het licht van de toenemende HIV 
prevalentie.
Deel i: DiAgnostiCeren vAn tuBerCulose
De kweek wordt gezien als de gouden standaard voor het aantonen van het oorzakelijke 
agens M. tuberculosis. De meeste klinische monsters bevatten echter een variëteit aan 
micro-organismen die M. tuberculosis kunnen overgroeien. Decontaminatie van deze 
monsters is dan ook essentieel om contaminatie van de mycobacteriële kweek te voor-
komen.
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De decontaminatie heeft echter ook invloed op het kweken van mycobacteriën; deze 
worden ook in de groei geremd en zelfs deels geïnactiveerd. In het onderzoek dat be-
schreven is in Hoofdstuk 2 wordt het effect van twee decontaminatie procedures; de 
NaOH-N-actetyl cysteine (NaOH-NALC) en de zwavelzuur methode op het kweken van 
M. tuberculosis complex en NTM in sputum samples vergeleken. De detectie van NTM 
met de zwavelzuurmethode was significant beter dan met de NaOH-NALC methode (p 
= 0.001). Er werd echter geen significant verschil gevonden voor de detectie van M. tu-
berculosis.
De decontaminatiemethode die wordt gebruikt heeft dus een duidelijke invloed op de 
detectie van mycobacteriën, hetgeen uiteindelijk belangrijke consequenties heeft voor 
zowel de microbiologische diagnose als de behandeling van de patiënt. Op basis van 
dit onderzoek lijkt het van belang om klinische monsters afkomstig van patiënten die 
mogelijk aan NTM longziekte lijden, te decontamineren met zwavelzuur in plaats van 
NaOH-NALC om zo de detectie van NTM te optimaliseren.
Hoewel sputumkweek de gouden standaard is voor de diagnose van pulmonale TB 
wordt deze diagnostische test in de meeste ziekenhuizen in ontwikkelingslanden niet 
standaard gebruikt, men heeft over het algemeen alleen de microscopie beschikbaar. 
Verder wordt het gebruik van de kweek als eerstelijns diagnostische test beperkt doordat 
kweken van mycobacteriën op een vast medium gemiddeld 3-8 weken duurt. De laatste 
decennia zijn er in de Westerse wereld vloeibare kweekmethoden beschikbaar gekomen 
die in 1-3 weken een uitslag kunnen geven. De vloeibare kweeksystemen worden echter 
nog nauwelijks in Afrika toegepast ten gevolge van de kosten en onderhoud van appara-
tuur. Tevens vereist het kweken van mycobacteriën gespecialiseerd personeel en betrouw-
bare voorziening van water en elektriciteit.
Om de diagnostiek van TB te versnellen zijn er de laatste decennia een aantal testen ont-
wikkeld, waarvan de moleculaire amplificatie technieken het meest prominent zijn. Deze 
amplificatie testen, zoals de Amplified Mycobacterium Tuberculosis Direct Test (MTD) 
(Gen-Probe, San Diego, California) en de Amplicor Mycobacterium Tuberculosis Test 
(Amplicor) (Roche Diagnostic Systems, Inc., Branchburg, New Jersey) hebben een hoge 
sensitiviteit en specificiteit en zijn direct toepasbaar op klinische specimens zoals sputum. 
De specificiteit van deze testen zou 98-100% zijn en de sensitiviteit meer dan 95% in 
microscopisch positief sputum, terwijl dit 60-70% zou zijn voor microscopisch negatief, 
kweek positief materiaal. Recentelijk ontwikkelde moleculaire amplificatie testen hebben 
een betere sensitiviteit in microscopisch negatieve monsters, terwijl de specificiteit blijft 
behouden. Tevens zijn deze testen waarschijnlijk ook toepasbaar op specimens anders 
dan sputum, zoals bloed, lymfklieren, beenmerg, liquor, urine, broncho-alveolaire lavage, 
hoewel de resultaten aanzienlijk verschillen. Vermoedelijk zal de toepassing van de mo-
leculaire amplificatie methode op monsters van diverse aard de sensitiviteit verhogen in 
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vergelijking met kweek. Niettemin, op dit moment zijn deze testen in minder ontwik-
kelde gebieden niet geschikt om toe te passen ten gevolge van de hoge kosten van zowel 
apparatuur als materiaal, de complexiteit in gebruik en lage specificiteit in het veld.
Eén van de regio’s op het genoom van mycobacteriën die vaak voor de species identifica-
tie wordt gebruikt is het 16S ribosomaal RNA (rRNA) gen. Sequencen van dit gen wordt 
tegenwoordig gezien als gouden standaard voor de identificatie. Het organisme wordt 
geïdentificeerd door vergelijking van de nucleotide sequence met referentie sequenties in 
verscheidene internet databases. Vanwege de grote nauwkeurigheid wordt 16S rRNA gen 
sequentie analyse door vrijwel alle referentie laboratoria gebruikt. In perifere laboratoria 
en vooral in ontwikkelingslanden wordt deze techniek niet gebruikt ten gevolge van tech-
nische overwegingen en kosten. Een bijkomend probleem is dat Mycobacterium species 
in ontwikkelingslanden waarschijnlijk een andere evolutionaire ontwikkeling hebben 
doorgemaakt dan de species in de Westerse wereld. Daardoor zijn nieuwe databases no-
dig die genetische informatie van de lokale populatie mycobacteriën bevatten, zodat een 
adequate en nauwkeurige identificatie kan plaatsvinden.
Een andere methode voor de identificatie van Mycobacterium species is gebaseerd op line 
probe hybridisatie welke zich richt op de 16S-23S rRNA gen spacer regio of 23S gen regio, 
zoals respectievelijk de Inno-Lipa Mycobacteria system (Innogenetics, Ghent, Belgium) 
en GenoType Mycobacterium CM/AS (Hain Lifescience GmbH, Nehren, Germany). 
Deze methode wordt momenteel gebruikt voor de identificatie van positieve kweken maar 
heeft de potentie om Mycobacterium species direct in klinisch materiaal te identificeren. 
Ook deze methode is echter op de meest voorkomende species in Europa gebaseerd en 
het is nog niet duidelijk of deze methode zondermeer in Afrika te gebruiken is.
In het kader van deze beperkingen is er met name in minder ontwikkelde gebieden 
behoefte aan snelle, minder gecompliceerde diagnostische testen die in principe direct 
toepasbaar zijn op bacteriën in klinisch materiaal.
Naar verwachting zal in de komende jaren de moleculaire diagnostiek van TB langzaam 
in Afrika worden geïntroduceerd. Er zijn al amplificatie methoden die DNA kunnen 
amplificeren zonder thermische cycli, zodat alle reacties onder isothermische condities, 
varierend van 60 tot 65°C, kunnen worden uitgevoerd. Loop-gemedieerde isothermische 
amplificatie (LAMP) is een nieuwe nucleinezuur amplificatie techniek waarin de reagen-
tia onder isothermische condities met hoge specificiteit, efficiëntie en snelheid met elkaar 
reageren. LAMP is al gebruikt voor de detectie van M. tuberculosis complex, M. avium en 
M. intracellulare zowel in sputum samples als in kweek. Door de gemakkelijke uitvoering 
van LAMP zonder gecompliceerde apparaten zal deze techniek eenvoudig genoeg zijn 
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om in kleinere ziekenhuizen en klinische laboratoria in ontwikkelingslanden te introdu-
ceren.
Een nieuwe diagnostische techniek voor de snelle identificatie van mycobacteriën is de 
Raman spectroscopie, beschreven in Hoofdstuk 3. De resultaten van dit onderzoek la-
ten duidelijk zien dat het mogelijk is de 63 verschillende Mycobacterium stammen van 
elkaar te onderscheiden en te groeperen in 8 clusters behorende tot M. tuberculosis, de 
meest relevante klinische NTM species in Nederland en M. lentiflavum. Tevens toonden 
de spectra van levende (en dus infectieuse) stammen en warmte-geïnactiveerde (onge-
vaarlijke) stammen minimale verschillen. Het was daarom mogelijk om de identificatie 
van mycobacteriën uit te voeren zonder biosafety level III inperkingsmaatregelen. Raman 
spectroscopie is een optische methode die het mogelijk maakt binnen enkele seconden 
spectroscopische fingerprints van samples te verkrijgen. De fingerprints zijn een afspie-
geling van de moleculaire samenstelling van het sample en daarom ideaal voor de iden-
tificatie van micro-organismen op zowel species als stam niveau. Belangrijke kenmerken 
van de methode zijn de eenvoud waarmee het sample gemeten kan worden, het geringe 
aantal handelingen, de geringe hoeveelheid aan benodigd materiaal en de hoge mate van 
reproduceerbaarheid. In de nabije toekomst zal de Raman analyse waarschijnlijk direct 
op klinische materialen toepasbaar worden. De laatste jaren zijn de kosten van Raman 
systemen aanzienlijk verminderd en de apparatuur is kleiner en minder kwetsbaar ge-
worden en daarom wordt de bruikbaarheid in Afrika realiteit in de toekomst.
Ook de elektronische neus (gas sensor array) heeft de potentie om op zeer snelle wijze 
mycobacteriën direct in klinisch materiaal te detecteren. In Hoofdstuk 4 wordt het ge-
bruik van de elektronische neus (EN) om verschillende Mycobacterium species en Pseu-
domonas aeruginosa in kweken, kunstmatige besmet sputum en sputum samples van 330 
kweek-positieve tuberculose and non-tuberculose patiënten te detecteren besproken. De 
EN differentieerde de verschillende Mycobacterium species en ook mycobacteriën ten op-
zichte van andere pathogenen, zowel in kweek als in het kunstmatig besmet sputum. De 
specificiteit en sensitiviteit waren respectievelijk 91% en 89% in vergelijking tot kweek. De 
detectie limiet in kweek en kunstmatig besmet sputum was 1 × 104 mycobacteriën ml−1.
Dit onderzoek toont aan dat het in principe mogelijk is om M. tuberculosis direct in 
klinische samples aan te tonen. Deze methode kan in de toekomst een goedkope, snelle 
en geautomatiseerde test zijn voor de vroege diagnose van respiratoire infecties in minder 
ontwikkelde gebieden.
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Deel ii: KlinisChe relevAntie vAn ntM
De meeste data betreffende prevalentie van NTM infecties zijn afkomstig van Noord 
Europese landen en de Verenigde Staten van Amerika. In Afrika zijn weinig NTM in-
fecties gerapporteerd, ondanks de hoge omgevingsblootstelling en het hoge percentage 
patiënten met AIDS. Het is echter niet duidelijk of hier sprake is van een daadwerkelijke 
lage prevalentie van NTM infectie of dat de omvang van het probleem nog niet voldoende 
in kaart is gebracht. In Afrika is de bijdrage van NTM aan het ziektebeeld tuberculose tot 
nu toe alleen zeer kleinschalig onderzocht.
In Zuid-Afrika is de epidemiologie van NTM in een aantal onderzoeken beschreven. 
In twee mycobacteriële studies werden de sputum kweek resultaten van Zuid-Afrikaanse 
personen gerapporteerd. De NTM prevalentie voor kolonisatie/infectie bedroeg in deze 
studies 1.400 and 6.700 per 100.000. Twee andere Zuid-Afrikaanse NTM studies concen-
treerden zich op een specifieke populatie goudmijnwerkers verdacht voor pulmonale my-
cobacteriële ziekte. Er werd een NTM incidentie voor infectie/ziekte van 101 per 100.000 
gevonden. De incidentie van de twee meest geïsoleerde organismen was voor M. kansasii 
66/100.000 en M. scrofulaceum 12/100.000.
In het Yeta District Ziekenhuis in Sesheke, gelegen in de Westelijke Provincie van Zam-
bia, werden gedurende de jaren 90 een toenemend aantal HIV-positieve patiënten, ver-
dacht voor pulmonale TB, met een negatieve sputumuitstrijk gezien die reageerde op 
anti-tuberculose behandeling. Deze bevinding suggereerde een toenemende prevalentie 
van sputumuitstrijk negatieve TB. Echter, de bijdrage van NTM aan tuberculose-achtige 
ziektebeelden was in Zambia nog niet eerder onderzocht.
Het doel van het eerste pilot onderzoek dat beschreven is in Hoofdstuk 5 was het evalu-
eren van de bijdrage van NTM in de ontwikkeling van tuberculose-achtige ziektebeelden 
in Zambia en de verwarring die NTM mogelijk veroorzaken in de diagnostiek van TB, 
gebaseerd op microscopie. In Sesheke werden 64 (zowel HIV positieve als negatieve) 
patiënten, die chronisch ziek waren gedurende meer dan twee weken, op mycobacteriën 
onderzocht met een vloeibare kweek en moderne identificatie methoden. Dertig van de 
64 (47%) patiënten hadden een positieve kweek voor mycobacteriën die werden geïden-
tificeerd als M. tuberculosis (8 keer), M. szulgai (7), M. avium-intracellulare (3), M. simiae 
(1) en M. terrae (1). Tien isolaten konden niet worden geïdentificeerd ten gevolge van 
contaminatie of kweek problemen. Twaalf van de 30 (43%) kweek positieve patiënten 
hadden ook een positieve sputumuitstrijk, inclusief vier patiënten met NTM isolaten. 
Zeven van de 22 NTM isolaten behoorden tot M. szulgai. De patiënten met een M. szulgai 
positief sputum presenteerden zich met symptomen die zeer vergelijkbaar waren met TB 
veroorzaakt door M. tuberculosis.
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Door middel van DNA fingerprinting analyse was het mogelijk vier verschillende pa-
tronen onder de zeven M. szulgai stammen te onderscheiden, waardoor de mogelijkheid 
van een gezamenlijke bron of laboratorium kruis-contaminatie werd uitgesloten. Drie van 
de vijf patiënten met een M. szulgai infectie reageerden op anti-tuberculose behandeling. 
In dit hoofdstuk wordt gesuggereerd dat bij een deel van de patiënten met chronische 
pulmonale klachten M. szulgai het oorzakelijke agens zou kunnen zijn.
M. szulgai wordt in de meeste delen van de wereld herkent als een oorzaak van infecties 
bij de mens. Afrika was tot nu toe het enige continent waar de isolatie van M. szulgai niet 
was beschreven. M. szulgai wordt niet vaak uit de omgeving geïsoleerd en de meeste lite-
ratuur suggereert dat het zelden een laboratoriumcontaminant is. Indien M. szulgai wordt 
geïsoleerd, moet deze Mycobacterium daarom als klinisch significant worden beschouwd. 
M. szulgai is net als andere NTM geassocieerd met een breed spectrum aan klinische 
beelden. Pulmonale ziekte, lijkend op TB, is het meest voorkomende ziektebeeld.
Aangezien de bijdrage van NTM, met name M. szulgai, aan tuberculose-achtige ziekte-
beelden in zowel HIV-positieve als HIV-negatieve patiënten in Sesheke leek te worden 
onderschat (hoofdstuk 5) was het volgende pilot onderzoek gericht op de bijdrage van 
NTM aan tuberculose-achtige ziektebeelden in verschillende geografische locaties in 
Zambia; zie Hoofdstuk 6. In 2001 werden 167 chronisch zieke patiënten in drie zieken-
huizen in Katete, Sesheke en Chilonga onderzocht. Een extreem hoog percentage van 
deze patiënten was HIV positief; tussen de 69 en 79%. Het percentage patiënten met een 
positieve kweek voor M. tuberculosis was vergelijkbaar op de drie geografische locaties 
(19 tot 25%). Echter, het percentage NTM positieve sputumkweken verschilde significant 
tussen de drie ziekenhuizen en varieerde van 78% in Katete, 65% in Sesheke, tot 21% in 
Chilonga. Verder was de verdeling van de NTM species tussen de drie plaatsen verschil-
lend.
Een deel van de patiënten waarbij NTM uit het sputum werd geïsoleerd voldeed bijna 
aan de criteria van de American Thoracic Society voor NTM ziekte: 7 van de 15 patiënten 
hadden twee maal dezelfde NTM in beide sputum monsters.
In deze studie, beschreven in hoofdstuk 6, vonden we niet alleen een hoog percentage 
patiënten met positieve NTM isolaten uit het sputum, maar ook uit klinische monsters die 
normaal gesproken steriel behoren te zijn, zoals lymfklieren en pleuravocht. In Hoofd-
stuk 7 worden 8 patiënten in detail beschreven bij wie uit normaliter steriele klinische 
materialen NTM werd gekweekt.
Er werden van chronisch zieke patiënten met klachten en symptomen die langer dan 
twee weken aanhielden, pleuravocht, ascites, abces materiaal of een vergrote lymfklier 
gekweekt op mycobacteriën. In totaal werden monsters van een normaliter steriel ma-
teriaal van 25 patiënten (60% HIV-positief) verzameld. NTM werden uit acht van de 25 
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monsters geïsoleerd. M. lentiflavum werd uit 4 patiënten en M. goodii werd bij één patiënt 
geïsoleerd. Om vervolgens de mogelijkheid van een laboratorium kruis-contaminatie uit 
te sluiten werd een nieuwe amplified fragment length polymorphism DNA typeringsme-
thode voor M. lentiflavum ontwikkeld. Het was mogelijk door middel van deze methode 
genetische variatie aan te tonen waardoor een laboratorium kruis-contaminatie onwaar-
schijnlijk werd. Deze studie beschrijft naar ons beste weten voor de eerste keer patiënten 
met een M. lentiflavum en M. goodii infectie in Afrika.
M. lentiflavum is een langzaam groeiende zuurvaste bacterie met biochemische karakte-
ristieken identiek aan mycobacteriën behorend tot het Mycobacterium avium complex. 
Deze bacterie heeft een mycolinezuur en vetzuur chromatografie patroon vergelijkbaar 
met Mycobacterium simiae, waardoor genetische analyse noodzakelijk is voor de identi-
ficatie. M. lentiflavum werd reeds geïsoleerd uit normaal gesproken steriele samples in 
Italië, Zwitserland, Duitsland, Frankrijk en Spanje en uit sputum samples in Brazilië en 
Italië. Patiënten met chronisch longlijden, cervicale lymphadenitis, leverabces en gedis-
semineerde infectie ten gevolgde van M. lentiflavum zijn in de literatuur beschreven.
In het eerste publicatie over M. goodii werden de meeste van de 28 isolaten van extra-
pulmonale monsters geïsoleerd, zoals infecties van de huid en subcutane weefsel en een 
osteomyelitis na een penetrerend chirurgisch trauma. Later gerapporteerde isolaten wa-
ren geassocieerd met nosocomiale infecties (catheter gerelateerde sepsis, infectie van de 
pacemaker site en andere chirurgische wonden) en pulmonale infectie. Een case-report 
beschrijft een olecranon bursitits in een patiënt met diabetes mellitus type 2 en een goed-
aardige monoklonale gammo-globulinopathie. Intrabursale injecties of chirurgie werden 
als mogelijke verklaringen van de bacteriële introductie gezien. Recentelijk is er nog een 
patiënt beschreven met een buikwandabces dat drie weken na een inguinale hernia ope-
ratie ontstond.
In de pilot onderzoeken beschreven in hoofdstuk 5 en 6 worden hoge percentages van 
NTM kweek positieve specimens in Zambia gevonden. De klinische relevantie van de 
geïsoleerde NTM van zowel HIV positieve als HIV negatieve patiënten werd daarom 
meer gedetailleerd onderzocht in het onderzoek dat beschreven is in Hoofdstuk 8. In 
2003 werden in het St. Francis Ziekenhuis in Katete 180 chronisch zieke patiënten onder-
zocht. Tevens werden 385 controle personen geïncludeerd in de studie. Het percentage 
NTM positieve sputum samples afkomstig van patiënten was significant hoger dan van 
de controle personen, respectievelijk 11% and 6% (p<0.05). In beide groepen werden veel 
(55 of the 171 NTM = 32%) niet eerder geïdentificeerde mycobacteriën geïsoleerd.
Van 154 patiënten en 383 controle personen werden twee opeenvolgende sputum sam-
ples gekweekt. Vier van deze 154 patiënten hadden twee positieve NTM kweken waarvan 
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één patiënt een pulmonale ziekte had, veroorzaakt door M. intracellulare. Verder waren 
er nog drie NTM positieve patiënten, waarbij één van de twee sputumkweken zuurvaste 
staven bevatte die niet konden worden geïdentificeerd, waarvan er twee pulmonale ziekte 
hadden die mogelijk veroorzaakt werd door M. intracellulare.
In tegenstelling hiermee had maar één controle persoon twee sputum samples positief 
voor (zelfs niet identieke) NTM. Dus patiënten hadden significant vaker twee positieve 
NTM kweken dan controle personen (p<0.05).
Waarschijnlijk spelen NTM een belangrijke rol in de etiologie van tuberculose-achtige 
ziektebeelden in Zambia. In ons onderzoek was de geschatte prevalentie kolonisatie in 
de patiënten populatie 9% (14/154), met een percentage ziekte van ongeveer 2 (3/154). 
In de controle populatie was het percentage kolonisatie 16 (61/383). Verder werd in deze 
studie duidelijk dat zowel patiënten als controle personen met NTM in het sputum vaker 
klachten en symptomen van algehele malaise (inclusief diarree en braken ) en onderge-
wicht (BMI <18) hadden en dat de thoraxfoto in deze NTM positieve personen vaker 
pathologie vertoonde dan in de NTM negatieve personen.
In Hoofdstuk 9 wordt de nauwkeurigheid van de klinische diagnose TB, gedurende een 
periode van toenemende HIV prevalentie in Zambia, beschreven. In Zambia worden 
patiënten met TB gediagnosticeerd op basis van respiratoire klachten die langer dan twee 
weken bestaan, geen verbetering tonen na twee kuren breed spectrum antibiotica, of een 
positieve ZN sputumuitstrijk hebben en/of pathologie op de thoraxfoto passend bij TB. In 
deze studie werd vervolgens het sputum van de gediagnosticeerde TB patiënten gekweekt 
in MGIT vloeibaar medium zodat onderscheid mogelijk werd tussen (1) tuberculose 
patiënten met geconfirmeerde positieve M. tuberculosis kweken, (2) mycobacteriosis ver-
oorzaakt door non-tuberculeuze mycobacteriën en (3) tuberculose-achtige ziektebeelden 
van niet mycobacteriële oorsprong.
In maar 47% van de 187 gediagnosticeerde TB patiënten werd M. tuberculosis gekweekt. 
In 19% van deze patiënten werd uitsluitend NTM gekweekt, terwijl in 12% een combinatie 
van zowel M. tuberculosis als NTM werd geïsoleerd. In de overige 29% van de klinisch ge-
diagnosticeerde TB patiënten werden geen mycobacteriën gekweekt. Een positieve HIV 
status bleek significant gecorreleerd te zijn met de isolatie van NTM uit het sputum en 
omgekeerd evenredig gecorreleerd te zijn met uitsluitend de isolatie van M. tuberculosis 
uit het sputum (p<0.05). Indien de diagnose TB wordt gebaseerd op symptomen, spu-
tumuitstrijk en/of thoraxfoto leidt dit in Zambia waarschijnlijk tot aanzienlijke aantallen 
foutpositief gediagnosticeerde TB patiënten ten gevolge van de toegenomen prevalentie 
HIV.
Bij het bepalen van de klinische relevantie van de geïsoleerde NTM in de patiënten be-
schreven in hoofdstuk 5, 6,8 en 9 was het niet altijd mogelijk om de ATS criteria afdoende 
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te toetsen. Dit had veelal betrekking op de werkcondities in Zambia. Vaak ontbraken 
klinische gegevens, of was het röntgenapparaat buiten werking. Het bleek buitengewoon 
moeilijk om meervoudige sputummonsters te analyseren. Een follow-up van de patiënten 
was in de praktijk bijna nooit mogelijk Verder werd in Zambia het aantal kolonies op het 
vaste kweekmedium niet gerapporteerd of werd er uitsluitend in een vloeibaar medium 
gekweekt. Een zeer beperkt aantal gekweekte kolonies zou een indicatie kunnen zijn van 
kolonisatie.
Verder zouden deze patiënten ook kweek-negatieve TB patiënten kunnen zijn. Helaas 
was het bij dit onderzoek niet mogelijk om met moleculaire amplificatie testen te scree-
nen op de aanwezigheid van M. tuberculosis. Het blijft ook de vraag of dit veel bij zou 
dragen. De gevoeligheid van dergelijke testen om M. tuberculosis in sputum aan te tonen 
is veelal niet groter dan de gevoeligheid van de kweek. Wel zou een moleculaire test bij de 
aanwezigheid van een mengsel van NTM en M. tuberculosis de laatstgenoemde bacteriën 
kunnen aantonen, terwijl dit bij een kweek vrijwel onmogelijk is.
Tevens werd nog geen onderzoek gedaan naar aanwezigheid van NTM in de omgeving, 
in de gebieden waar de patiënten en gezonde Zambianen leefden. Dit zou informatie 
kunnen hebben opgeleverd over de blootstelling aan bepaalde NTM. Toch zou ook bij 
veelvuldige blootstelling aan NTM in het milieu dezelfde vraag over klinische relevantie 
van isolatie van NTM van verdachte personen overeind blijven.
De factoren die iemands risico op infectie en ontwikkeling naar actieve ziekte bepalen 
zijn multi-factorieel en bevatten zowel gastheer-pathogeen interacties als omgevingsele-
menten. Epidemiologische data ondersteunen de rol van gastheer genetische factoren in 
de vatbaarheid voor TB en mycobacteriosis. Gastheer immuniteit voor mycobacteriële 
infecties is afhankelijk van een precies samenspel van T-lymfocyten sensibilisatie en mo-
nocyten recrutering. Verscheidene cytokine en chemokine signalen spelen hierbij een 
cruciale rol. Eén van deze factoren is de monocyte chemoattractant protein-1, MCP-1, 
een chemokine dat sterk betrokken is bij het ontstekingsproces.
In het onderzoek beschreven in Hoofdstuk 10 wordt in Zambiaanse personen onder-
zocht of polymorfisme in het MCP-1 promotor gen geassocieerd is met de vatbaarheid 
voor het ontwikkelen van TB na infectie. De resultaten demonstreerden dat het G allel van 
de MCP-1 promotor regio was geassocieerd met een toegenomen risico op de ontwikke-
ling van actieve pulmonale TB na infectie. Personen met MCP-1 genotype AG hadden 2.7 
keer meer kans op het ontwikkelen van TB dan degene met een AA genotype. Alhoewel 
er een klein aantal patiënten en controle personen in deze studie werden geïncludeerd 
kon echter al een significante associatie tussen de vatbaarheid voor het ontwikkelen van 
TB en een specifiek polymorfisme in dit gen worden aangetoond. Dit is voor zover be-
kend de eerste studie die het polymorfisme van het MCP-1 gen in Afrikaanse personen 
onderzocht heeft en dit zou een eerste indicatie kunnen zijn dat met name dit gen een 
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cruciale rol speelt in de vatbaarheid voor TB in bepaalde populaties. Er zijn meer studies 
met voldoende power nodig om de daadwerkelijke bijdrage van het MCP-1 gen aan de 
vatbaarheid voor het ontwikkelen van TB in Afrikaanse populaties in kaart te brengen.
suggesties voor verDer onDerzoeK
In dit proefschrift worden hoge percentages van NTM kolonisatie en NTM ziekte
in Zambia gerapporteerd. Tevens werden er verschillen geobserveerd in de geogra-
fische verdeling van geïsoleerde NTM species in chronisch zieke patiënten in de drie 
ziekenhuizen in Zambia. Tot dusver zijn er maar een paar epidemiologische studies be-
treffende NTM prevalenties verricht in Afrika, en hoofdzakelijk Zuid-Afrika, waardoor 
referentie data nauwelijks beschikbaar zijn. Om de daadwerkelijke omvang van NTM 
kolonisatie en infectie in Afrika te bepalen zullen meer uitgebreide onderzoeken in zowel 
duur als grootte nodig zijn. Tevens is onderzoek naar het voorkomen van NTM in de 
omgeving waar de patiënten en gezonde Zambianen leven van belang. Door het beperkte 
aantal geïncludeerd patiënten en controle personen in onze studies is het niet mogelijk 
de bevindingen te generaliseren naar de algehele populatie. Tevens werden de patiënten 
gedurende bepaalde maanden van het jaar onderzocht waardoor seizoensinvloeden ook 
een rol kunnen hebben gespeeld.
Data van patiënten zullen consistent moeten worden verzameld. Verder zou een mini-
male hoeveelheid data geïncludeerd moeten worden om de criteria van de ATS te kunnen 
toetsen: (1) thoraxfoto met nodulaire afwijkingen of holtevorming of een high-resolution 
computed tomography (HRCT) scan die multifocale bronchiectasieën met multipele 
kleine noduli laat zien, (2) drie of meer sputum samples voor analyse van zuurvaste staven 
en (3) uitsluiting van andere pathologie zoals TB. De voorkeur gaat uit naar Fluorescentie 
microscopie en specimens zouden zowel in een vloeibaar als op een vast medium moeten 
worden gekweekt. NTM zouden tot op species niveau geïdentificeerd moeten worden, 
omdat het anders moeilijk wordt om de klinische significantie te bepalen. Introductie van 
diagnostische methoden, adequate laboratorium faciliteiten en het trainen van analisten 
zal daarom noodzakelijk zijn in Afrika. Het is aan te raden om klinisch materiaal van 
patiënten die verdacht zijn van TB met moleculaire amplificatie methoden te testen op 
de aanwezigheid van M. tuberculosis, naast het uitvoeren van de microscopie en kweek 
op mycobacteriën, om zo een aantal werkelijke TB patiënt te identificeren ondanks het 
ontbreken van een positieve kweek op M. tuberculosis.
Het gebruik van een vloeibaar medium in combinatie met een vast medium is hierbij 
aan te bevelen, omdat het aantal kolonies op het vaste medium een indicatie van ziekte 
of kolonisatie kan zijn.
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Om het bovenstaande te bereiken, zal er in de Afrikaanse setting tenminste één goed 
uitgerust referentielaboratorium in elk land nodig zijn met bij voorkeur een langdurige 
samenwerking met een laboratorium in de Westerse wereld.
In het algemeen worden NTM infecties momenteel in Afrika niet behandeld terwijl er 
aanwijzingen zijn dat tenminste een deel van geïsoleerde NTM in Afrikaanse patiënten 
klinisch relevant is. Patiënten die gediagnosticeerd zijn met NTM ziekte zouden moeten 
worden geëvalueerd voor behandeling en de respons zou gedurende langere tijd moe-
ten worden vervolgd. Tevens zouden patiënten die verdacht zijn voor pulmonale NTM 
ziekte, maar niet voldoen aan de diagnostische criteria, moeten worden vervolgd totdat 
de diagnose wordt bevestigd of verworpen.
De behandeling van NTM ziekte is in het algemeen niet gelijk aan de behandeling van 
TB. Meestal wordt in de geneesmiddelen regimes een macrolide (azithromycin, clari-
thromycin) geïncludeerd. In vitro gevoeligheid voor veel NTM correleert niet goed met 
de klinische respons op anti-mycobacteriele geneesmiddelen, aanbevelingen voor in vitro 
routine testen van gevoeligheden zijn echter beperkt. De duur van de behandeling van 
de meeste pulmonale NTM infecties is tenminste een jaar, indien de opeenvolgende spu-
tumkweken gedurende therapie negatief zijn geworden.
Bepaalde condities, zoals een HIV infectie, lijken het krijgen van een NTM infectie te 
bevorderen en aan patiënten met zulke risicofactoren zal in de toekomst extra aandacht 
moeten worden besteed. In HIV positieve patiënten treedt een gedissemineerde NTM 
infectie typisch op nadat het CD4+ T-lymfocyten getal onder de 50/µl is gedaald. Long-
ziekte ten gevolge van NTM treedt hoofdzakelijk op in reeds beschadigde longen zoals 
bij chronisch obstructieve longziekte (COPD), bronchiectasieën, CF, pneumoconiosis en 
eerdere longtuberculose. NTM longziekte ziet men ook in vrouwen zonder duidelijke 
herkenbare predisponerende factoren. Aanvullende case-control studies zijn nodig om 
mogelijke risico factoren voor NTM kolonisatie en infectie te identificeren.
Concluderend kan men stellen dat de klassieke diagnose tuberculose, gedefinieerd op 
basis van de ZN sputumuitstrijk en thoraxfoto, in toenemende mate leidt tot foutpositief 
gediagnosticeerde patiënten ten gevolge van de toegenomen prevalentie HIV en onnauw-
keurigheden in de diagnostiek van TB in Afrika, zoals beschreven in dit proefschrift. 
Verder wordt een belangrijk deel van de tuberculose-achtige ziektebeelden in Afrika 
waarschijnlijk veroorzaakt door NTM en behandeling van deze infecties dient overwogen 
te worden. Misdiagnose van TB kan worden gereduceerd door de introductie van nieuwe 
diagnostische technieken, naast ZN sputumuitstrijk, die ook pulmonale NTM pathologie 
kunnen aantonen. Daarnaast moeten diagnostische scorings systemen en algoritmes 
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worden ontwikkeld en gevalideerd die de clinicus begeleiden in de benadering van NTM 
infecties in ontwikkelingsgebieden met een hoge HIV prevalentie.
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AD Aquadest
AFB Acid-fast bacilli
AFLP Amplified fragment length polymorphism
AIDS Acquired immune deficiency syndrome
AMC Academic Medical Centre, Amsterdam
ANN Artificial neural network
ATS American thoracic society
BAL Broncho-alveolar lavage
BCG Bacillus Calmette-Guerin
BMI Body mass index
BSL Biosafety level
BTS British Thoracic Society
CDC Centers for Disease Control
CF Cystic fibrosis
CFU Colony-forming units
CI Confidence interval
COPD Chronic obstructive pulmonary disease
DFA Discriminant function analysis
DNA Deoxyribonucleic acid
EMSC extended multiplicative signal correction
EN Electronic nose
HAART Highly active antiretroviral therapy
HCA Hierarchical cluster analysis
HIV Human immunodeficiency virus
HRCT scan High-resolution computed tomography scan
HPLC High-performance liquid chromatography
HPRM High performance Raman module
HWE Hardy-Weinberg equilibrium
IFN-γ Interferon-γ
KIT Royal Tropical Institute /
 Koninklijk Instituut voor de Tropen
LAM Lipoarabinomannan membrane
LAMP Loop-mediated isothermal amplification
LJ Löwenstein-Jensen
MAC M. avium complex
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MBL Mannose-binding lectin
MCP-1 Monocyte chemoattractant protein-1
MCRZ Medisch Centrum Rijnmond-Zuid
MGIT Mycobacteria Growth Indicator Tube
MIC Minimal inhibition concentration
MTD Mycobacterium tuberculosis Direct Test
NAA Nucleic acid amplification
NALC N-acetyl l-cysteine
NTM Non-tuberculous mycobacteria
OR Odds ratio
PC Principal component
PCA Principal component analysis
PCR Polymerase chain reaction
PPD purified protein derivative
PRA Polymerase chain reaction restriction analysis
R2 Squared Pearson’s correlation coefficient
RAPD Random amplified polymorphic DNA
RFLP Restriction fragment length polymorphism
RIVM National institute for Public Health and Environment /
 Rijksinstituut voor Volksgezondheid en Milieu
RLB Reverse line blot
RNA Ribonucleic acid
rRNA ribosomal RNA
SDS Sodium dodecyl sulfate
SNP Single nucleotide polymorphisms
TB Tuberculosis
TNF-α Tumor necrosis factor-α
VOC Volatile organic compound
WHO World Health Organisation
ZN Ziehl-Neelsen
